




Cell line Engineering and Bioassay Development for 
Therapeutic Monoclonal Antibodies  
by  
Urvashi Bhati (M.Sc.) 
 
Submitted in fulfillment of the requirements for the degree of 
 
















                      Acknowledgements 
 
The completion of my PhD was a long journey, filled with both eureka moments and 
experimental failures. I praise God for providing me the wisdom and strength to 
undertake and accomplish it. I would not have succeeded without the invaluable 
support from so many people. It gives me enormous pleasure to acknowledge them. 
First of all, I am extremely grateful to Mr. K V Subramaniam, President and CEO 
of Reliance Life Sciences Pvt Ltd (RLS), for granting me this opportunity to pursue 
PhD while working in RLS. 
My utmost thanks to my Principal Supervisor Prof. Colin J. Barrow, Alfred Deakin 
Professor and Chair in Biotechnology, School of Life & Environmental Sciences, for 
his constant guidance, scholarly inputs, feedbacks and encouragement. 
I would like to express my heartfelt thanks to my Co-Principal Supervisor Dr. 
Rupinder Kanwar, Senior Lecturer in Biomedicine, for excellent supervision, 
consistent support, insightful comments and valuable feedbacks and for meticulously 
editing my thesis and publications. You have set an example of being a proficient 
researcher and a caring guide. Thanks for being a tremendous mentor. 
 I am also thankful to Prof. Jagat Kanwar, Professor in Nanomedicine, School of 
Medicine, for giving me scientific advices and feedbacks.  
I would like to wholeheartedly thank my Supervisor Dr. Venkata Ramana, CSO, 
RLS for contributing significantly towards making my endeavour a success. I feel 
privileged and have always enjoyed learning under his supervision for the last eleven 
years in Therapeutic Protein group, RLS headed by him. I praise him for the 
v 
 
enormous amount of generous support and unsurpassed knowledge extended by him 
all through these years. His patience, understanding and flexibility has allowed me to 
complete my PhD without stress.  
 My profound thanks to Dr. Arnab Kapat, Director, Reliance Institute of Life 
Sciences for providing this fantastic opportunity, consistent support, valuable 
guidance, feedbacks and for going far beyond the way and making himself available 
for any doubt and discussion. His intellect and scientific approach had always 
inspired me. He constantly reminded and enquired about my progress which kept me 
on track and provided the impetus to complete. I can’t thank him enough. 
I am grateful to Dr. Praveen Rao for his generous and prompt help for the Flow. He 
has always been very encouraging and supportive. Thank you Sir for teaching me 
FACS. 
My sincere thanks to Ms. Pradnya Palande for encouraging my research. I am also 
thankful to all my lab mates- Pritha, Anjali, Heena, Khalander, Kriti, Yogesh,  
Tejal, Sravana, Vijesh for extending their kind help at all the stages. 
I am thankful to Dr. Viraf Vasania for helping me with microscopic images. I was 
privileged to learn the fine cell culture art from him when I joined RLS and which 
has always stayed with me. 
I am hugely appreciative to Ms. Sheena for providing insightful thoughts during my 
thesis writing and also for helping in capturing microscopic images. 
During my PhD, I got this wonderful opportunity to make amazing friends with 
Sheena, Sanjukta, Harshali, Leena, Shivani, Doli, Pavani, Kavya and Moti. I 
thank you all for the support and the special friendship moments shared in Geelong, 
which would be cherished for rest of my life. 
vi 
 
This PhD would not have been possible without the immense support from my 
parents in laws Mrs. Dropadi Devi and Mr. Ram Gopal Poswal.  I am grateful to 
them for all their blessings. 
I am indebted to my husband Dr. Himanshu Kumar Poswal for believing in me 
and supporting me in all the possible ways. 
I don’t have words to express my gratitude to my kids Nitya and Hitansh for 
bearing with me at times when I had to bring them to second priority and had to 
devote myself to my research work. 
Special mention goes to my brother Mr. Prashant Bhati who provided me moral 
and emotional support throughout. He was always keen to know my progress and 
always longed to see me accomplish this. 
Finally, I would like to express my gratitude to my Mummy and Papa, Mrs. Usha 
and Dr. P.C. Bhati who inculcated in me the desire to excel academically. They 
were my pillars of strength who motivated and helped me at all the stages. I hope 







List of Figures ........................................................................................................... xiii 
List of Tables .......................................................................................................... xviii 
Manuscripts in preparation ........................................................................................xix 
List of Abbreviations .................................................................................................. xx 
Abstract ................................................................................................................... xxiii 
1 Literature Review .................................................................................................. 2 
1.1 Introduction .................................................................................................... 2 
1.1.1 Bioassay and its requirements ................................................................. 3 
1.1.2 Quality Control requirements ................................................................. 4 
1.1.3 Requirement of in vitro cell based assay ................................................ 4 
1.1.4 Engineering cell lines with receptors for the development of cell based 
bioassay 5 
1.2 Monoclonal antibodies and their mechanism of action .................................. 5 
1.2.1 mAbs eliciting Fc effector functions....................................................... 8 
1.2.2 Anti VEGF/VEGFR2 drugs .................................................................. 17 
1.3 Developing the Bioassays ............................................................................ 36 
1.3.1 Bioassay optimization ........................................................................... 36 
1.3.2 Bioassay validation: Definition and terms ............................................ 37 
1.4 Project Overview .......................................................................................... 39 
1.4.1 Rationale ............................................................................................... 39 
1.4.2 Research Questions ............................................................................... 40 
1.4.3 Aims and Methodology......................................................................... 41 
viii 
 
2 Materials and Methods ........................................................................................ 44 
2.1 Methods for cloning the CD16a and VEGFR2 receptors in the vectors ...... 44 
2.1.1 Agarose gel electrophoresis .................................................................. 44 
2.1.2 Restriction enzyme digestion ................................................................ 45 
2.1.3 Ligation of DNA fragments .................................................................. 46 
2.1.4 Transformation ...................................................................................... 47 
2.1.5 Preparation of competent cells .............................................................. 47 
2.1.6 Plasmid DNA isolation-In house method ............................................. 48 
2.1.7 Gel Extraction ....................................................................................... 49 
2.1.8 Glycerol Stock preparation ................................................................... 50 
2.1.9 Polymerase Chain Reaction (PCR) ....................................................... 50 
2.1.10 Sequencing reaction cleanup................................................................. 54 
2.2 Methods for engineering the cell line with the receptors ............................. 55 
2.2.1 Revival of a cell line ............................................................................. 55 
2.2.2 Subculture of cells................................................................................. 56 
2.2.3 Freezing of cell line .............................................................................. 56 
2.2.4 Ethanol precipitation of DNA ............................................................... 57 
2.2.5 Electroporation ...................................................................................... 57 
2.2.6 Clone expansion .................................................................................... 58 
2.2.7 Cell based ELISA for CD16a expressing CHOKISV GS-KO cells ..... 59 
2.2.8 Cell based ELISA for VEGFR2 expressing CHOKISV GS-KO cells . 60 
2.2.9 Cell Banking ......................................................................................... 61 
2.3 Methods for bioassays development ............................................................ 61 
2.3.1 FACS based CD16a receptor binding assay ......................................... 61 
2.3.2 FACS based VEGFR2 receptor binding assay ..................................... 62 
2.3.3 Calcein AM labelling of cells ............................................................... 63 
ix 
 
2.3.4 DiI labelling of cells.............................................................................. 63 
2.3.5 CHOKISV GS- KO phagocytosis assay ............................................... 63 
2.3.6 EA.hy926 +VEGF cell proliferation inhibition assay........................... 64 
2.4 Methods for validation of Bioassays ............................................................ 65 
2.5 Materials ....................................................................................................... 67 
3 CD16a receptor Binding Assay ........................................................................... 72 
3.1 Introduction .................................................................................................. 72 
3.1.1 Receptor binding assays ........................................................................ 72 
3.1.2 CD16a receptor binding assay .............................................................. 73 
3.1.3 Developing CD16a receptor binding assay ........................................... 75 
3.2 Cloning of the receptors ............................................................................... 77 
3.2.1 FcεRI-γ  cloning: ................................................................................... 79 
3.2.2 CD16a cloning ...................................................................................... 85 
3.2.3 Double gene construction ..................................................................... 91 
3.3 Expression studies ........................................................................................ 94 
3.3.1 Stable transfection ................................................................................. 94 
3.3.2 Clone development and selection of clone with highest receptor 
expression (Cell based ELISA and FACS) .......................................................... 96 
3.3.3 Cell Banking ......................................................................................... 99 
3.4 Standardization of the assay ......................................................................... 99 
3.4.1 Cell number ......................................................................................... 100 
3.4.2 Selection of secondary antibody ......................................................... 101 
3.4.3 Concentration of secondary antibody ................................................. 102 
3.4.4 Working range for primary antibody .................................................. 103 
3.5 Bioassay validation .................................................................................... 105 
3.5.1 Criterion: Specificity ........................................................................... 105 
x 
 
3.5.2 Criterion: Precision ............................................................................. 106 
3.5.3 Criterion: Accuracy ............................................................................. 108 
3.5.4 Criterion: Linearity ............................................................................. 110 
3.5.5 Criterion: Robustness .......................................................................... 112 
4 VEGFR2 receptor binding assay ....................................................................... 118 
4.1 Introduction ................................................................................................ 118 
4.2 Cloning of the VEGFR2 Receptor ............................................................. 122 
4.2.1 VEGFR2 amplification........................................................................ 123 
4.2.2 Sub cloning of VEGFR2 in pXC 17.4 vector ..................................... 127 
4.3 Expression studies ...................................................................................... 130 
4.3.1 Stable transfection ............................................................................... 130 
4.3.2 Clone development and selection of clone with highest receptor 
expression (Cell based ELISA and FACS) ........................................................ 132 
4.3.3 Cell Banking ....................................................................................... 135 
4.4 Standardization of the assay ....................................................................... 135 
4.5 Selection of a secondary antibody .............................................................. 136 
4.5.1 Concentration of a secondary antibody............................................... 138 
4.5.2 Working range for primary antibody .................................................. 139 
4.6 Bioassay validation .................................................................................... 140 
4.6.1 Criterion: Specificity ........................................................................... 140 
4.6.2 Criterion: Precision ............................................................................. 142 
4.6.3 Criterion: Accuracy ............................................................................. 144 
4.6.4 Criterion: Linearity ............................................................................. 147 
4.6.5 Criterion: Robustness .......................................................................... 148 
5 EA.hy926 cell proliferation inhibition assay ..................................................... 155 
5.1 Introduction ................................................................................................ 155 
xi 
 
5.2 Cloning of the VEGFR2 Receptor ............................................................. 159 
5.2.1 VEGFR2 subcloning in pcDNA3.1 (+) .............................................. 160 
5.2.2 VEGFR2 subcloning in pEGFP-N1 .................................................... 163 
5.3 Expression studies ...................................................................................... 165 
5.3.1 Stable transfection ............................................................................... 165 
5.3.2 Kill curve of EA.hy926 cells in presence of gentamycin ................... 166 
5.3.3 Lipofectamine 2000 mediated transfection ......................................... 167 
5.3.4 Effectene and Superfect mediated transfection................................... 168 
5.3.5 PEI mediated transfection ................................................................... 168 
5.3.6 Electroporation .................................................................................... 169 
5.3.7 Confirmation of VEGFR2 gene integration and its expression on 
EA.hy926 cells................................................................................................... 176 
5.3.8 Cell banking ........................................................................................ 179 
5.4 Standardization of the assay ....................................................................... 179 
5.4.1 Standardization of bioassay media and VEGF concentration............. 179 
5.4.2 Standardization of cell number and incubation time .......................... 181 
5.4.3 For standardization of Bevacizumab concentration ............................ 183 
6 ADCP assay ....................................................................................................... 187 
6.1 Introduction ................................................................................................ 187 
6.2 Standardization of ADCP bioassay using CD16a engineered CHO KI 
SVGS-KO cells ..................................................................................................... 190 
6.2.1 Optimization of calcein AM labelling of CHOKISV GS-KO cells .... 193 
6.2.2 Optimization of effector:target cell ratio ............................................ 194 
6.2.3 Repeating ADCP assay after optimization ......................................... 195 
7 Summary and Conclusions ................................................................................ 199 
7.1 Introduction ................................................................................................ 199 
xii 
 
7.2 Engineering CD16a receptor in CHOKISV GS-KO cells and developing 
CD16a receptor binding assay............................................................................... 200 
7.3 Engineering VEGFR2 receptor in EA.hy926 cells and developing cell 
proliferation inhibition assay for anti-VEGF drugs .............................................. 201 
7.4 Engineering VEGFR2 receptor in CHOKISV GS-KO cells and developing 
VEGFR2 receptor binding assay ........................................................................... 203 
7.5 Exploring VEGFR2 engineered CHOKISV GS-KO cells proliferation in 
presence of VEGF ................................................................................................. 204 
7.6 Investigating CD16a engineered CHOKISV GS-KO cells phagocytic 
activity for developing ADCP bioassay ................................................................ 207 
7.7 Future perspectives ..................................................................................... 208 
8 Appendix ........................................................................................................... 210 







List of Figures 
Figure 1.1: Mechanisms of action of monoclonal antibodies. ..................................... 7 
Figure 1.2: Diagrammatic representation of ADCC. ................................................. 12 
Figure 1.3: Diagrammatic representation of ADCP................................................... 15 
Figure 1.4: Schematic representation of VEGF-R2 signalling. ................................. 20 
Figure 1.5: Global sales and forecast for Anti-VEGF drugs. .................................... 26 
Figure 1.6:  Schematic representation of corneal angiogenesis assay ....................... 29 
Figure 1.7:  Schematic representation of Aortic ring assay ....................................... 32 
Figure 1.8:  Schematic representation of in vitro angiogenesis assays ...................... 34 
Figure 1.9: Schematic representation of the validation parameters ........................... 38 
Figure 3.1: Diagrammatic representation of the CD16a receptor binding assay. ...... 74 
Figure 3.2: Major steps for the development of the CD16a receptor binding assay. 76 
Figure 3.3: Outline of construction of pXC17.4+CD16a+ FcεRI-γ. ......................... 78 
Figure 3.4: Nucleotide Sequence of FcεRI-γ after amplification. ............................. 79 
Figure 3.5: Agarose gel electrophoresis image to show FcεRI-γ gene amplification.
..................................................................................................................................... 81 
Figure 3.6: Agarose gel electrophoresis image to check FcεRI-γ gene containing 
colonies and plasmids. ................................................................................................ 83 
Figure 3.7: Agarose gel electrophoresis image to check FcεRI-γ gene containing 
colonies and plasmids. ................................................................................................ 85 
Figure 3.8: Nucleotide Sequence of CD16a. ............................................................. 86 
 Figure 3.9: Agarose gel electrophoresis image to show CD16a gene amplification.
..................................................................................................................................... 88 
Figure 3.10: Agarose gel electrophoresis image to check CD16a gene containing 
plasmids. ..................................................................................................................... 89 
xiv 
 
Figure 3.11: Agarose gel electrophoresis image for cloning CD16a gene in pXC 17.4 
plasmid. . ..................................................................................................................... 91 
Figure 3.12: Agarose gel electrophoresis image for constructing CD16a + FcεRI-γ 
/pXC 17.4 Cl# 5. ......................................................................................................... 93 
Figure 3.13: Agarose gel electrophoresis image to show Pvu I linearization of pXC 
17.4+CD16a+FcεRIγ Cl #9. ....................................................................................... 95 
Figure 3.14: Fluorescence microscopy images of CHOKISV GS-KO cells 
transfected with pXC 14.4+GFP. ................................................................................ 96 
Figure 3.15: Identification of a lead cell line with highest CD16a expression based 
on ELISA and FACS analysis..................................................................................... 98 
Figure 3.16: Histogram depicting FITC expression of various mAbs. .................... 100 
Figure 3.17: Optimization of the cell number for the assay. ................................... 101 
Figure 3.18: Secondary antibody selection data. ..................................................... 102 
Figure 3.19: Evaluation of working range concentration for Trastuzumab and 
Rituximab. ................................................................................................................. 104 
Figure 3.20: Comparison  of CD16a receptor binding with IgG1 mAbs, IgG2 and 
IgG4 mAbs. ............................................................................................................... 106 
Figure 3.21: Comparison of CD16a receptor binding response of three sets to 
evaluate Repeatability. .............................................................................................. 107 
Figure 3.22: Evaluation of Accuracy. ...................................................................... 109 
Figure 3.23: Evaluation of Linearity for the observed average potency against the 
expected potency. ...................................................................................................... 112 
Figure 3.24: Dose responses of samples with altered incubation time to evaluate 
Robustness. ............................................................................................................... 113 
Figure 4.1: Diagrammatic representation of the VEGFR2 receptor binding 
assay.CHOKISV GS-KO .......................................................................................... 120 
xv 
 
Figure 4.2: Major steps for the development of VEGFR2 receptor binding assay. . 122 
Figure 4.3: Outline of construction of pXC17.4+VEGFR2. .................................... 123 
Figure 4.4: Agarose gel electrophoresis image to show VEGFR2 amplification. ... 124 
Figure 4.5: Nucleotide Sequence of VEGFR2. ........................................................ 127 
Figure 4.6: Agarose gel electrophoresis image for cloning VEGFR2 in pXC 17.4 
plasmid. ..................................................................................................................... 129 
Figure 4.7: Agarose gel electrophoresis image to show Pvu I linearization of 
VEGFR2/ pXC 17.4 Cl #5. ....................................................................................... 130 
Figure 4.8: FACS analysis of CHOKISV GS-KO cells transfected with pXC14.4 
+GFP. ........................................................................................................................ 131 
Figure 4.9: Screening of the lead cell line with highest VEGFR2 expression. ........ 134 
Figure 4.10: FACS analysis to confirm VEGFR2 expression on transfected 
CHOKISV GS-KO cells. .......................................................................................... 136 
Figure 4.11: Comparison of the secondary antibodies. ........................................... 137 
Figure 4.12: Histogram graph representing secondary antibody concentration 
optimization data. ...................................................................................................... 138 
Figure 4.13: Evaluation of working range for Ramucirumab. ................................. 139 
Figure 4.14: VEGFR2 receptor binding is specific to Ramucirumab. ..................... 141 
Figure 4.15: Comparison of VEGFR2 receptor binding response of three sets to 
evaluate Repeatability. .............................................................................................. 143 
 Figure 4.16: Evaluation of Accuracy. ..................................................................... 145 
Figure 4.17: The observed average potency against the expected potency to evaluate 
Linearity. ................................................................................................................... 148 
Figure 4.18: Illustration of the evaluation of robustness of the assay. .................... 149 
Figure 5.1: FACS analysis for comparing VEGFR2 expression on HUVEC and         
EA.hy926 cells. ......................................................................................................... 156 
xvi 
 
Figure 5.2: Diagrammatic representation of the EA.hy926 cell proliferation   
inhibition assay. ........................................................................................................ 157 
Figure 5.3: Major steps for the development of the EA.hy926 cell proliferation 
inhibition assay. ........................................................................................................ 159 
Figure 5.4: Outline of construction of pcDNA 3.1(+) +VEGFR2 and pEGFP-N1 
+VEGFR2. ................................................................................................................. 160 
Figure 5.5: Agarose gel electrophoresis images of cloning of VEGFR2 gene in 
pcDNA3.1 (+) plasmid. ............................................................................................ 162 
Figure 5.6: Agarose gel electrophoresis image of cloning of VEGFR2 gene in 
pEGFP-N1 plasmid. .................................................................................................. 164 
Figure 5.7: Agarose gel electrophoresis image to show linearization of VEGFR2/ 
pcDNA3.1 (+) Cl# 7 and VEGFR2/ pEGFP-N1Cl#8 plasmids. ............................... 166 
Figure 5.8: Fluorescence microscopy images of transfected cells. .......................... 175 
Figure 5.9: FACS analysis of VEGFR2 expression confirmation on transfected 
EA.hy926 cells. ......................................................................................................... 177 
Figure 5.10: VEGFR2 gene integration confirmation on EA.hy926 cells. .............. 178 
Figure5.11: Histogram graphs representing bioassay media and VEGF concentration 
optimization data. ...................................................................................................... 180 
Figure 5.12: Cell number and incubation time optimization. .................................. 182 
Figure 5.13: EA.hy926 cells proliferation inhibition in presence of Bevacizumab.183 
Figure 6.1: Diagrammatic representation of the ADCP bioassay for Rituximab. ... 189 
Figure 6.2: Phagocytosis of WIL2S cells by CD16a engineered CHOKISV GS-KO 
cells in presence of Rituximab. ................................................................................. 192 
Figure 6.3: FACS dot plot analysis of CHOKISV GS-KO cells labelled with 
different concentrations of calcein AM. ................................................................... 193 
xvii 
 
Figure 6.4: Comparison of PE in FITC in Q2+Q4 for different effector: target cell 
ratios. ......................................................................................................................... 194 
Figure 6.5: Fluorescent and superimposed images of CD16a engineered CHOKISV 
GS-KO cells and WIL2S cells. ................................................................................. 195 
Figure 6.6: FACS analysis of phagocytosis of WIL2S cells by CD16a engineered 
CHOKISV GS-KO cells in presence of Rituximab. ................................................. 196 
Figure 7.1: Summary of the project work carried out for the current PhD study. ... 200 
Figure 7.2: VEGFR2-transfected CHOKISV GS-KO cell viability under different 


















List of Tables 
 
Table 1.1: mAbs eliciting Fc effector functions. ......................................................... 9 
Table 1.2: Approved drugs that inhibit VEGF or VEGF receptors ........................... 22 
Table 1.3: Angiogenesis bioassays. ........................................................................... 27 
Table 2.1: Restriction enzyme digestion reaction mixture setup. .............................. 46 
Table 2.2: Amplification PCR conditions. ................................................................. 51 
Table 2.3: Touchdown PCR conditions. .................................................................... 52 
Table 2.4 Colony PCR conditions. ............................................................................. 53 
Table 2.5 Sequencing PCR conditions. ...................................................................... 54 
Table 3.1 Secondary antibody concentration optimization data. ............................. 103 
Table 3.2 Summary of CD16a receptor binding bioassay optimization. ................. 104 
Table 3.3 Observations for various acceptance criteria to assess Repeatability. ..... 108 
Table 3.4: Evaluation of linearity. ........................................................................... 111 
Table 3.5: Evaluation of Robustness........................................................................ 113 
Table 3.6: Summary of the observations of the validation test method. .................. 114 
Table 4.1: Summary of VEGFR2 receptor binding bioassay optimization. ............ 140 
Table 4.2: The various acceptance criteria to assess Repeatability. ........................ 143 
Table 4.3: Various acceptance criteria for the formulation of conclusion. .............. 146 
Table 4.4: Evaluation of linearity. ........................................................................... 147 
Table 4.5: Evaluation of Robustness of the assay. ................................................... 149 
Table 4.6: Summarized data of the validation test methods. ................................... 150 
Table 5.1: Summary of Electroporations for transfecting EA.hy926 cells. ............. 170 
Table 8.1: Materials ................................................................................................. 210 




Manuscripts in preparation 
i. Review article Bioassays development in a quest for anti-VEGF drugs (based on 
Chapter 1).  
ii. Research article “Cell based Receptor binding bioassay for Ramucirumab using 
engineered cell line” (based on Chapter 4). 




 Urvashi Bhati, C. J. Barrow, R.K. Kanwar, J.R. Kanwar, Dr. Venkata Ramana 
(2015). Cell line engineering and Bioassay development. DIRI International 
Symposium 2015, New Delhi, India, December 6-9, 2015. 
 
Conferences Attended  
DIRI International Symposium organized by TERI-Deakin, New Delhi, India, Nov 
29 -31, 2012.  
DIRI Workshop on “Special higher degree by research”, New Delhi, India, 
November 5-6, 2014.  
DIRI International Symposium on Translational Research, TERI Deakin NanoBio 




List of Abbreviations 
ADCC                                            Antibody-dependent cellular cytotoxicity 
ADCP                                             Antibody dependent cellular phagocytosis 
AMD                                              Age- related macular degeneration  
BC                                                  Breast cancer 
BrdU                                              -bromo-2’-deoxyuridine 
CAM assay                                    Chick chorioallantoic membrane assay 
CD                                                 Cluster of Differentiation 
CDC                                              Complement-dependent cytotoxicity  
CO2                                                                       Carbon dioxide 
CLL                                               Chronic lymphocytic leukemia 
CRC                                               Colorectal cancer 
CRPC                                             Castration –resistant prostate cancer 
CV                                                  Coefficients of variation 
DME                                               Diabetic macular edema 
EGF                                                Epidermal growth factor 
EGFR                                             Epidermal growth factor receptor 
EHS                                                Engelbreth-Holm-Swarm           
EMEA                                            European Medicines Agency 
ERK                                               Extracellular signal-regulated kinase  
Fab                                                 Antigen binding fragment 
Fc                                                   Crystalline fragment 
Flk                                                  Fetal Liver Kinase 
GBM                                              Glioblastomamultiforme 
xxi 
 
GFP                                                Green fluorescent protein 
GIST                                               Gastrointestinal stromal tumour 
HCAEC                                          Human Coronary artery endothelial cells 
HCC                                                Hepatocellular carcinoma   
HER2                                              Human epidermal growth factor receptor 2 
HPEC                                              Human placental endothelial cells 
HMVEC                                          Human micro vascular endothelial cells 
HNSCC                                           Head and neck squamous cell carcinoma 
HUVEC                                           Human umbilical vein endothelial cells   
ICH                                                  International Conference on Harmonization 
ITAM                                               Immunoreceptor tyrosine-based activation motif  
ITIM                                                 Immunoreceptor tyrosine-based inhibitory motif  
KDR                                                 Kinase insert domain receptor 
mAbs                                                Monoclonal antibodies  
MCRC                                              Metastatic colorectal cancer 
MCS                                                 Multiple cloning sites 
MOA                                                Mechanism of action 
MPM                                                Malignant pleural mesothelioma 
 mRNA                                             messenger Ribonucleic acid 
MTC                                                 Medullary thyroid cancer 
MTS                                                 2H-Tetrazolium,5-[3-(carboxymethyl)phenyl]-3-               
                                                         (4,5-dimethyl-2-thiazolyl)-2-(4-sulfophenyl)-2-     
                                                         (4- sulfophenyl) 
MTT                                               3-(4, 5-dimethyltetrazolium bromide)  
NHL                                                Non-Hodgkin’s Lymphoma 
NK cells                                          Natural killer cells 
xxii 
 
NRP                                                 Neuropilin  
NSCLC                                            Non-small cell lung cancer 
PAE                                                  Porcine aortic endothelial cells 
PBMC                                              Peripheral blood mononuclear cells  
PCR                                                  Polymerase chain reaction 
PDGF                                               Platelet derived growth factor  
PGF                                                  Placental growth factor  
PLA 2.0                                            Parallel-Line and Parallel-Logistics Assays 
QC                                                    Quality Control 
RA                                                    Rheumatoid arthritis 
RCC                                                  Renal cell carcinoma 
RSD                                                  Relative standard deviation 
SAPK                                                Stress activated protein kinase 
SPR                                                   Surface plasmon resonance 
svVEGF                                            Snake venom vascular endothelial growth factor 
TCR                                                   T Cell receptor 
TGF-α                                               Transforming growth factor alpha 
TGF-β1                                             Transforming growth factor beta-1 
TKI                                                    Tyrosine kinase inhibitors  
US-FDA                        United States - Food and Drug Administration 
USP/EP                                              United States Pharmacopeia/ European                    
                                                           Pharmacopeia 
UTR                                                   Untranslated region 
VEGF                                                 Vascular endothelial growth factor 
VPF                                                    Vascular permeability factor 
xxiii 
 
                                    Abstract 
 
Bioassay screenings play a crucial role in drug development, beginning with the drug 
discovery stage to the final stage of Quality Control (QC) drug testing. The 
discovery of novel molecular targets for cancer therapy over the past two decades to 
overcome inherent limitations of standard chemotherapy, has no doubt led to the 
rapid expansion in development of targeted agents in oncology. However, due to 
lack of suitable preclinical bioassays for assessing the efficacy and clinically 
significant toxicity there has been limited success in bench to bedside translation of 
targeted agents. Also before the drugs are commercially released in the market, 
biopharmaceutical companies are required to fulfil the internationally accepted 
guidelines, which have mandated bioassays to assess the potency of the drugs. 
Consequently, bioassays have gained extraordinary importance in drug development. 
QC set up requires a bioassay which is simple, convenient and robust for successful 
regulatory submission package, lot release and stability studies. The in vivo 
bioassays based on animal studies are expensive, time consuming, labour intensive, 
accounts for lot of variations and have ethical issues. All these problems limit the use 
of in vivo bioassays for routine analysis by the QC. For some of the bioassays, 
primary cells are used, which are difficult to propagate and are stable up to few 
passages only, accounting for lot of variations. All these problems can be 
circumvented by developing a cell based bioassay using continuous cell lines, which 
would not only be a low cost means of testing the drug but also, would have greatly 
reduced time frames and variations. The cell based bioassays can be developed using 
cell lines with specific receptor which is the target for a protein drug. But for certain 
drugs such cell lines are not available. Bioassays can be developed for such drugs by 
xxiv 
 
generating cell lines expressing required receptors and other cofactors. Such 
engineered cell lines can then be used for the development and optimization of 
various functional bioassays. This thesis describes the work done to develop 
bioassays for two major classes of anti-cancer drugs including mAbs eliciting Fc 
mediated effector functions and anti-VEGF/VEGFR2 drugs. 
mAbs which kill target tumour cell by their Fc mediated effector functions constitute 
a dominant class of anti-cancer drugs. Such mAbs bridge between the tumour cells 
and the immune effector cells in our body. They interact with specific Fc receptors 
on the effector cells to activate them. Fc mediated effector functions include 
antibody dependent cell mediated cytotoxicity (ADCC), complement dependent 
cytotoxicity (CDC), antibody dependent cellular phagocytosis (ADCP) and 
apoptosis.   
Other leading category of anti-cancer drug is anti VEGF/VEGFR2 drugs. VEGF is 
the key angiogenic factor. Here the mAbs function by blocking the ligand, VEGF or 
its receptor, VEGFR2 and as a result angiogenesis of tumour cells is arrested which 
eventually halts their proliferation and survival.  
The study is aimed to develop convenient, robust and precise receptor binding and 
functional bioassays pertaining to the above mentioned categories of drugs. 
Accelerating demand of mAbs with Fc effector functions has created a dearth of cell 
line based ADCC bioassays. To alleviate this bottleneck, it was hypothesized that 
CHOKISV GS-KO cells could be engineered to express CD16a receptor to develop 
CD16a receptor binding assay as a surrogate ADCC assay.  Chapter Three 
illustrates development of FcγRIIIa or CD16a receptor binding assay. Binding of 
CD16a receptor, present on natural killer cells to Fc region of specific mAb 
constitutes the main step in ADCC response. For developing the ADCC bioassay, 
xxv 
 
CHOKISV GS-KO expressing CD16a receptor cell line was first generated and then 
the assay was optimized and validated for Trastuzumab.  
Similarly for developing the receptor binding assay for anti- VEGF/VEGFR2 drugs 
it was also hypothesized that CHOKISV GS-KO cells could be engineered with 
VEGFR2 receptor to develop VEGFR2 receptor binding assay. Chapter Four 
describes the development of VEGFR2 receptor binding assay for anti VEGFR2 
drugs. For developing the bioassay, CHOKISV GS-KO cells were engineered with 
VEGFR2 receptor and the cell line thus generated was employed in optimizing and 
validating the bioassay for antiVEGFR2 mAb, Ramucirumab. The hypothesis that 
VEGFR2 expressing CHOKISV GS-KO cell line can proliferate in presence of 
VEGF for developing cell proliferation inhibition assay for these drugs was also 
verified. In this study, it was found that these cells don’t respond to VEGF.  
For developing functional assays for anti VEGF/VEGFR2 drugs, EA.hy926 cell line 
was selected. This is a hybrid endothelial cell line having less expression of 
VEGFR2 as compared to primary HUVEC cells. So it was hypothesized that if 
EA.hy926 cells can overexpress VEGFR2 receptor then there is a possibility to 
develop better functional bioassays for anti VEGF/VEGFR2 drugs. Chapter Five 
depicts the approaches tried to transfect EA.hy926 cell line which is reported to be 
hard to transfect. Experiments included transfecting the cells with various 
transfection reagents and attempting different electroporation protocols. In this 
study, these cells were only transiently transfected and VEGFR2 expression lasted 
up to few passages only. Cell proliferation inhibition assay for anti VEGF mAb, 
Bevacizumab was optimized using these VEGFR2 engineered EA.hy926 cells. 
Literature suggests that Fc receptor engineered CHO cells can elicit phagocytosis, so 
it was hypothesized that CHOKISV GS-KO cells expressing CD16a could be 
employed as effector cells to develop ADCP bioassay. Chapter Six assesses 
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CHOKISV GS-KO expressing CD16a receptor cell line’s ability to elicit 
phagocytosis. It was confirmed that CD16a engineered CHOKISV GS-KO cells can 
phagocytose CD20 expressing WIL2S cells in presence of anti CD20 mAb, 
Rituximab and thus functional ADCP bioassay can be developed for Rituximab. The 
engineered cell line would act as effector cells. 
Collectively, the work carried out in this study includes generating CD16a receptor 
expressing CHOKISV GS-KO cell line and developing receptor binding assay as a 
surrogate ADCC assay as well as developing functional ADCP assay using this cell 
line. Also, VEGFR2 receptor expressing CHOKISV GS-KO cell line was generated. 
VEGFR2 receptor binding assay was developed for anti-VEGFR2 mAbs and an 
approach to develop functional assay for anti VEGF/VEGFR2 mAbs using 
engineered EA.hy926 cells was verified. The receptor binding and functional 
bioassays thus developed were simple, convenient and robust. They could be 
successfully technology transferred to QC, facilitating successful regulatory 
submissions and lot release of the drugs in the market and would thus help the 
biopharmaceutical companies to accelerate development and consistent production 




















1 Literature Review 
 
1.1 Introduction 
The history of regulations governing biologics is almost as old as biologics itself. In 
1901, Emil von Behring was awarded the first Nobel Prize in medicine “for his work 
on serum therapy, especially its application against diphtheria, by which he had 
opened a new road in the domain of medical science and thereby placed in the hands 
of the physician a victorious weapon against illness and deaths.”(1989). Following 
this in the same year, there was death of thirteen children in Saint Louis, Missouri, 
after receiving diphtheria antitoxin contaminated with tetanus (Borchers et al., 2007). 
In response to this, the Biologics Control Act was passed in 1902 (Lilienfeld, 2008). 
This was the first legislation to control the quality of drugs (Lilienfeld, 2008). 
Regulatory bodies such as the United States - Food and Drug Administration (US-
FDA), International Conference on Harmonization (ICH), United States Pharmacopeia/ 
European Pharmacopeia (USP/EP) and European Medicines Agency (EMA) control 
the commercial distribution of biopharmaceuticals/drugs in the market. 
Biopharmaceutical companies need to follow set internationally accepted guidelines 
for manufacturing and marketing their products. A biopharmaceutical’s complete 
analytical profile comprises of physiochemical tests as well as bioassays (Noel 
Rieder, 2010). Both are equally important and are required in combination to 




can well characterize the drug in terms of its structure, only bioassays can  assess the 
functionality of the drug (FDA, 2012a). 
1.1.1 Bioassay and its requirements 
Bioassay is a technique, carried out on some living system to estimate the potency or 
biological activity of a drug. Bioassays play a crucial role in therapeutic drug 
characterization throughout the span of drug development, manufacture and release 
in the market. They are required for screening and establishing the potency of new 
drug candidates and for the stability and lot release testing of the drugs. A 
combination of in vitro, ex vivo and in vivo bioassays can be employed to assess the 
functionality, safety and potency of the drugs at preclinical levels. In order to fulfil 
the regulatory requirements, the bioassay needs to be reflective of the clinical mode 
of action of the drug (Shah et al., 2000).  
Biologics are innovative drugs generated in genetically modified living cells through 
genetic engineering techniques. Since biologics are inherently complex protein 
molecules, generating exact copy is not possible. However, similar copies can be 
produced using genetic engineering technique and therefore these copies are known 
as biosimilars. Bioassays find application not only in the innovator’s biologics but 
also in the successful development of biosimilars of the innovator molecule (Bryant, 
2013). They determine the relative potency of the biosimilar drug, by comparing the 







1.1.2 Quality Control requirements 
In biopharmaceuticals, Quality control (QC) group routinely performs these 
bioassays for successful regulatory submission packages, stability and lot release 
testing of the drug substance and the drug product. The QC laboratory requires a 
bioassay which is simple, convenient, robust and reproducible. At the same time, the 
bioassay should mimic clinical mode of action of the drug in order to fulfil the 
regulatory requirements. Bioassay should be designed in a manner to reduce 
variability and bias i.e. bioassay should be validatable. Validation parameters include 
precision, accuracy, specificity, robustness, detection range etc. with low percentage 
coefficients of variation (%CV) and low standard deviation (SD) and high fit R2 
(Shah et al., 2000).  
1.1.3 Requirement of in vitro cell based assay 
In the in vivo animal studies, animal models are used to check the response of the 
drug. These are expensive, time consuming, labour intensive and have low 
throughput. These assays account for a lot of variations arising due to complexities 
of living systems and also due to species differences. Quantification is a problematic 
task and moreover, there are ethical concerns as well. All these problems limit the 
use of in vivo bioassays for routine analysis by the QC.  
On the other hand, cell based in vitro bioassays are reliable indicators of the 
bioactivity of the drug and are easy to use. They are used to assess a variety of 
cellular aspects including viability, cytotoxicity, apoptosis, signal transduction and 
metabolic functions. Cell based assays are consistent with respect to time. This is 




1.1.4 Engineering cell lines with receptors for the development of cell 
based bioassay 
Cell based bioassays for many biopharmaceutical drugs are based on cell lines with 
required receptors, to which drug binds specifically and responds. But for some of 
the drugs, cell line based bioassays have not been developed. This may be because 
cell lines with required receptors are not available. In such cases, understanding 
various cell signalling pathways and leveraging them to generate cell line with 
required receptors by engineering these receptors on cell lines would hold the 
potential to develop cell based bioassay for these drugs.  
1.2 Monoclonal antibodies and their mechanism of action 
Antibodies are the immuno-glycoproteins which circulate in our blood. Their 
function is to attack and destroy any foreign substance called antigen. Monoclonal 
antibodies are the antibodies that selectively react to a single epitope. They show 
remarkably high specificity in binding to their targets, as they are clones of the same 
parent immune cells, in contrast to the polyclonal antibodies which are derived from 
the different parent cells. Monoclonal antibodies are also called the “magic bullets” 
(Brodsky, 1988).  
G. Kohler and C. Milstein invented hybridoma technology for the development of 
mouse monoclonal antibodies (Kohler and Milstein, 1975). This invention led to the 
generation of present day modernised therapeutic monoclonal antibodies. 
Therapeutic monoclonal antibodies comprises of the majority of successful protein 
drugs and have emerged as one of the most dominant biopharmaceutical product 




Since the commercialization of the first monoclonal antibody OKT3 by 1986, there 
is a big list of monoclonal antibodies (mAbs) that have got the regulatory approval 
and even much more are in the different phases of clinical trials (Ecker et al., 2015) 
(Parekh et al., 2012b). The monoclonal antibodies function by specifically targeting 
extracellular domains of transmembrane receptors on the cells. mAbs either recruit 
the immune system to cause the effector functions such as complement-dependent 
cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody- 
dependent cellular phagocytosis (ADCP) and Fc dependent apoptosis or they may 
signal for apoptosis (receptor agonist) or simply block receptor thus preventing 
ligand binding which leads to reduced cell proliferation and increased apoptosis 
(receptor antagonist). They can even block the ligand and thereby prevent from 
binding to the receptor (Weiner et al., 2010) (Jiang et al., 2011a, Scott et al., 2012) . 





    Figure 1.1: Mechanisms of action of monoclonal antibodies.  mAbs either directly 
kill the target tumour cells by their Fc mediated effector functions or indirectly by 
focusing on the target tumour environment i.e. by blocking the ligand or its receptor.  
ADCC: antibody-dependent cellular cytotoxicity, CDC: complement-dependent 
cytotoxicity, ADCP: antibody- dependent cellular phagocytosis. 
 
Monoclonal antibodies have Y shaped structure. The upper two arms constitute Fab 
(antigen binding) fragment and the lower arm is the Fc (crystalline) fragment (Harris 
et al., 1998). Functionality of the antibody is dependent on these two domains. Fab 
domain confers the specific binding to the target. It contains variable region with 
three complementarity determining regions which confers the specificity to bind to 
the antigen (Schroeder and Cavacini, 2010). On the other hand, Fc domain is 
responsible for the effector functions including ADCP, CDC and ADCC (Moore et 
al., 2010).  
One of the criterion on which therapeutic potential of mAb depends is its subclass 




Fc portion of mAb to FcγR present on effector cells activates various immune 
effector functions. IgG1 and IgG3 binds with higher affinity to FcγRs whereas IgG2 
and IgG4 have much lesser affinity (Vidarsson et al., 2014). IgG3 has highly reduced 
serum half-life, more number of allotypes as compared to other subclasses making it 
a non-suitable option for being a therapeutic mAb (Irani et al., 2015). On the other 
hand IgG1 is the most prevalent subclass in the serum and is highly potent in 
eliciting Fc mediated effector functions and hence is preferred choice while 
designing mAbs meant for eliciting Fc mediated effector functions (Steplewski et al., 
1988). IgG2 and IgG4 do not elicit effector functions and are mainly used for 
blocking the interaction between the receptor and its ligand which is critical for 
tumour cell survival (Carter, 2006). 
1.2.1 mAbs eliciting Fc effector functions 
mAbs which kill target cell by Fc mediated effector functions including CDC, 
ADCC, ADCP and apoptosis are a dominant class of anti-tumour drugs. In CDC, Fc 
domain exerts its function by interacting with C1q protein whereas in ADCC and 
ADCP, Fc domain interacts with different kind of Fc receptors expressed differently 
on immune system cells (Weiner et al., 2010). It is necessary to perform multiple 
assays, for all different mechanisms of action of drug, to ensure that the proper 
functionality of the whole molecule is retained (Noel Rieder, 2010).   
Currently the mAbs in the market that kill the tumour cells by their Fc mediated 
effector functions includes Rituximab, Trastuzumab, Cetuximab etc. (Jiang et al., 





Table 1.1: mAbs eliciting Fc effector functions. 
Generic Name Trade 
Name 








(Mehra et al., 
2008) 
















(Lemery et al., 
2010) 
Arzerra CD20 CLL Genmab/ 
GlaxoSmithKline 
Alemtuzumab 
(Demko et al., 
2008) 
Campath CD52 CLL Genzyme / Bayer 
Ocaratuzumab 
(Cheney et al., 
2014) 






Gazyva CD20 CLL Genentech 
Daratumumab 
(Raedler, 2016) 

















Abbreviations: CLL, chronic lymphocytic leukemia; HNSCC, Head and neck 
squamous cell carcinoma; MCRC, Colorectal cancer; NHL, Non-Hodgkin’s 








Fc receptors are glycoproteins which are members of immunoglobulin superfamily 
(Gessner et al., 1998). Fc receptors fall in the following classes: FcαR, FcδR, FcεR, 
FcγR and FcμR, for different immunoglobulin classes including IgA, IgD, IgE, IgG 
and IgM respectively. Out of these, FcγR are mainly responsible for the monoclonal 
antibody functions (Ravetch, 1997).  
FcγRs are expressed on leucocytes and are further divided into three classes: FcγR I 
(CD 64), FcγR II (CD 32) and FcγR III (CD 16) (Sibéril et al.). There are many cells 
which can express more than one FcγRs and further each FcγR can exhibit 
polymorphism. Nimmerjahn Falk and Ravetch Jeffrey have studied Fc receptor 
structure, all three FcγRs have homologous extracellular domains but differ 
remarkably in their transmembrane and cytoplasmic domains, indicating the fact that 
they have different functional specificities. The transmembrane protein is hetero-
oligomeric (except FcγR IIIb), with a ligand binding chain and a signalling chain. 
The signalling chains have unique immunoreceptor tyrosine-based activation motif 
(ITAM), responsible for activating functions and immunoreceptor tyrosine-based 
inhibitory motif (ITIM), responsible for inhibitory functions (Nimmerjahn and 
Ravetch, 2007). The conserved leucine and tyrosine residues are crucial for FcγR 
mediated signalling (Deo et al., 1997). FcγR I is mainly confined to monocytes and 
neutrophils. FcγR II is further of two types: FcγR II A present on granulocytes, 
monocytes, macrophages and dendritic cells whereas FcγR IIB is present on B cells, 
dendritic cells and basophils. FcγR III comprises of FcγRIIIa and FcγR IIIb. FcγR 
IIIb is present on neutrophils and activates them. FcγRIIIa (CD16a) is mainly present 




Binding of IgG with FcγRs is required to initiate the cell mediated effector functions 
including ADCC and ADCP. The differential binding of FcγRs to the distinct 
subclasses of IgG (IgG1, IgG2 IgG3 and IgG4) leads to differences in the effector 
functions. Broadly, IgG1and IgG3 has better binding affinity to FcγRs than IgG2and 
IgG4 (Wernersson et al., 1999). FcγR I bind with high affinity to IgG, followed by 
FcγR III and then FcγR II, which has the least binding affinity (Bruhns et al., 2009). 
1.2.1.1 Antibody- Dependent Cellular Cytotoxicity (ADCC) 
Among the various mechanisms of action of mAbs, ADCC is one of the most 
important mechanism of action of the antibody, responsible for efficient killing of 
the target cell and most of the antibody drugs, especially the ones for oncology 
targets are based on ADCC as an important and desirable biological activity (Surowy 
et al., 2012). In ADCC, an antibody binds to the target tumour cell and then it binds 
to the effector cell i.e. natural killer (NK) cell. The Fab region of the antibody is 
specific to antigen on target cell and through its Fc region it binds to Fcγ R IIIa or 
CD 16a receptor on the effector cell (Heijnen and van de Winkel, 1997). This 
interaction activates the effector cell leading to the release of molecules in the 
cytotoxic granules such as perforin, granulysin and granyzymes. These cytotoxic 
granules causes the cytotoxicity of the target cells (Jiang et al., 2011a). Figure 1.2 
shows diagrammatic representation of ADCC. 
CD16a shows single nucleotide polymorphism at nucleotide 526 i.e. thymidine to 
guanine. This results in its two allotypic forms which differ by the presence of amino 
acid, Valine or Phenylalanine at 158 position in the polypeptide chain (Wu et al., 
1997). The more commonly occurring form is with Phenylalanine at 158 position 




Valine at 158 position of the polypeptide. So FcγRIIIa,V-158 can elicit better ADCC 
response (Koene et al., 1997).  
 
Figure 1.2: Diagrammatic representation of ADCC. mAb bind to receptor on target 
tumour cell at its Fab region, followed by employing NK cell by binding to FcγRIIIa 
at its Fc region. This interaction triggers NK cells to cause lysis of target cell.  
 
1.2.1.1.1 Natural Killer cells 
Natural Killer cells (NK cells) were discovered in 1970’s (Kiessling et al., 1975). 
These are large granulocytes, taking part in innate immunity. NK cells secrete 
cytokines and cytotoxic granules having perforin and granzymes and thereby kill 
tumour cells and virus infected cells (Topham and Hewitt, 2009). NK cells do not 
kill normal cells of our body which shows expression of MHC-I (Waldhauer and 
Steinle, 2008). NK cells show immediate response as they have IFN-γ pre- stored 




Phenotypically, NK cells are defined by the expression of CD56 and absence of 
CD3. Human NK cells exist in two subsets based on the CD56 antigen cell surface 
density i.e. CD56dim NK cells and CD56bright NK cells. CD56dim NK cells shows 
higher CD16a expression and are more potent in eliciting ADCC response than 
CD56bright NK cells (Cooper et al., 2001). 
1.2.1.1.2 NK cell receptor signalling 
Any immune response is the result of the effects of positive and negative signals. If 
positive signals dominate, immune response is mounted whereas if negative signals 
dominate immune response is perturbed. NK cells activation is a complex process 
requiring co-receptors, inhibitory receptors and the activating receptors (Lanier, 
2003). 
NK cells inhibitory receptors transmit negative signals when they encounter MHC-I 
displayed on the normal self-cells. This prevents NK cells from destroying the 
normal self-cells. The inhibitory receptors have ITIM (immunoreceptor tyrosine-
based inhibition motifs). On ligand binding these ITIM on NK inhibitory receptors 
gets phosphorylated at tyrosine residue and recruit phosphatases through their SH2 
domains. The phosphatases directly or indirectly prevent Ca2+ dependent signalling 
and other signalling proteins including FcεRI, Syk, and ZAP70 etc. (Lanier, 2005). 
On the other hand, NK cells activating receptor utilize adapter proteins like FcεRI-γ 
(Park et al., 1993), CD3ζ (Anderson et al., 1990, Kurosaki et al., 1991) and DAP12 
having ITAM from signalling (Nagarajan et al., 1995b). All CD16a expressing cells 
co-express inhibitory receptor FcγRII b except NK cells, hence they are the key 
players of ADCC. NK cells receptors, including CD16a, bind specifically to a ligand 




receptor tyrosine-based activation motifs (ITAM) (Leibson, 1997)by the Src kinase 
family members. Following this, tyrosine kinases like Syk, ZAP70 are recruited at 
the SH2 domain. This causes recruitment of phosphatidylinositol3-kinase and 
phospholipase C which activates protein kinase C.  These events stimulates Ca2+ 
influx causing degranulation and further downstream signalling (Nimmerjahn and 
Ravetch, 2006).  
1.2.1.1.3 Bioassays available for ADCC 
The conventional ADCC bioassays are based on use of effector cell population in 
human peripheral blood mononuclear cells (PBMCs), which are isolated from the 
blood. These are highly variable because of donor to donor variability (genetic 
reasons and physiological status) and also due to intrinsic polyclonal nature of NK 
cells, raising questions about their effectiveness (Natsume et al., 2008) (Jiang et al., 
2011a, Golay and Introna, 2012). Moreover, the protocol for PBMCs isolation is 
time consuming, tedious and costly (Nilsson et al., 2008). Thus there is a need for 
better assays i.e. the bioassays that possess less inherent variability, more convenient 
to perform and at the same time they should be able to quantify Fc effector 
functions. Currently ADCC bioassay protocols are available in the market, which use 
clonal human NK engineered cell line (Surowy et al., 2012). These may offer 
bioassay solutions having low variability, improved accuracy and precision with low 
background but are highly priced and are not easily available. Therefore, developing 
an ADCC bioassay using engineered cell line holds the potential for minimizing the 




1.2.1.2 Antibody- Dependent Cellular Phagocytosis (ADCP) 
ADCP is one of the primary mechanism of action of mAbs employing macrophages. 
(Montalvao et al., 2013). Macrophages are one of the most prominent effector cells 
which very efficiently eliminate the circulating tumour cells. In ADCP, specific mAb 
binds to its target tumour cell through its Fab portion and then it binds to Fcγ 
receptor on macrophages through its Fc portion. This binding triggers the phagocytic 
pathway in macrophages and they eat up the target tumour cell presented by the 
antibody (Oflazoglu et al., 2007, Oflazoglu et al., 2009, Kinder et al., 2015, Grugan 
et al., 2012). Figure 1.3 shows diagrammatic representation of ADCP.  
  
Figure 1.3: Diagrammatic representation of ADCP. Here mAb first binds to the 
receptor present on the target cell at its Fab region, and then at its Fc region it binds 






Macrophages were discovered by Metchnikoff, who won the Nobel prize for 
describing phagocytosis (Nathan, 2008). Macrophages are the immune cells, a type 
of white blood cells that eat up foreign substances, cellular debris, pathogens and 
other invaders by the process of phagocytosis. They are the large amoeba like cells 
that are derived from monocytes, their precursor cells present in the bone marrow. 
Monocytes move through bloodstream to the damage tissue site where they 
differentiate into macrophages. Macrophages are plastic and depending upon their 
environment can change their phenotypes. They play role in adaptive immunity, 
wound healing and anti-inflammation (Mosser and Edwards, 2008). 
1.2.1.3.1 Macrophage mediated phagocytosis 
Phagocytosis is a kind of endocytosis wherein the phagocyte engulfs larger size 
particles like cellular debris, micro-organisms or even the entire cell. Macrophages 
or monocytes and neutrophils are called “professional” phagocytes as they are very 
efficient in internalizing large particles (Aderem and Underhill, 1999). There are 
numerous receptors present on the surface of the macrophage which by 
physiochemical interactions bind to the antigens directly or through opsonins like 
antibodies or complement proteins. The signalling pathways are activated leading to 
actin polymerization under the site of contact. This causes extension of plasma 
membrane to form the phagosomes which fuse with lysosomes to form 
phagolysosomes. Here the ingested particles are digested and broken down by 




The most common receptor expressed on macrophages are the Fc receptors and 
unlike NK-92 which express only FcγRIIIa, macrophages expresses FcγRI, FcγRIIa, 
FcγRIIIa as well as the inhibitory FcγRIIb receptors (Bournazos et al., 2016).  
1.2.1.3.2 Bioassays available for ADCP  
Bioassays being performed to assess ADCP response of mAbs also uses PBMCs as 
effector cells, where monocytes in PBMCs are allowed to differentiate to 
macrophages before the bioassay is performed (Kinder et al., 2013, Nesspor et al., 
2012, Richards et al., 2008). Consequently, this conventional method suffers from 
the same limitations as described in previous section (section 1.2.1.1.3, Bioassays for 
ADCC) and hence there is a need for better cell based assays. 
1.2.2 Anti VEGF/VEGFR2 drugs 
1.2.2.1 Angiogenesis 
Mammalian cells require oxygen and nutrients to survive and grow. All these 
substrates are supplied to the cells by the blood vessels, which are formed by the 
process of angiogenesis. The term “angiogenesis”  first coined in 1935 to describe 
the formation of new blood vessels in placenta (Hertig, 1935) was later on extended 
to blood vessel formation in tumour growth and wound healing (Fan et al., 2012). 
Angiogenesis is essential for normal physiological conditions such as 
embryogenesis, ovulation and wound repair. It can also take place under pathological 
conditions such as tumour neo-vascularization and retinopathies (Red-Horse et al., 
2007). Angiogenesis is a complex process, regulated by the balance between a 
number of pro-angiogenic and anti-angiogenic factors in a coordinated fashion 
(Risau, 1997). The pro-angiogenic factors mainly include, platelet derived growth 




factor, fibroblast growth factor, platelet derived endothelial cell growth factor, 
angiopoietin-1, angiogenin, transforming growth factor beta-1 (TGF-β1), 
transforming growth factor alpha (TGF-α), and epidermal growth factor (EGF). 
Among them, VEGF is the key regulator of angiogenesis (Ferrara, 2002). 
1.2.2.2 Biology of vascular endothelial growth factor and its receptors 
Vascular endothelial growth factor was discovered in the 1980s (Senger et al., 1983, 
Ferrara and Henzel, 1989).VEGF is unique among other growth regulators of 
angiogenesis in terms of its specificity for the vascular endothelium (Korpelainen 
and Alitalo, 1998). Endothelial cells are the main cells lining the blood vessels and 
capillaries. VEGF stimulates endothelial cells to undergo proliferation, migration, 
tube formation and also acts as an anti-apoptotic factor for endothelial cells (Alon et 
al., 1995, Gerber et al., 1998). 
The VEGF family consists of PLGF (placental growth factor), VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E and snake venom VEGF (sv VEGF). VEGF-A, also 
known as VEGF or vascular permeability factor (VPF), has been shown to play a 
major role in angiogenesis (Ferrara and DavisSmyth, 1997). These growth factors 
exert their effects by binding with high affinity to different transmembrane tyrosine 
kinase receptors (Ferrara et al., 2003). The three main kind of VEGF receptors 
include VEGFR-1 (Flt-1), VEGFR-2 (Flk-1or KDR) and VEGFR-3 (Flt-4). VEGF-
R1 and VEGF-R2 are mainly expressed on the surface of blood endothelial cells 
whereas VEGF-R3 is largely confined to lymphatic endothelial cells (Devries et al., 
1992, Terman et al., 1991, Karkkainen and Petrova, 2000, Aprelikova et al., 1992). 
In addition to these receptors, VEGF also interacts with co-receptors, the neuropilins 




binding affinity of VEGF to its receptors (Soker et al., 1998, Chen et al., 1997, 
Neufeld et al., 2002).  PLGF is selectively expressed in placenta, and VEGF-B bind 
to VEGFR-1 (Park et al., 1994), (Olofsson et al., 1998). In contrast, VEGF-C and 
VEGF-D stimulate lymphangiogenesis and angiogenesis by activating VEGF-R3 
and VEGF-R2 (Joukov et al., 1996, Achen et al., 1998). VEGF-E, present in the 
genome of parapoxvirus ORF virus, binds and activates VEGF-R2 (Ogawa et al., 
1998, Meyer et al., 1999). svVEGF, binds to both VEGF-R1 and VEGF-R2 
(Takahashi et al., 2004). 
VEGF has nine isoforms. VEGF121, VEGF165, VEGF189 and VEGF206 are the more 
common isoforms whereas VEGF145, VEGF148, VEGF162, VEGF165b and VEGF183 
are less frequent forms. The isoforms  are the different heparin binding, 
homodimeric molecular species formed by alternative splicing of mRNA (Tischer et 
al., 1991, Houck et al., 1991, Poltorak et al., 1997, Lange et al., 2003, Whittle et al., 
1999, Takahashi and Shibuya, 2005, Jingjing et al., 1999). All the VEGF isoforms 
have similar biological activity, but differ in their secretion pattern (Houck et al., 
1991, Houck et al., 1992). Amongst all the VEGF isoforms, VEGF 165 is the most 
important and abundant isoform. VEGF binds to both VEGF-R1 and VEGF-R2 and 
also to the co-receptor, neuropilin-1. The binding of VEGF to the VEGFRs, causes 
receptor dimerization, which in turn activates their intrinsic tyrosine kinase activity. 
Although VEGFR1 has higher affinity for VEGF as compared with VEGF-R2, 
VEGFR-2 is the prime receptor responsible for VEGF stimulated proliferation in the 
endothelial cells. This is because, VEGF-R1 exhibits weak receptor tyrosine 
phosphorylation on VEGF activation (Rahimi et al., 2000, Waltenberger et al., 1994, 
Shalaby et al., 1995). VEGF-R2 is responsible for the activation for major signalling 




responsible for endothelial cell proliferation. It also activates stress activated protein 
kinase (SAPK) 2 /p38 which causes endothelial cell migration by cytoskeleton 
remodelling and actin reorganization (Rousseau et al., 1997, Lamalice et al., 2004). 
Figure 1.4 shows schematic representation of VEGFR2 signalling. 
       
Figure 1.4: Schematic representation of VEGF-R2 signalling. VEGF-A binding to 
VEGFR2 causes dimerization of the receptor, followed by intrinsic tyrosine kinase 
activity and VEGF-R2 signal for endothelial cell proliferation, migration, 
permeability and survival by various pathways. 
 
1.2.2.3 Angiogenesis related disorders   
Angiogenesis is crucial for normal physiological conditions such as development, 
reproduction and wound healing. Unregulated and abnormal angiogenesis leads to 
tumorigenesis, age- related macular degeneration (AMD), inflammatory diseases 
such as rheumatoid arthritis, psoriasis, Crohn’s disease and proliferative 




2007, Ferrara and Alitalo, 1999, Carmeliet and Jain, 2000, Ferrara and Kerbel, 
2005). 
Targeting VEGF or its receptors 
Advances in understanding the process of tumour angiogenesis have led to the 
development of various anti-angiogenic therapies. VEGF is the most attractive 
therapeutic target in tumour angiogenesis due to a number of reasons (Yancopoulos 
et al., 2000, Ferrara, 1999, Ferrara, 2004b). VEGF is the key regulator of 
angiogenesis. It acts mainly on endothelial cells, which are relatively stable. 
Various approaches to disrupt VEGF mediated signalling in angiogenesis are being 
investigated (Glade-Bender et al., 2003, Ellis and Hicklin, 2008). The main 
strategies include molecules binding and neutralizing VEGF or VEGF receptors, 
antisense VEGF mRNA or VEGFR mRNA expressing constructs (Im et al., 1999, 
Becker et al., 2002), toxins conjugated to VEGF for targeting the endothelial cells 
(Arora et al., 1999) and the use of ribozymes against VEGF receptors (Weng and 
Usman, 2001). 
Drugs inhibiting VEGF and VEGF receptors 
The most dominant approach to inhibit tumour angiogenesis is to block VEGF. A 
number of VEGF inhibitor drugs are available in the market. They bind to VEGF 
and prevent its interaction with its receptors, thereby reducing endothelial cell 
proliferation and formation of new blood vessels. Once the tumour does not get 
required vascular support, its growth and expansion ceases. The VEGF inhibitors 
largely include antibodies, aptamers and the soluble receptor constructs (Table 1). 
The drugs which have been approved for the treatment of various solid tumours are 




aptamer i.e. Pegaptanib sodium and recently fusion proteins including Aflibercept 
and Ziv –aflibercept have also come up.  
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Abbreviations: AMD, age related macular degeneration; BC, Breast cancer; CRC, Colorectal 
cancer; DME, diabetic macular edema; GBM, glioblastomamultiforme; GEJ, 
gastroesophageal junction; GIST, Gastrointestinal stromal tumour; HCC, Hepatocellular 
carcinoma; IPC, idiopathic pulmonary fibrosis; MTC, medullary thyroid cancer; NSCLC, 





Another approach to block downstream VEGF signalling is to inhibit VEGF 
receptors. The VEGF receptor inhibitors mainly include the small molecule tyrosine 
kinase inhibitors (TKI) and monoclonal antibodies. TKI are capable of targeting 
multiple receptors and can be administered orally. As shown in Table 1.2, the 
various TKI in the market are Sunitinib, Sorafenib, Vandetanib, Axitinib, 
Cabozantinib, Pazopanib and Regorafenib. 
Table1.3. Drugs under clinical development for inhibiting VEGF or VEGF 
receptors. 
Generic Name Type Target Indication Manufacturer 
Apatinib(Mi et al., 
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Abbreviations: BC, Breast cancer; CRC, Colorectal cancer; CRPC, Castration –resistant 
prostate cancer; HCC, Hepatocellular carcinoma; HNSCC, Head and neck squamous cell 
carcinoma; MPM, malignant pleural mesothelioma; NSCLC, Non-small cell lung cancer; 
RCC, renal cell carcinoma.  
 
Global sales of anti-VEGF drugs 
Bevacizumab was the first anti-angiogenic agent to be approved by Food and Drug 
Administration (FDA) for cancer therapy to treat metastatic colorectal cancer on 
February 26, 2004. Since then a number of different categories of anti-VEGF drugs 
have been approved for different pathological conditions (Table 1.2) and many more 
are expected to reach the market soon (Table 1.3). After the approval of 
Bevacizumab, the anti-VEGF drug market has increased tremendously and 
considering the implications of angiogenesis in number of diseases, it is predicted to 
rise further in coming years. The global sales market for ant-VEGF drugs has 




already approved anti-VEGF drugs are estimated to reach $19.976 billion in 2020 
(GEN news, 2013,). (Figure. 1.5) 
       
Figure 1.5: Global sales and forecast for Anti-VEGF drugs.  
1.2.2.4 Bioassays available for anti VEGF drugs 
Bioassays available for anti VEGF drugs are mainly based on animal studies. In vitro 
cell based assays are mainly performed using primary cell lines (Philip E. Thorpe, 











Table 1.3: Angiogenesis bioassays. 
S. No Angiogenesis Bioassays 
In vivo Bioassays 
1 Chick chorioallantoic membrane(CAM) assay 
2 Corneal angiogenesis assay 
3 Hindlimb ischemia assay 
4 Chamber assays 
5. Matrigel plug assay 
Ex vivo (Organ culture)assays 
1. Aortic ring assay 
2. Porcine carotid artery assay 
3. Chick aortic arch assay 
In vitro assays 
1. Endothelial cell proliferation assay 
2. Endothelial cell migration assay 
3. Endothelial cell tube formation assay 
In vivo assays 
The in vivo animal study uses an animal model to compare changes in biological 
responses, on application of the drug. The in vivo bioassay facilitates understanding 
of the full regulation of the angiogenic process, which involves a number of co-
ordinately and spatially regulated steps. The effect of regulators on different cell 
types, involved in the process can be examined. Most commonly used bioassays are 
mentioned below: 
 
Chick Chorioallantoic membrane (CAM) assay 
The chick chorioallantoic assay is used to study tumour angiogenesis. 
Chorioallantoic membrane (CAM) functions as a respiratory tissue in the chick 
embryo. It is highly angiogenic until day eleven and is suitable for studying 




egg shell of seven-nine days pre-incubated eggs and the test substance is then placed 
on the extra embryonic membrane. After the re-incubation of eggs, grafts are 
recovered and the extent of angiogenesis is determined by image analysis (Brooks et 
al., 1999, Nguyen et al., 1994). CAM assay is relatively inexpensive and easy to 
carry out. However, it cannot score as a properly validated assay due to the use of 
CAM which is highly sensitive and undergoes rapid morphological changes. 
Moreover, there are concerns raised earlier about using a non-mammalian, avian 
system (Jain et al., 1997). 
 
Corneal angiogenesis assay 
Originally this assay was developed for rabbit eyes, but now it is more frequently 
used in mice (Gimbrone et al., 1972).  For carrying out the assay, a pocket is 
surgically created in the cornea. Uniform pellets of the test substance are prepared by 
mixing it with a stabilizer and a slow release polymer (Rogers et al., 2007). This 
pellet is then inserted into the micro pocket. The new vascular response from limbal 
vasculature is then monitored and quantified by fluorescence techniques or by 
measuring the area of vessel penetration. Figure 1.6 shows the diagrammatic 
representation of the assay. The cornea being avascular, is an ideal model for 
studying in vivo angiogenesis (Ziche, 2001). 
Considerable advantages of the assay include the absence of any vascular 
background in the cornea and its adaptation for use in mice. The assay suffers from 
the limitations of surgical processes. Moreover, inflammation risks are also common 





Figure 1.6:  Schematic representation of corneal angiogenesis assay: Schematic 
structure of an eye (B) and (C).Creation of a micropocket by making an incision in 
the cornea. (D) Insertion of pellet in micropocket (E) release of angiogenic factors 
from pellet (F) leads to new vessel growth from the limbus.  
 
 
Hindlimb ischemia assay 
Angiogenesis regulators can be evaluated in rabbit or mouse model of hindlimb 
ischemia. Hindlimb ischemia assay is based on the haemodynamic changes 
responsible for the formation of new blood vessels. In this assay, an incision is made 
in the skin overlying the middle portion of the hind limb of the anaesthetized test 
animal. This is followed by tying of proximal end of femoral artery and the distal 
end of the saphenous artery and then cutting their side branches. Blood flow can be 
observed at the ischemic distal location and vascular outcome is assessed mainly by 
capillary density, laser Doppler blood perfusion imaging, Tarlov and ischemia scores 






Chamber assays are designed for continuous monitoring of angiogenesis in 
transparent chambers containing chronic tissues. The various chamber assays are 
dorsal skinfold chamber, rabbit ear chamber and the cranial window chamber. In 
these assays tissue is removed from the anesthetised animal and test preparations are 
placed on the exposed surface. It is then covered with glass. Quantification involves 
microscopy and image analysis (Jain et al., 1997, Dellian et al., 1996, Gerlowski and 
Jain, 1986). Such assays allow one to study physiological effects like blood flow 
perturbations but the surgical methods involved make these assays technically 
difficult to perform. 
 
Matrigel plug assay 
Matrigel is the laminin rich extract secreted by the EHS (Engelbreth-Holm-Swarm) 
mice sarcoma cells. It is liquid at 4C and solidifies at 37C. The assay is carried out 
by subcutaneously injecting the matrigel, which contains the test substance into the 
animal model. The injection of foreign substance in the animal stimulates 
angiogenesis. Matrigel solidifies to form a plug which can be recovered after 7-21 
days. Matrigel is avascular when injected and hence, after recovery, newly recruited 
vessels can be easily distinguished. Angiogenic response can be assessed by 
measuring haemoglobin in the plug or can be examined histologically. For this 
assay, mice are the most commonly used animal model (Hasan et al., 2004). 
The assay is rapid and easy to perform. Disadvantages include quantification, 
although new methods of evaluation like using reverse transcription- quantitative 





Ex vivo (Organ culture assays) 
The idea behind organ culture assays is to bridge the gap between in vivo and in vitro 
assays. The in vitro assays cannot recapitulate the full process of angiogenesis which 
involves not only the endothelial cells but also complex interactions with the 
surrounding cells. The in vivo assays depict the entire regulation of the neo-
vascularization. However, sometimes it becomes difficult to distinguish between the 
autocrine and the paracrine responses.  
 
Aortic ring assay 
The aortic ring assay was first developed in rats (Nicosia and Ottinetti, 1990), but 
now it has also been adapted to mouse (Aplin et al., 2008). This assay involves 
isolation of the mouse thoracic aorta, followed by culturing of rings of aorta in serum 
free media in three dimensional collagen gels. The injury due to dissection procedure 
will give rise to new microvessel network of branched endothelial channels. Test 
substances are added to analyse their effect on the process. The abundance and 
lengths of these new vessels is assessed by image analysis softwares (Baker et al., 
2012, Masson et al., 2002). Figure 1.7 shows the schematic representation of the 
aortic ring assay. 
The advantage of aortic ring assay is that it is a more physiologically relevant assay 
and can be carried out in serum free media. Nevertheless, aorta is not an ideal choice 
because angiogenesis is mainly a microvascular event. Other disadvantages include 






Figure 1.7:  Schematic representation of Aortic ring assay (A) Schematic diagram of 
heart with aortic arch (B) aortic ring in collagen gel with test substances in serum 
free medium (C) new vessel growth from aortic ring.  
 
Porcine carotid artery assay 
Porcine carotid artery assay is the modification of aortic ring assay. This assay 
utilizes the porcine carotid artery. Porcine arteries are a better source as they are 
more closely related to human vasculature, readily available and can be easily 
handled. A number of tests can be run from a single carotid artery thereby decreasing 
the statistical variations. Drawback is the use of a single donor that would not be a 





Chick aortic arch assay 
Chick aortic arch assay is also the modification of aortic ring assay. For this assay, 
aortic arches are removed from the 12-14 days old chick embryo, cut into rings and 
then transferred to the Matrigel. Substantial microvascular growth is observed within 
48 hours. In both the assays quantification can be performed by using fluorescence 
labelled lectins or by staining with CD31 labelled antibodies (Oh et al., 2008). 
It is more rapid than the aortic arch assay. Embryonic arch resembles microvascular 
endothelial cells more closely than the mouse aorta. However, a growing embryo 
involves rapidly proliferating cell populations (Muthukkaruppan et al., 2000). In 
addition to these, other new ex vivo assays are being reported for testing the anti-
angiogenic drugs (Rezzola et al., 2013).  
In vitro assays 
The endothelial cells are the choice of cells for studying VEGF pathways because 
VEGF is specific to endothelial cells. During the angiogenesis cascade, in the 
presence of VEGF and other growth regulators, endothelial cells undergo cell 
proliferation, migration, differentiation and finally apoptosis. These particular 
cellular events can be assessed in vitro. Figure 1.8 shows schematic representation 
of the in vitro assays. Researchers have isolated and cultured different endothelial 
cells for in vitro studies of angiogenesis, including Human Micro Vascular 
Endothelial Cells (HMVEC) (Petzelbauer et al., 1993), Human Coronary artery 
Endothelial cells (HCAEC), Human Aortic Endothelial Cells, Human placental 
endothelial cells (HPEC) (Schutz and Friedl, 1996), Human Umbilical Vein 
Endothelial cells (HUVEC) (Jaffe et al., 1972) etc. Among the various endothelial 




available from the discarded umbilical cords and can be efficiently isolated (Ganguly 
et al., 2012). HUVECS can be cultured for maximum of ten serial passages. 
Various commercially available kits are available in the market for endothelial cell 
proliferation, endothelial cell migration and endothelial tube formation assays.  
 
Figure 1.8:  Schematic representation of in vitro angiogenesis assays (A) 
Endothelial cell proliferation (B) Endothelial tube formation and (C) Endothelial cell 
migration.  
 
Endothelial cell proliferation assay 
Endothelial cells when established in culture are capable of undergoing cell division 
and proliferation. There are numerous endothelial cell proliferation assays. In this 
assay, a specific number of endothelial cells are seeded followed by the addition of 
an angiogenesis regulator. After incubation at 37C in CO2 for a certain time, effect 
of the test substance on the endothelial cells is determined by measuring the number 




dimethyltetrazolium bromide) (MTT) assay, 2H-Tetrazolium,5-[3-
(carboxymethyl)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-(4-sulfophenyl)-2-(4-
sulfophenyl)-,innersalt (MTS) assay; fluorimetry based assays  like Alamar 
blue(O'Brien et al., 2000) and CyQUANT, and  luminescence assays. Cell cycle 
analysis can be done by 5-bromo-2’-deoxyuridine (BrdU) colorimetric assay (Gomez 
and Reich, 2003).  
Endothelial cell proliferation can be precisely quantitated, rapid and is easy to 
perform. 
Endothelial cell migration assay 
During angiogenesis, endothelial cells degrade basement membrane and 
directionally migrate towards the chemical gradient established by angiogenic 
factors (Lamalice et al., 2007). Cell migration assay is use to study the endothelial 
cells migratory response (Albini et al., 2004, Smith et al., 2004, Boyden, 1962, 
Mastyugin et al., 2004, Valster et al., 2005). In the assay, endothelial cells are placed 
over a layer and allowed to migrate to the attractants kept at lower layer through a 
filter that allows passage of cells. Although, it is rapid and highly sensitive assay, it 
is technically difficult to carry out.  
Endothelial Cell Tube Formation Assay 
Tube formation assay exploits the ability of the endothelial cells to form capillary 
tube like structures during angiogenesis (Kubota et al., 1988). Endothelial cells 
specifically forms capillary like tubes, when plated on basement membrane matrix 
such as collagen or matrigel. The extend of tube formation can be quantified by 




such as Image J software. It is one of the most widely used first screen assays for 
various angiogenic and anti-angiogenic agents. It is quantitative, rapid, easy to 
perform and measures multiple steps of angiogenesis including cell adhesion, cell 
migration, alignment, and tube formation (Arnaoutova et al., 2009) (Guidolin and 
Albertin, 2012). 
The above mentioned assays are used in combination to assess the anti 
VEGF/VEGFR2 drug potency but they are not suitable for QC setup, so there is a 
huge requirement for cell based assays. 
1.3 Developing the Bioassays  
1.3.1 Bioassay optimization 
Development and standardization of any bioassay requires detailed scientific 
insights. For developing and standardizing the bioassay, following parameters would 
need to be optimized: 
Culture conditions for the cell line: Once there is a suitable cell line for the assay, 
culture conditions i.e.  passage number, cell densities for culturing, number of days 
in culture before splitting, incubation conditions etc. should be optimized such that 
they give best results for the assay.  
Bioassay media: All the critical reagents must be identified. Serum percentage in 
the bioassay sample is especially important. 
Seeding density of cells in the assay: Cell number is used as a source of assay 
readout. Cell number per well giving maximum signal, after the incubation time, 




 Working Range: For the determination of working range of the drug which shows 
gradation, wide range should be analysed. Antibody concentrations falling on the 
linear part of the slope of dose response curve would be selected as the working 
range.  
 Incubation time: Standardization of incubation time in the assay includes starvation 
time, cells incubation with the assay reagents etc. Incubation time that accounts for 
maximum response and minimum background should be selected.  
Measurement of cellular activity: The method to measure the output that is most 
quantitative, needs to be optimized. 
Standard Curve: Standard curve should be such that linear part of the curve has 
maximum points while saturation at both the ends of the curve should also be 
presented. 
Controls: As in any other experiment, controls are essential. Bioassay should have 
all the required positive and negative controls. 
Thus lot of fine-tunings are required to reach the final design. 
Data Analysis: For the analysis of data, various statistical tools and properly 
validated software such as PLA 2.0 should be used.  
1.3.2 Bioassay validation: Definition and terms 
It is important to establish a validated assay which is in compliance with guidelines 
established by the FDA and other regulatory agencies. Validation exhibits that an 
assay is right for its desired effect. The approaches that would be evaluated includes 
accuracy, precision, specificity, linearity, range and robustness etc. (Noel Rieder, 






Figure 1.9: Schematic representation of the validation parameters 
 
Accuracy: Accuracy is the measure of the closeness of the measured value to the 
real value. Experiments are carried out in the replicates of two, three or more. 
Bioassays should be accurate as drug product specifications are based on it. 
Specificity: Specificity is the tendency to detect the test compound in the presence 
of interfering matrix and product components. Validation studies should include 
experiments to check the specificity of the drug demonstrating that the assay is 
specific to the drug. 
Precision: Precision is the measure of the closeness of individual measure of sample 
when the test is repeated again and again. Precision includes repeatability, 
reproducibility and intermediate precision. It is mainly calculated in terms of 
standard deviation and coefficient of variance. For determining all these, bioassay 
needs to be carried out in different 96-well plates, in different labs and at different 
time points i.e. intra run and inter run influencing factors are assessed. Such 
variations introduced in the assay should not affect the activity of the drug. The 
results would then demonstrate precision. 
Robustness: Robustness measures assay ability to be unaffected of the small, 
intended changes made in the assay procedures like altering incubation time, 




Acceptance Criteria: After the bioassay standardization, some minimum 
acceptance criteria should be established.  
Bioassay layout is also important factor and should be designed in such a manner 
that there are minimum variations. Mainly the wells of microtitre plate at the edges 
are subjected to maximum variations (edge effect), so these wells can be excluded 
while designing the layout. There should be randomization of sample positions all 
over the plate to avoid the internal plate variations. Thus the properly designed 
experiment based on statistically relevant methods would ensure that quality is built 
in and would help to meet the same specifications at any given time. 
1.4 Project Overview 
1.4.1 Rationale  
Research is picking up for the development of new bioassays for various 
biopharmaceuticals. Bioassays determine the potency of a biopharmaceutical by 
comparing its biological response which is reflective of mechanism of action, with 
that of the standard or control preparation. For all the biopharmaceuticals, bioassays 
are mandatory for their regulatory submission and lot release. QC set up requires a 
bioassay which is relevant, reproducible, robust, simple to emulate and economical 
in terms of time and resources. In vivo bioassays based on animal studies accounts 
for complex inter-cellular and inter-tissue effects but it is not possible to use in vivo 
methods for routine analysis because they are expensive, time consuming, labour 
intensive, accounts for lot of variations and have ethical issues. The solution could 
be a cell based in vitro bioassay that uses a specified cell system, which on addition 




of action of the drug. These in vitro bioassays are able to yield statistically robust 
data, are convenient, cost-effective and can be performed quickly.  
The development of ADCC and ADCP bioassays using engineered cell line with CD 
16a receptors and other co factors can replace costly ADCC and ADCP bioassay kits 
available in the market, as wells as use of conventional ADCC and ADCP bioassays 
using human PBMCs. This assay can be used to assess the functionality of mAbs 
such as Rituximab, Cetuximab, Trastuzumab etc. which have Fc mediated effector 
function as their mechanism of action. 
 The engineering of endothelial cell line with VEGFR2 receptor, which can 
proliferate in presence of VEGF, would lead to development of cell based bioassay 
for anti VEGF/VEGFR2 drugs such as monoclonal antibody- Bevacizumab, 
Ramucirumab, Ranibizumab, Aflibercept etc. This cell based bioassay can replace 
the existing cell based bioassays performed using primary cell line i.e. HUVEC cell 
line and can also replace animal studies. 
1.4.2 Research Questions 
Can robust, reproducible and convenient cell based bioassays be developed to 
expedite drug discovery and development for the following category of drugs? 
a. Anti-VEGF/VEGFR2 drugs – circumventing the requirement for animal studies 
and primary cells based assays and 
b.  Anti-cancer mAbs with Fc effector functions – bypassing the need for 





The hypothesis that in-house cell based bioassays replace conventional assays and 
the costly kit based assays, was addressed by pursuing the following aims. 
1.4.3 Aims and Methodology 
 Engineering CHOKISV GS-KO cell line with CD16a receptor and using it to 
develop CD16a receptor binding assay as a surrogate ADCC assay. 
 Verifying phagocytic response of CD16a expressing CHOKISV GS-KO cell 
line and developing ADCP bioassay. 
 Engineering CHOKISV GS-KO cell line with VEGFR2 receptor and using it 
to develop VEGFR2 receptor binding assay for antiVEGFR2 drugs. 
 Engineering Ea.hy926 cell line with VEGFR2 receptor and using it to develop 
cell proliferation inhibition bioassay for anti-VEGF drugs. 
The study work has been discussed in the following chapters: 
Chapter two - Materials and methods, assembles all the methodologies used in the 
study. 
Chapter three – CD16a receptor binding assay, reports the work done to engineer 
CHOKISV GS-KO cell line with CD16a receptor as well as development and 
validation of CD16a receptor binding assay for Trastuzumab, using the engineered 
cell line. 
Chapter four – VEGFR2 receptor binding assay, focuses on the study carried out to 
engineer CHOKISV GS-KO cell line with VEGFR2 receptor and employing it to 




Chapter five – EA.hy926 cell proliferation inhibition assay, illustrates the attempts 
made to transfect EA.hy926 cell line and developing cell proliferation assay for 
Bevacizumab. 
Chapter Six – ADCP bioassay, investigates phagocytic activity of CD16a 
expressing CHOKISV GS-KO cell line to develop ADCP assay for Rituximab. 


















2 Materials and Methods 
 
In this study, CHOKISV GS-KO and EA.hy926 cell lines were engineered with 
receptors and bioassays were developed for the mAbs eliciting Fc mediated effector 
functions and anti VEGF/VEGFR2 drugs. Receptor genes were cloned in the vectors 
and transfected in the desired cell lines so that they can be expressed on the cell line. 
After the receptor expression was confirmed on the cell line, cell based bioassays for 
different drugs were optimized using these engineered cell line. In this chapter all the 
methods and protocols have been described, and all the materials that were used for 
the study are listed in detail (Section 2.5). 
2.1 Methods for cloning the CD16a and VEGFR2 receptors in the 
vectors 
Various molecular biology techniques were used to clone receptors encoding genes 
in different vectors. 
2.1.1  Agarose gel electrophoresis 
Agarose gel electrophoresis is done to estimate the length of DNA or RNA 
fragments. An electric field is applied and negatively charged nucleic acid molecules 
are made to pass through agarose matrix, where they get separated based on their 
sizes ranging from 100bp to 25kb (Lee et al., 2012). Smaller molecules move faster 
and farther as compared to the longer ones.  For preparing the agarose gel, specific 
percentage of agarose solution was made in 1X TBE buffer (45mM Tris borate and 
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1mM EDTA). 0.8% agarose gel was prepared for separating DNA molecules of 
more than 3Kb size and 1.2% agarose gel for separating DNA molecules less than 
3Kb size. The solution was boiled in microwave oven, until it became clear. 
Ethidium bromide (EtBr) was added to the gel solution (0.5-1μg/ml) once it cooled 
down. EtBr is a DNA intercalating dye which stains DNA so that it becomes visible 
under UV light. The gel solution was poured in the gel tray and comb was inserted. 
After the gel solidified, comb was removed to form the wells. The gel, together with 
the tray was put in the electrophoresis unit. 1X TBE was poured in the 
electrophoresis unit such that the gel is completely immersed in TBE, and that the 
wells are at the negative terminal (cathode). DNA or RNA samples were mixed with 
6X orange dye (Sigma) and were loaded in the wells. A commercial ladder or 
standard DNA size marker (NEB 100bp or 1Kb) was also loaded along with the 
experimental samples to accurately estimate their size. The current was allowed to 
pass through the gel for duration of 30-40 min at 100 volts. The gel was observed 
under UV transilluminator and image was captured. 
2.1.2 Restriction enzyme digestion 
Restriction enzymes are naturally occurring enzymes that cleave DNA sequences at 
specific sites. Gene and the plasmid are digested with specific restriction enzymes to 
make the ends of DNA compatible so that it can be ligated with selected plasmid for 
directional or non-directional cloning (Pingoud et al., 2005). DNA can be digested 
with one or two restriction enzyme depending on the planned cloning strategy. 
Different restriction enzymes have specific requirements for the restriction digestion 
reactions. NEB restriction enzymes were used and reaction conditions mentioned in 
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the manual were followed. Generalized reaction conditions for digesting 1μg DNA 
are mentioned in the Table2.1. The reactions were set up at 37°C for 2 h.  
Table 2.1: Restriction enzyme digestion reaction mixture setup. 
 
Reagents Volume  
( µl) 
Restriction enzyme 0.2 
Buffer(10X) 5 
BSA (10X) (optional) 5 
DNA 5 
Sterile M.Q. 35 
Total Volume 50 
 
2.1.3 Ligation of DNA fragments 
BacteriophageT4 have DNA ligase enzyme which covalently joins cohesive or blunt 
ends of double stranded DNA in the presence of ATP (Ellenberger and Tomkinson, 
2008). In the lab, matching sticky ends or cohesive ends created by restriction 
enzyme digestion were ligated by DNA ligase to join insert and vector during 
molecular cloning.  50 ng of vector was added to a threefold molar excess of insert. 
Then after, 1μl of Ligation Buffer and 1 μl T4 DNA Ligase were added. The volume 
was adjusted to 10 μl with Milli-Q water. It was briefly centrifuged and incubated at 
16°C for overnight. It was stored at -20°C till it was used for transformation. 
 
 




Transformation is the process in which foreign DNA generally a plasmid, is 
transferred in the bacterial cell causing alterations in the genetic makeup of the 
recipient bacterial cell. It was first reported in 1928 by Griffith in Streptococcus 
pneumoniae. Usually strains of Escherichia coli (E.coli) are used for transformation. 
The competent cells which were stored at -80°C were allowed to thaw on ice for five 
min. The ligation mixture of the vector and the insert were added to the competent 
cells and tapped gently to assure uniform mixing. This was kept on ice for 10 min, 
after that the cells were given heat shock at 42°C for 90 s. The cells were then 
quickly placed on ice for 10 min. About 900µl of Luria Bertani (LB) medium was 
added to the mix. The cells were then incubated at 37°C, 200 rpm for 1 h followed 
by centrifugation at 5,000 rpm for 5 min (Froger and Hall, 2007). About 800µl of the 
supernatant was removed and the pellet was resuspended with the remaining 200µl 
of the supernatant. This was plated on a nutrient agar plate containing specific 
antibiotic and incubated overnight at 37°C. Next morning bacterial colonies were 
formed from single transformed cells. These bacterial colonies were further 
confirmed by colony PCR and the positive colonies were inoculated in 5ml LB broth 
with the specific antibiotic for plasmid purification. 
2.1.5 Preparation of competent cells 
The prerequisite of bacterial cells to internalize foreign DNA from its surrounding 
environment during transformation is that their cell wall should be altered such that 
DNA can easily pass through. Such cells are the competent cells. Competent cells 
were prepared by calcium chloride treatment (Green and Rogers, 2013). XL1-Blue 
strain of E.coli was streaked on LB-tetracyclin (20μg/ml) plate and incubated at 
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37°C for overnight. A single colony was inoculated in 5ml LB broth containing 
tetracycline (20μg/ml) and incubated at 37°C, 200 rpm for overnight. From the 
overnight culture 1% inoculum was taken and subcultured in 100ml LB at 37°C 
shaker with constant shaking (200 rpm). The O.D (600nm) was checked every 1h 
until it reached 0.4-0.6 so that E.coli were in their exponential growth phase. The 
culture was kept on ice for 30min for arresting the growth of bacteria. This was 
followed by centrifugation at 4,000 rpm at 4°C for 15min. The supernatant was 
discarded and 20ml of buffer TFB1 (CH3COOK (30mM), RbCl (10mM), 
CaCl2.2H2O (100mM), MnCl2.4H2O (50mM)) was added to the pellet and kept on 
ice for 45min. The culture was again centrifuged at 4,000 rpm at 4°C for 15min. The 
supernatant was discarded and the pellet was gently resuspended in Buffer TFB2 
[(MOPS (10mM), CaCl2.2H2O (75mM), RbCl (10mM), Glycerol (15% v/v)] and the 
culture was aliquot into the pre-chilled Eppendorf tubes. The competent cells were 
snap frozen in liquid N2 and stored at -80°C.  
2.1.6 Plasmid DNA isolation-In house method 
Plasmids were purified by alkaline lysis extraction method where bacterial cell wall 
and cell membrane is made to lyse in presence of alkaline lysis buffer and genomic 
DNA is denatured (Bimboim and Doly, 1979). This is followed by the neutralization 
and precipitation of cellular debris and then it is bound to a resin. Plasmid DNA is 
washed and concentrated with ethanol and finally eluted. In the lab, bacterial 
cultures containing plasmid of interest were inoculated for plasmid DNA isolation. 
After overnight incubation at 37C, 2,000 rpm, bacterial culture were pelleted and 
processed for plasmid isolation. Pellets were resuspended in 150μl of resuspension 
solution (50mM Tris base, 10mM EDTA) and 150μl of lysis solution (0.03M SDS, 
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0.2M NaOH) was added to it. After mixing by inverting, 250μl of neutralizing 
solution (2.5 M CH3COOK, 4.7M Glacial acetic acid) was added and it was 
centrifuged at high speed (13,000 rpm). Clear supernatant was collected and added 
to tube containing 600μl of 6M GuCl. This mixture was loaded onto in house 
prepared diatomaceous earth column. Vacuum was applied and the column was 
washed with 70% ethanol. Plasmid DNA was eluted in 50µl sterile Milli-Q water. 
Estimation of DNA concentration was done using the NanoDrop Spectrophotometer 
(UV Spectrophotometry). 
  
2.1.7 Gel Extraction 
Gel extraction is a technique to isolate and purify desired DNA from agarose gel 
after agarose gel electrophoresis. Gel extractions were done using Qiagen kit.  The 
DNA fragment was excised from the agarose gel with a clean, sharp scalpel. The 
weight of the agarose gel slice was checked in a pre-weighed micro centrifuge tube. 
Three volumes of Buffer QG was added to 1 volume of the gel and incubated in 
water bath set at 50°C for 10 min, to melt the gel slice. Then 1 volume of absolute 
isopropanol (IPA) was added and mixed well. The sample was applied to QIAquick 
column and centrifuged (13,000 rpm for 1 min). The flow-through was discarded 
and QIAquick column was washed with 0.75 ml of Buffer PE by centrifuging for 1 
min. Again flow-through was discarded and QIAquick column was placed into a 
clean 1.5 ml microcentrifuge tube and eluted in 20µl of sterile Milli-Q water. The 
DNA concentration was estimated using the NanoDrop Spectrophotometer.  
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2.1.8 Glycerol Stock preparation 
Glycerol stocks of the bacterial cultures having DNA of interest were prepared for 
long term storage. Glycerol acts as a cryoprotectant and brings about depression in 
freezing point of the bacterial cells and thus enhances supercooling (Howard, 1956). 
A plate was streaked to have a single colony of desired plasmid harbouring bacteria 
and incubated at 37°C for overnight. The colony was inoculated in 5 ml appropriate 
antibiotic media for overnight to have stationary phase culture. 4 ml of the overnight 
grown culture was mixed with 0.8g glycerol and 2 ml was aliquot as glycerol stock 
in screw cap tube with appropriate label. The vials were transferred to -80°C 
refrigerator. The vial locations and clone details were noted down. 
2.1.9 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a molecular biology technique to amplify 
the DNA of interest and also to modify the DNA. It was developed by Nobel 
Laureate Kary Mullis in 1983 (Mullis et al., 1986). The heat stable Taq DNA 
polymerase enzyme isolated from heat tolerant bacterium Thermus aquaticus 
synthesizes DNA in presence DNA template strand, primer, nucleotides and other 
enzyme cofactors when subjected to repeated cooling and heating cycles. The main 
steps include template strand denaturation to separate double strands, annealing of 
primers and extension of the newly synthesized strand by Taq DNA polymerase. At 
the end of 30 cycles, billions of copies of DNA are obtained. Various PCR programs 
were carried out in the lab for different purposes. 
2.1.9.1 Amplification PCR 
A DNA sequence of interest was amplified by amplification PCR program. PCR 
reaction setup and cycling conditions are summarized in Table 2.2. 




Table 2.2: Amplification PCR conditions. 
Reaction Mixture  Thermal cycling conditions 
Reagents Volume  
( µl) 
 Temperature Time No. of 
cycles 
Template DNA 1  95 C 2 min 1  
Forward Primer 1  94 C 30 s   
Reverse Primer 1  55C 30 s 30 
DNA polymerase 
enzyme 
0.2  72 C 30-60 s  
Buffer 5  72 C 10 min 1 
Sterile M.Q. 41.8  4 C hold  
Total Volume 50     
 
2.1.9.2 Overlap PCR 
Overlap PCR is generally done to carry out site directed mutagenesis. Here in this 
study overlap PCR was done to silent a specific restriction site in a gene which was 
required for further cloning the gene in a particular vector. Forward and reverse 
primer sets with required silent restriction enzyme site were designed using Gene 
design and Vector NTI software. Amplification PCR was done to create two 
overlapping fragments having nucleotide substitution for silencing the restriction 
enzyme site. These two fragments were then used as template for overlap PCR. Their 
overlapping strands having substituted nucleotide hybridized and flanking primers 
were used to generate full length gene with silent restriction enzyme site. PCR 
conditions would be same as amplification PCR. Overlap PCR was done for 
silencing Sal I site in CD16a and FcεRI-γ genes. 
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2.1.9.3 Touchdown PCR 
Touchdown PCR is carried out to increase the specificity and the yield when primer 
sets are not very compatible. In a PCR, annealing temperature would depends upon 
the melting temperature (Tm) of the primer and template pair and should be 
optimum. If annealing temperature is too high it causes primer dimer formation and 
hence nonspecific amplifications. On the other hand, at too low annealing 
temperature primer would not anneal to template and yield would be low. So in the 
touchdown PCR, initial cycles have higher temperature than Tm, to ensure 
specificity and then in later cycles temperature is gradually decreased to prevent the 
lower yields. Touchdown PCR was done to amplify VEGFR2 gene from human 
cDNA library. Protocol is summarized in the Table 2.3. 
Table 2.3: Touchdown PCR conditions. 
 
Reaction Mixture  Thermal cycling conditions 
Reagents Volume 
( µl) 
 Temperature Time No. of 
cycles 
Template DNA 1  95 C 2 min 1 




Decrease 0.5oC      
per cycle 
30 s 14 
Pfu native DNA   
Polymerase enzyme 0.5  72 C 6 min  
10X Pfu Native 
Buffer 5  95 C 30 s  
10mM dNTPs 3  54.2 C 30 s 19 
Sterile M.Q. 37.5  72 C 6 min  
   72 C 10 min 1 
Total Volume 50  4 C hold  
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2.1.9.4 Colony PCR 
Colony PCR was carried out for screening the bacterial colonies after transformation 
for the presence or absence of specific DNA of interest with the plasmids. A reaction 
mixture was prepared containing 2X master mix, primers (forward primer and 
reverse primer) and Milli Q water. 20µL of the above prepared reaction mixture was 
aliquoted into 0.2mL pre labelled PCR tubes. Inside the Laminar hood, each 
bacterial colony was aliquoted into respective PCR tubes and also master plate was 
also prepared by streaking colony on to LB agar plate containing respective 
antibiotic. Then set up Colony PCR as per the PCR program in the Table 2.4. 
Table 2.4 Colony PCR conditions. 
 
2.1.9.5 Sequencing PCR 
DNA sequencing is carried out to know the precise order of nucleotides in a strand 
of DNA. It is based on Sanger sequencing or chain termination method. Here a 
single strand of DNA is synthesized in presence of a DNA template strand, a primer, 
DNA polymerase enzyme, deoxynucleosidetriphosphates and fluorescently labelled 
dideoxynucleosidetriphosphates which terminate the DNA strand elongation at 
3’end. The terminated DNA fragments differing by single base pair are separated by 
Reaction Mixture  Thermal cycling conditions 
Reagents Volume  
( µl) 
 Temperature Time No. of 
cycles Econotaq master 
mix 
10  95 C 2 min 1  
Forward Primer 1  94 C 30 s   
Reverse Primer 1  55C 30 s 30 
Sterile M.Q. 8  72 C 30-60 s  
Total Volume 20  72 C 10 min 1 
   4 C hold  
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capillary electrophoresis and fluorescence is translated into chromatograms and 
sequence is inferred by software. In the lab, sequencing reaction was setup by 
Applied Biosystem sequencing Kit. Sequencing PCR conditions are summarized in 
the Table2.5. 




Thermal cycling conditions 
Reagents Volume  
( µl) 
 Temperature Time No. of 
cycles Sequencing Buffer 1  95 C 2 min 1  
BDT mix 1  94 C 10 s  
Plasmid 2(300ng)  50 C 5 s 25 
Forward/Reverse 
Primer 
1  60 C 4 min  
Total Volume 5  4 C hold  
 
 
The Sequencing PCR product was then cleaned, to remove the salts and extra unused 
ddNTPs, dNTPs and primer, before sequencing. 
2.1.10  Sequencing reaction cleanup  
After sequencing PCR, the sequencing extension products are purified from 
sequencing reaction mixture containing Big dye terminator, primers etc. by reaction 
cleanup. The sequencing reaction cleanup was done by using Millipore SEQ96 
cleanup kit. After the sequencing reactions were set up and the samples were 
amplified using an appropriate thermal cycling program, the samples were diluted by 
adding 30µl of Injection solution and transferred to SEQ96 plate wells and placed on 
the vacuum manifolds. The vacuum was applied until the solution was completely 
removed from the wells. The excess liquid was wiped from the bottom of the SEQ96 
plate. For washing, 30µl of injection solution was again added to the sample wells 
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and vacuum dried. Finally the purified sequencing products were resuspended in 
30µl of injection solution and transferred to an injection plate for loading in ABI 
Prism 3100 Genetic Analyzer. 
Sequencing data analysis 
The raw sequences were aligned with the reference standard sequences by using 
Clustal W multiple sequence alignment and CAP3 softwares. 
2.2   Methods for engineering the cell line with the receptors 
Cloned receptors were transfected in suitable cell line, followed by selection of 
higher receptor expressing cell line. Various cell culture methodologies that were 
routinely employed in the study are detailed below. 
2.2.1 Revival of a cell line 
Cell revival is routinely carried out by thawing the cryopreserved cells. The frozen 
culture vial was removed from liquid nitrogen and thawed in a water bath set at 
37C. The cell suspension was transferred in complete growth medium. Cells were 
pelleted at 1,000 rpm for 5 min. Cell count was performed by Trypan blue dye 
exclusion method. The cell viability should be more than 80% at the time of revival. 
The cells were seeded as per the seeding density of the cell line in the appropriate 
treated /non-treated Tissue culture flask for suspension or the adherent cell line. The 
tissue culture flask was incubated at 37C, 5% CO2, humidified chamber and 
observed daily under inverted microscope for cell growth, viability and absence of 
any microbial contamination. 
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2.2.2 Subculture of cells 
After few days in culture, cells proliferate and increase in numbers. The cell 
suspension was pelleted at 1,000 rpm for 5 min at room temperature. In case of 
anchorage dependent cells, the cells were washed with serum free media or 1X PBS, 
trypsinized and pelleted. After pelleting the suspension or adherent cell cultures, the 
cell pellet was resuspended in 5ml of complete growth medium. The cell viability 
was analyzed by Trypan blue dye exclusion method and depending on the cell count, 
the cells were seeded in the appropriate split ratio in the required size of the non-
treated flask (suspension cells) or the treated flask (adherent cells). The flask was 
placed in the 5% CO2 incubator at 37°C and observed daily.  
2.2.3 Freezing of cell line 
Cells were frozen and stored for future use. The adherent or suspension cells were 
harvested accordingly. Fresh freezing medium was prepared containing the complete 
growth media with 10% (V/V) DMSO.  The freezing media was added to the cells 
dropwise such that each ml of freezing mixture will contain 5 X 106 cells/ml or 10 X 
106 cells/ml. Quickly the 1.0 ml of the cell suspension was dispensed to each of the 
previously labeled (cell line name, date of freezing, passage no.), sterile screw-
capped cryovials and transferred in IPA containing freezing container (Mr Frosty). It 
ensured slow freezing (1ºC/minute), to avoid ice crystal formation. The Mr Frosty 
was kept at - 80ºC freezer for overnight and then transferred the vials into 
cryostorage boxes in liquid nitrogen containers (-196ºC).  
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2.2.4 Ethanol precipitation of DNA 
Ethanol precipitation is a technique used to precipitate and purify the nucleic acids 
(Green and Sambrook, 2016). Absolute ethanol, three times the volume of DNA 
suspension and 3M sodium acetate, one tenth the volume of DNA suspension, were 
added to the pre-digested DNA reaction. The contents were mixed by vortexing and 
DNA threads became visible. The reaction tube was incubated at -70oC for one h. 
After incubation the tube was centrifuged at 10,000 rpm for 20 min at 4 oC. The 
ethanol in suspension was discarded and 100µl of 70% ethanol was added to the 
pellet. Again centrifugation was repeated.  After washing, the reaction tube was 
dried in bio-safety cabinet. DNA appeared white in colour due to presence of ethanol 
and became transparent once ethanol got completely dried. The pellet was 
resuspended in TE buffer and the concentration of purified DNA was determined by 
UV-absorbance at 260/280nm (NanoDrop).   DNA was stored at -20 oC for further 
usage. 
2.2.5 Electroporation   
Electroporation is the transfection method wherein high voltage electric pulse is used 
to create temporary pores in the cell membrane, through which DNA can be 
introduced (Potter and Heller, 2003). Electroporation was carried out as per the 
Lonza’s protocol. Briefly, electroporation was performed, 2 to 3 days after 
subculturing, when the cells were in their exponential growth phase. CHOKISV GS-
KO cells were washed 3 times with plain CDCHO media, to completely remove the 
L-glutamine. The cell viability and cell concentration was measured by Trypan blue 
dye using haemocytometer. Cell viability should be more than 90%. The cell 
concentration was adjusted to 1.4X107 cells/ml. 0.7 ml of cell suspension was added 
Materials and Methods 
58 
 
to the electroporation cuvette (0.4  cm, Biorad). Also 100 μl of, 40 μg of linearized 
and ethanol precipitated DNA was added in the electroporation cuvette. The cells 
were electroporated by delivering a pulse of 300 Volts, 900 µF capacitance and 
resistance set at infinity. Actual voltage and time constants were noted. Time 
constant should be in the range of 12-20 milliseconds. Immediately after delivering 
the pulse, the electroporated cells were added to 200 ml CDCHO media. This was 
distributed over twenty, 96-well plates i.e. 100 μl/well. The plates were incubated at 
37°C in humidified CO2 incubator, set at 10% CO2 in air. Next day, selection media 
(CDCHO+ 50 µM MSX) was added to the cells at the volume of 100 µl/well, such 
that the final concentration of MSX is 25 µM MSX. The plates were incubated for 
three to four weeks. 
2.2.6 Clone expansion  
After 21 to 28 days post transfection, 96-well plates were visibly screened for the 
colonies and after the colonies were identified, the wells in the 96-well plate having 
the colonies were gently flushed 2-3 times using micro-pipette, with the media 
surrounding the cells to disperse the colonies. The contents were then transferred to 
the fresh 1 ml media in a 24-well plate. Each colony in the single well in 96-well 
plate was transferred to a separate well in 24-well plate. These were incubated at 
37C, in humidified CO2 incubator, set at 10% CO2 in air. After 4-6 days in culture, 
cell suspension with ~ 70% confluency, was transferred to T-25 flask with 5 ml 
CDCHO media. T-25 flasks were incubated for 4-6 days in culture at 10% CO2.  
Following this, 1ml of culture was removed from each flask and was used to screen 
the cell lines. Screening was done by cell based ELISA (cell based ELISA was 
developed for this study and is described in the below section). The high receptor 
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expressing cell lines were identified and progressed to T-75 flasks. For that, cultures 
in T-25 flasks were transferred to centrifuge tubes, cells were pelleted by 
centrifugation, supernatant discarded and cell viability and cell concentration were 
determined by Trypan blue dye using haemocytometer. The new culture in T-75 
flask was inoculated with cells at 2X105 cells/ml seeding density in approximately 
25-30 ml growth media. After 3-4 days of incubation at 5% CO2, when cell 
suspension was again ~ 70% confluence, cell lines were again screened by cell based 
ELISA. High receptor expressing cell lines were selected and expanded to T-175 
flasks with approximately 45-55ml growth media. Cell lines were again screened by 
cell based ELISA and selected cell lines were cryopreserved. FACS analysis was 
done to identify the lead cell line with highest receptor expression. Cell banking was 
done for the same.  
2.2.7 Cell based ELISA for CD16a expressing CHOKISV GS-KO cells 
A novel cell based ELISA was developed to analyse and compare the expression of 
CD16a receptor on CHOKISV GS-KO cells. 96-well round bottom plate was 
blocked with PBST (pH 7.4) +10% BSA for one h (Grunow et al., 1994). After 
blocking, plate was washed three times with PBST. CHOKISV GSKO cells 
expressing CD16a were harvested and cell count was adjusted to 0.5 million cells 
per sample. Cells were added to the 96-well round bottom plate. Primary antibody 
(Trastuzumab) dilutions and secondary antibody (goat anti-human IgG (Fab) 2 
fragment specific- HRP conjugated) antibody dilutions were prepared in buffer 
(PBST+0.1% BSA). Primary and secondary antibody dilutions were mixed and 
incubated for 2 h at room temperature in dark. After 2 h of incubation, primary and 
secondary mixture were added to the cells in 96-well plate with the cells and 
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incubated for 1 h. Cells were washed three times by centrifuging cells in 96-well 
plate, discarding the supernatant and resuspending cells in PBST. This was followed 
by two washes with PBS. TMB substrate was added and after 20 min, reaction was 
stopped with 1N H2SO4. Cells were pelleted and the supernatant was transferred to 
fresh 96-well plate. Absorbance was measured at 450 nm. 
2.2.8 Cell based ELISA for VEGFR2 expressing CHOKISV GS-KO cells 
Cell based ELISA was developed to analyse and compare the expression of 
VEGFR2 receptor on CHOKISV GS-KO cells. 96-well round bottom plate was 
blocked with PBST+10% BSA for 1 h. After blocking, plate was washed three times 
with PBST. CHOKISV GSKO cells expressing VEGFR2 were harvested and cell 
count was adjusted to 0.5 million cells per sample. Cells were added to the 96-well 
round bottom plate and incubated with different concentrations of primary antibody 
(Ramucirumab) dilutions for one h at room temperature. Cells were washed by 
centrifuging cells in 96-well plate, discarding the supernatant and resuspending cells 
in PBST. Secondary antibody [goat anti-human IgG (Fab) 2 fragment specific- HRP 
conjugated] dilution (1:100) was prepared in buffer (PBST+0.1% BSA). Cells were 
incubated with secondary antibody for half an hour at room temperature in dark. 
This was followed by washing the cells two times with PBST, followed by two 
washes with PBS. TMB substrate was added and after 20 min, reaction was stopped 
with 1N H2SO4. Cells were pelleted and the supernatant was transferred to fresh 96-
well plate. Absorbance was measured at 450 nm. 
 
 
Materials and Methods 
61 
 
2.2.9 Cell Banking 
Cell banking is cell storage for future use. Dimethyl sulphoxide (DMSO) was used 
as cryoprotectant. Cells were revived and expanded to required number of cells for 
cryopreservation. Suspension cells were expanded in roller bottles and adherent cells 
were expanded in T-175 treated flasks. On the day of cell banking, the cells while in 
their exponential phase of growth were harvested and the cell count was adjusted. 
Cells were resuspended in freezing media (growth media + 10% DMSO). Cooled 
DMSO was added drop-wise to the cells. The cells were aliquoted in previously 
labelled cryovials and the vials were frozen as described in previous section 
(2.2.3).Storage details were noted. 
2.3 Methods for bioassays development 
2.3.1 FACS based CD16a receptor binding assay  
CD16a receptor binding assay was carried out to check IgG1 mAbs binding to 
CD16a receptor which is required for ADCC mechanism of action. CHOKISV GS-
KO cells engineered with CD16a were used for the assay. The engineered cells 
(CHOKISV GS-KO + pXC 17.4+ CD16a+ FcεRIγ Cl# 2F11) were harvested and 
resuspended in 1XAssay Buffer (PBS+1%FBS). The cell count was adjusted to 
10X106 cells/ml and added 100 μl (1X106cells/ml) in 96-well plate (round bottom). 
The dilutions of primary antibody (Trastuzumab) i.e. 200 μg/ml were prepared in 
assay buffer and 100 μl was added to the 100 μl of cell suspension to get the final 
effective concentration of antibody as 100μg/ml. Two-fold serial dilutions were done 
to get effective concentrations as 100 μg/ml, 50 μg/ml, 25 μg/ml, 12.5 μg/ml, 6.25 
μg/ml, 3.12 μg/ml and 1.56 μg/ml. Each sample concentration was analysed in 
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triplicates.  Unstained cells, cells with primary antibody only and cells with 
secondary antibody only, were used as the required controls. After incubation at 
room temperature for 1 h, the cells were washed with 1XAssay Buffer. The 
secondary antibody (Goat anti-human IgG-Fab specific FITC) was added at 1:100 
times dilution. After incubation at room temperature, in dark for 30 min, cells were 
washed with 1X Assay buffer and finally resuspended in 500 μl PBS in FACS tubes. 
The processed cells were acquired on FACS instrument (BD FACS CantoII). 30,000 
events were recorded for each sample. The assay was repeated three times for each 
sample. The dot plot and histogram were plotted. Considering MFI (Mean 
Fluorescence Intensity) of cells stained with secondary antibody only, as the basal 
expression level, the MFI of test samples was estimated. These MFI values 
correspond to CD16a receptor binding ability of the antibody. Antibody 
concentration vs MFI values graph was plotted and data was analysed using PLA 2 
software. 
2.3.2 FACS based VEGFR2 receptor binding assay  
VEGFR2 receptor binding assay was carried out to determine, Ramucirumab binding 
to VEGFR2 receptor. CHOKISV GS-KO cells engineered with VEGFR2 were used 
for the assay. The engineered cells (CHOKISV GS-KO + pXC 17.4 + VEGFR2 Cl# 
9D10) were harvested and resuspended in 1X Assay Buffer (PBS+1%FBS). The 
protocol was the same as detailed for CD16a receptor binding assay in section 2.3.1. 
Here Ramucirumab was used as the primary antibody.  
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2.3.3 Calcein AM labelling of cells 
Calcein AM is a nonfluorescent dye that permeates live cells and hydrolyzed by 
intracellular esterases which convert it to green fluorescent Calcein. The labeled 
cells can be analyzed by fluorescence imaging and flow cytometry. Calcein AM 
(C3100MP, Invitrogen) lyophilized powder was dissolved in 25 μl of DMSO to 
make 2 mM stock solution. It was further diluted with sterile Milli-Q water. and used 
at 0.005 μM concentration. The cells that were needed to be labeled were harvested 
and washed in serum free media. Cells were resuspended at a concentration of 5X104 
cells/ml and calcein AM was added. Cells were incubated at 37ºC for 30 min with 
constant shaking. This was followed by washing the cells twice in assay buffer and 
resuspending in PBS. Labelled cells were analyzed by flowcytometry or 
fluorescence microscopy. 
2.3.4 DiI labelling of cells 
DiI is weakly fluorescent outside but becomes highly fluorescence when it diffuses 
laterally in live cell membrane and thus it labels the entire cell. It is a stable dye. For 
staining, the cells were harvested, washed in serum free media and resuspended at a 
concentration of 1X106 cells/ml. 5 μl of DiI (V22888, Invitrogen) was added per ml 
of the cells. This was followed by incubation at 37ºC for twenty min while 
constantly shaking. The cells were washed thrice and resuspended in PBS for 
analysis by flowcytometry or fluorescence microscopy. 
2.3.5 CHOKISV GS- KO phagocytosis assay 
CHOKISV GS-KO phagocytosis assay was carried out as a surrogate assay for the 
ADCC assay. CHOKISV GS-KO cells were harvested and labelled with calcein AM. 
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WIL2S cells were harvested and labelled with DiI. Ten-fold serial dilutions of 
Rituximab were prepared in assay medium (PBS + 1%FBS) ranging from 30 μg/ml 
to 0.03μg/ml.  100 μL of each dilution was added to separate well of 96-well plate 
and mixed with 100 μl of 0.5 X106 WIL2S cells (target cells). The plate was 
incubated at 37ºC for 30 min. After that 100μl of 0.5 X106 CHOKISV GS-KO cells 
(effector cells) were added per well. The final concentration of Rituximab would be 
ranging from 10 µg/mL to 0.01 μg/ml. Controls were also included. They were 
unstained CHOKISV GS-KO and WIL2S cells, CHOKISV GS-KO stained with 
calcein AM, WIL2S cells stained with DiI and CHOKISV GS-KO and WIL2S cells 
mixture without the antibody. After two hours long incubation, cells were washed 
with assay buffer, resuspended in PBS and analysed by FACS or a cell slide was 
prepared to check under fluorescence microscope. 
2.3.6 EA.hy926 +VEGF cell proliferation inhibition assay 
In the assay, EA.hy926 + VEGFR2 Cl# 1 cells were harvested and cell count was 
adjusted. 30,000 cells/ 100 μl were seeded per well in a 96-well plate and incubated 
at 37°C for overnight in a humidified incubator with 5% CO2.  Next day, a dilution 
series of Bevacizumab were prepared ranging from 50ng/ml to 0.75ng/ml with two-
fold serial dilutions and 100 μl of each dilution were added to 96-well plate. An 
optimized concentration of VEGF-165 i.e. 50ng/ml was added to all the 
Bevacizumab dilutions (100 μl). The neutralization mixtures of VEGF-165 and 
Bevacizumab were incubated at 37°C for a period of two hours. After incubation, 
100μl of the neutralization mixture were added to the EA.hy926 + VEGFR2 Cl# 1 
cell plate and further incubated at 37°C for a period of six days in a humidified 
incubator with 5% CO2. After incubation, 20 μl (10% of total volume) of Alamar 
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blue was added to the wells and incubated at 37°C for a period of six hours.  Alamar 
Blue is an indigo coloured resazurin dye. It is cell permeable, non-toxic to the cells 
and quantitatively measures cell viability. Resazurin is an indicator of REDOX 
reactions. It changes to fluorescent pink colour compound known as resorufin on 
reduction by the proliferating live cells. This fluorescence was measured at 544 nm 
excitation wavelength and 590 nm emission wavelengths using BMG Lab tech Polar 
star OPTIMA plate reader. The fluorescence reading was directly proportional to the 
number of live cells in the well. The results were reported as relative fluorescence 
units (RFU) against the concentration of Bevacizumab. 
2.4 Methods for validation of Bioassays 
For validating the assay International Conference on Harmonization (ICH) 
guidelines (FDA, 2015) were followed. Validation parameters that were evaluated 
are as below. 
Specificity: Specificity of the bioassay was determined by setting up the assay,   
comparing nonspecific and specific monoclonal antibodies.  
Precision: It includes repeatability, reproducibility and intermediate precision. 
Repeatability was evaluated. For that, the assay was carried out in three sets 
independently on the same day, by the same analyst to evaluate intra assay precision.  
Accuracy: The simulated potency samples of 70%, 80%, 100%, 120% and 130% 
were all separately compared with 100% standard. The assay was repeated for three 
days. 
Robustness: For evaluating robustness, few of the assay parameters were changed 
within limits such as changing of the incubation times and compared with the normal 
in an assay set up. 




For the analysis of data, various statistical tools were used. Throughout, the 
experiments were performed in triplicates. Average of all the triplicates was 
calculated and Standard deviation was determined. To compare degree of variation 
between the triplicate values, %CV (Coefficient of Variation) was also calculated as 
Standard deviation divided by its mean, multiplied by100.  Statistical significance 
was checked by using PLA-2 software.  PLA 2.0 is a statistical software for parallel 
line and parallel logistic analysis. It takes care of USP and European pharmacopeia 
standards. It uses standard statistical methods to reject the outliers in the replicates. 
PLA analysis includes test of linearity of the dose response curve, comparison of 
parallelism between the test and the standard and also evaluation of the slope. 
PLA2.0 software determines relative potency values. Relative potency value 
compares the potency of the sample in reference to the standard, where standard is 
assigned 100% or 1.0 potency. Relative potency values should be consistent, to show 
that the bioassay is consistent and robust.  
Acceptance Criteria: After the bioassay standardization, the assay should meet 
following minimum acceptance criteria to arrive at logical conclusions.  
S. No Parameter Criteria 
1 %CV between the replicates for the single repetition < 15% 
2 %CV between the repetition < 15% 
3 Relative Potency Between80-120% 
4 Test of  parallelism, linearity and  slope as estimated PLA 2.0 Test passed 
 




Monoclonal antibodies, primers and cell lines are listed below and rest of the 
materials that were used in the study are listed in Appendix, Table 8.1. 































Primer 1: 5’d (GGATCCGCCGCCACCATGATTCCAGCAGTGGTCTT) 3’ 
Forward primer for amplifying FcεRI-γ gene. It includes BamHI site and Kozak sequence. 
 
Primer 2: 5’d(GGATCCCTACTGTGGTGGTTTCTCAT)3’ 
Reverse primer for amplifying FcεRI-γ. It has BamHI site as well. 
 
Primer 3: 5’d (CACCCTCCTCTACTGCCGACTGAAGATCCAAGTG) 3’ 
Forward SDM primer for FcεRIγ. This primer is designed to silent the Sal I site in FcεRIγ, 
so that double gene construction can be carried out in pXC 17.4 
 
Primer 4: 5’d (CACTTGGATCTTCAGTCGGCAGTAGAGGAGGGTG) 3’ 
Reverse SDM primer for FcεRIγ. This primer is designed to silent the Sal I site in FcεRIγ, so 
that double gene construction can be carried out in pXC 17.4.  
 
Primer 5: 5’d (CATGGTCATAGCTGTT) 3’ 
PUC/M13 forward sequencing primer 
Primer 6: 5’d (GTCGTGACTGGGAAAAC) 3’ 
PUC/M13 reverse sequencing primer 
Primer 7: 5’d (CAAATGTGGTATGGCTGA) 3’ 
Reverse primer for sequencing genes cloned into Lonza pXC 18.4 vector 
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Primer 8: 5’d(CGCCACCAGACATAATAGCTGACA) 3’ 
Forward primer for sequencing genes cloned into Lonza pXC 18.4 vector 
 
Primer 9: 5’d (GCAAGCTTGCCGCCACCATGTGGCAGCTGCTCCTC) 3’ 
Forward primer for PCR amplification of CD16a with the addition of HindIII site and Kozak 
sequences at the 5’ end.  
 
Primer 10: 5’d(GCGAATTCTCATTTGTCTTGAGGGTC) 3’ 
Reverse primer for PCR amplification of full length CD16a with the addition of EcoRI site 
at the 5’ end.  
Primer 11: 5’d (ACGCTGCCACAATCGACGACAGTGGAGAGTAC) 3’ 
 Forward SDM primer for CD16a. This primer is designed to silent the Sal I site in CD16a, 
so that double gene construction can be carried out in pXC 17.4. 
 
Primer 12: 5’d (GTACTCTCCACTGTCGTCGATTGTGGCAGCGT) 3’  
Reverse SDM primer for CD16a. This primer is designed to silent the Sal I site in CD16a, so 
that double gene construction can be carried out in pXC 17.4.  
 
Primer 13: 5’d (CCTCAATGGTACAGGGTGCT) 3’ 
Forward sequencing primer for CD16a gene  
 
Primer 14: 5’d (GTCCTGTGTCCACTGCAAAA) 3’ 
Reverse sequencing primer for CD16a gene (654-673bp) 
 
Primer 15: 5’d( TAACGGTGGAGGGCAGTGTAGT) 3’ 
Forward primer for sequencing genes cloned into Lonza pEE14.4 vector 
 
Primer 16: 5’d (ATTTCTGATCGGGAATGCCC)3’ 
Reverse primer for sequencing genes cloned into Lonza pXC 17.4 vector. It binds at 343-
362 bp 
  
Primer 17: 5’d (CCTGGATATCCTCTCCTACCG) 3’ 
Forward primer for amplification of VEGFR2 (Full length). This binds in the 5’UTR region. 
Primer 18:  5’d (GCAAATCCTTCCCATCTTCA) 3’ 
Reverse primer for amplification of VEGFR2 (Full length). This binds in the 3’UTR region. 
Primer 19:  5’d (ATCTCCATTTATTGCTTCTG) 3’ 
Forward sequencing primer for VEGFR2. Binds in sequencing domain #2( 402 to 802) 
 
Primer 20:  5’d (CCGGGTTACACCATCTATAG) 3’ 
Reverse sequencing primer for VEGFR2. Binds in sequencing domain #9(484 to 884) 
 
Primer 21:  5’d (TTGACTTCAACTGGGAATAC) 3’ 
Forward sequencing primer for VEGFR2. Binds in sequencing domain # 3(803 to 1203) 
 
Primer 22:  5’d (ACAGGAGAGATTAGAGATTTC) 3’ 
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Reverse sequencing primer for VEGFR2. Binds in sequencing domain #8 (885 to 1285) 
 
Primer 23:  5’d (TGAAAGAGACACAGGAAATT) 3’ 
Forward sequencing primer for VEGFR2. Binds in sequencing domain #4( 1204 to 1604) 
 
Primer 24:  5’d (TGCTCAGTGGGCTGCATGTC) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#7(1286 to 1686) 
 
Primer 25: 5’d (AATGTGTCAGCTTTGTACAA) 3’ 
 Forward sequencing primer for VEGFR2. Binds in sequencing domain#5(1605 to 2005) 
 
Primer 26: 5’d (TTTAAACCACATGATCTGTG) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#6(1687 to 2087) 
 
Primer 27: 5’d (TTCAGCCGGTCTCTGGGGAA) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#5( 2088 to 2488) 
 
Primer 28: 5’d (GTTAAGCGGGCCAATGGAGG) 3’ 
 Forward sequencing primer for VEGFR2. Binds in sequencing domain#7 (2407 to 2807) 
 
Primer 29: 5’d (CTGTCCAAGCGCCGTTTCAG) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#4( 2489 to 2889) 
 
Primer 30: 5’d (TGTCCACTTACCTGAGGAGC) 3’ 
 Forward sequencing primer for VEGFR2. Binds in sequencing domain #8( 2808 to 3208) 
 
Primer 31: 5’d (AATATTTCCCACAGCAAAAC) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#3( 2890 to 3290) 
 
Primer 32: 5’d (TTATGTCAGAAAAGGAGATG) 3’ 
 Forward sequencing primer for VEGFR2. Binds in sequencing domain #9: from 3209 to 
3609 
 
Primer 33:  5’d (CCGGCTCTTTCGCTTACTGT) 3’ 
 Reverse sequencing primer for VEGFR2. Binds in sequencing domain#2: from 3291 to 
3691 
 
Primer 34:  5’d (AAGCTTGCCGCCACCATGCA) 3’ 
Forward sequencing primer for VEGFR2 
 
Primer 35:  5’d (GAATTCTTAAACAGGAGGAG) 3’ 












CHOKISVGSKO: (Lonza) suspension version of CHOKI, where GS gene is knocked out. 
It was cultured in CDCHO media. 
 
EA.hy926: (ATCC, CRL-2922) Hybrid endothelial cell line produced by fusing HUVEC 
and A549. It is an adherent cell line and was cultured in DMEM+10% FBS+4mM L-
Glutamine. 
 
Huvec: (ATCC, CRL-1730) Human umbilical vein/vascular endothelial cell line. It is an 
adherent, primary cell line. It was cultured in EBM-2+EGM-2. 
 
WIL2S: (ATCC, CRL-8885) Human B lymphoblast cell line. It is suspension cell line 
cultured in RPMI 1640+10%FBS. 
 
HEK293T: (ATCC, CRL-3216):  Human embryonic kidney cell line. It is an adherent cell 
line and was cultured in DMEM +10% FBS.  HEK293T cell line is derivative of 293 cells. It 
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3 CD16a receptor Binding Assay 
3.1 Introduction 
3.1.1 Receptor binding assays 
Biosimilars are the generic drugs that are “identical” to the drugs that are approved 
and already in the market. They can be manufactured by any process but the final 
proposed product should be exactly similar to the reference drug in terms of its 
structure and function (FDA, 2015). Biotherapeutics are complex structures and it is 
a challenging task to mimic them. Even the minute variations in structure can affect 
the bioactivity of the drug. A comprehensive comparative data is required to 
demonstrate the biosimilarity of the proposed product to the FDA approved 
reference product. Such comparative data is required in the early stages of product 
development to allow elaborate discussion in advisory meetings with licensing and 
regulatory agencies. The comparative data includes relevant physiochemical tests 
and functional studies which can evaluate the products purity, safety and potency. 
Where binding of drug to the receptors on cell surface is inherent part of proteins 
function, there receptor binding analysis is also the part of comparative studies 
(FDA, 2015). Such receptor binding assays provide additional evidence that the 
higher order structure and biological potency of proposed product and reference 
product are similar. Receptor binding assays are mainly carried out by Surface 
plasmon resonance (SPR) analysis and ELISA. Cell based receptor binding assays 
are a step ahead as they are more clinically relevant. Additional advantage of such 
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cell based assays is that they do not require the soluble binding receptors and their 
production or characterization, as it is present on the cell membrane itself.  
3.1.2 CD16a receptor binding assay 
Most of the antibody drugs, especially the ones for oncology targets are based on 
antibody dependent cell cytotoxicity (ADCC) as an important and desirable 
biological activity (Surowy et al., 2012). In ADCC, an antibody binds to its target 
cancerous cell at its Fab portion. This is followed by binding of the Fc portion of the 
antibody to the CD16a receptor on NK cells. This binding is indispensable for 
ADCC mechanism as it activates the NK cells, which in turn releases particle to lyse 
the target cells. The crucial step of Fc portion of the antibody binding to CD16a 
receptor for the ADCC response of an antibody can be determined and compared by 
the CD16a receptor binding assay. In the assay, primary antibody i.e. the test 
antibody and secondary antibody conjugated to FITC are incubated, so as to allow 
secondary antibody forming dimers of the test antibody. This primary and secondary 
antibody complex is then added to the cell line expressing CD16a.  The Fc portion of 
the test antibody binds to CD16a receptors on the cells. CD16a expressing cells 
would be incubated with different concentrations of the test antibody which are 
bound to secondary antibody conjugated to FITC. The fluorescence intensity, due to 
FITC conjugated to secondary antibody is measured by FACS and it is expressed in 
MFI (mean fluorescence intensity) units. With increasing concentrations of test 
antibody, increase in MFI values is observed and these dose responses can be used to 
compare the ADCC responses of the drugs, since higher the CD16a receptor binding 
capacity of the drug, better would be its ability to elicit the ADCC response. Figure 
3.1 shows diagrammatic representation of the CD16a receptor binding assay. 




Figure 3.1: Diagrammatic representation of the CD16a receptor binding assay. 
CHOKISV GS-KO cells expressing CD16a receptor binds to increasing 
concentrations of primary or the test antibody complexed with secondary antibody. 
Fluorescence due to FITC conjugated to secondary antibody is analyzed by the flow 
cytometry. Higher test antibody concentrations corresponds to higher fluorescence 
intensity indicating more CD16a binding to the antibody. CD16a receptor binding is 
reflective of the ADCC response. 
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3.1.3 Developing CD16a receptor binding assay 
For developing the assay, first of all, a cell line needs to be generated which can 
express CD16a receptor. This would be followed by assay optimization. Figure 3.2 
summarizes the main steps involved in the development of the assay. Lonza’s GS 
Xceed Expression system at RLS was used for generating the cell line expressing 
CD16a receptor. Lonza’s GS Xceed Expression system is based on use of glutamine 
synthetase (GS) gene as a selection marker and has robust viral promoter. It enables 
generation of high expressing cell line. There are two expression plasmids pXC17.4, 
as the primary plasmid and pXC18.4, as an auxiliary plasmid for co-expression of 
two genes. If two genes need to be co-expressed than both the vectors are combined 
to get a double gene vector. The Lonza’s system has CHOKISV GS-KO as the host 
cell line. CHO-K1 strain is derived from original CHO cells and is dependent on 
glycine supplementation(Kao and Puck, 1968). Lonza’s suspension version of CHO-
K1 is CHO-K1SV. The endogenous GS (glutamine synthetase) gene has been 
knocked out (KO) in CHOKISV GS-KO derivative, generating requirement for 
exogenous glutamine.  
Cloning was carried out by the traditional method, where restriction enzyme 
digestion is done to insert the gene of interest in the vector. Both the genes i.e. 
CD16a and FcεRI-γ were first cloned in the cloning vectors. Cloning vector is use to 
amplify single copy of the gene into many copies in E.coli host cells. This was 
followed by subcloning in expression vectors. Expression vector introduces the gene 
in target cells and makes the cells to efficiently express the gene. CD16a was cloned 
in pXC 17.4 vector and FcεRI-γ was cloned in auxiliary pXC 18.4 vector. 
CHOKISV GS-KO cells were transfected with vector construct having both the 
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genes. Transfection was done by electroporation (detailed in Chapter 2). The highest 
CD16a expressing cell line was screened and selected and a cell bank was prepared 
for the same. 
After engineering the cell line, the CD16a receptor binding assay was developed for 
Trastuzumab by optimizing various parameters like number of CD16a expressing 
CHOKISV GS-KO cells required, selection of most suitable secondary antibody, 
concentration of secondary antibody and working range for the primary antibody. 
The assay was then validated. 
 
Figure 3.2: Major steps for the development of the CD16a receptor binding assay. 
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3.2 Cloning of the receptors 
CD16a receptor gene needs to be cloned and expressed on the CHOKI SV GSKO 
cell line. However CD16a gene requires other accessory signalling polypeptides for 
its surface expression. These accessory signalling polypeptides includes either 
FcεRI-γ or TCRζ. Here FcεRI-γ was cloned and expressed along with CD16a on the 
cell line. Both the genes were amplified from human cDNA library. CD16a gene was 
found to have Valine at 158 position of the polypeptide. This allotypic form of 
CD16a where it is Valine instead of Phenylalanine at 158 position, has high affinity 
for Fc region of the antibody and thus elicits better ADCC activity. Both the gene 
sequences were modified to simplify cloning and expression. They were cloned in 
pGEMT easy cloning vector. CD16a was subcloned in pXC 17.4 vector and FcεRI-γ 
was subcloned in pXC 18.4 vector. A double gene was constructed having both 
CD16a and FcεRI-γ, for the co-expression of the genes. Figure 3.3 outlines the 


















Figure 3.3: Outline of construction of pXC17.4+CD16a+ FcεRI-γ. 
  




3.2.1 FcεRI-γ  cloning: 
3.2.1.1 FcεRI-γ  gene amplification and silencing Sal I restriction enzyme 
site: 
FcεRI-γ sequence was derived from different sources, which included- Patent- US 
2008/0247990, Gene Bank (https://www.ncbi.nlm.nih.gov/nuccore/NM_004106.1) 
i.e. Homo sapiens Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide (FCER1G), mRNA (NCBI Reference Sequence: NM_004106.1).  
After the gene sequence was confirmed, primers were designed to amplify the gene 
(primer1 and primer2 - listed in Chapter 2, section 2.5, Materials). Forward primer 
was designed with Kozak sequence (GCCGCCACC) and BamHI restriction enzyme 
site (GGATCC) on the 5’ end and reverse primer has BamHI site on 3’ end. Kozak 
sequence enhances translation initiation process. Figure 3.4 shows the nucleotide 






Figure 3.4: Nucleotide Sequence of FcεRI-γ after amplification. Nucleotide 
Sequence of FcεRI-γ was amplified with primers that would modify the gene so as to 
ease its cloning and expression. The modified gene design includes BamHI site (in 
red), Kozak sequence (in blue), FcεRIγ sequence (in black) with Sal I site silent i.e. 
C nucleotide instead of T (in green), BamHI site (in red).  
 
The FcεRI-γ gene was amplified from Human leukocyte cDNA library (Clonetech, 
7182-1) using Pfu native DNA polymerase enzyme by amplification PCR (protocol 
described in Materials and Methods, Chapter 2). Total gene amplified product was of 




282bp. Figure 3.5.a shows agarose gel electrophoresis image of amplified PCR 
product of FcεRI-γ. The band was gel eluted using Qiagen gel extraction kit 
(protocol described in Materials and Methods, Chapter 2) and DNA concentration 
was quantitated by Nanodrop.  
Sal I restriction enzyme site was observed in FcεRI-γ gene sequence that needed to 
be silent so that later double gene could be constructed using Sal I and NotI 
restriction sites. So, primer set was designed to modify Sal I site in FcεRI-γ gene 
using Gene design and Vector NTI softwares (primer3 and primer4). T nucleotide in 
GTCGAC would be replaced with C nucleotide. Two fragments were amplified, 
taking gel eluted FcεRI-γ as template sequence, using Pfu turbo DNA polymerase 
enzyme (protocol described in Materials and Methods, Chapter 2). First fragment of 
151bp was amplified using primer2 and primer 3 and second fragment of 165bp was 
amplified using primer1 and primer 4. Figure 3.5.b shows agarose gel 
electrophoresis image of amplified PCR products of fragments of FcεRI-γ. The 
bands were gel eluted using Qiagen gel extraction kit and DNA concentration was 
quantitated by Nanodrop. An overlap PCR of the two fragments of FcεRI-γ was 
done, taking gel eluted fragments as templates and using Econotaq enzyme (protocol 
described in Materials and Methods, Chapter 2). Primer1 and primer2 were used. 
The final FcεRI-γ of 282bp has silent Sal I restriction enzyme site. Figure 3.5.c 
shows agarose gel electrophoresis image of the same. The band was gel eluted using 








           
 
Figure 3.5: Agarose gel electrophoresis image to show FcεRI-γ gene amplification. 
a. FcεRIγ was amplified from human leukocyte cDNA library. Lane1- NEB 100bp 
DNA ladder, lane 2 - 282bp of FcεRIγ amplified PCR product; b. Two fragments of 
FcεRIγ were amplified using primer sets to silent Sal I restriction enzyme site. Lane 
1 – 151bp of first fragment of FcεRIγ (circled), lane 2 - NEB 100bp DNA ladder , 
lane3- 165bp of second fragment of FcεRIγ (circled), other bands are nonspecific 
amplifications; c. Overlap PCR of two fragments of FcεRIγ. Lane 1 – 282bp of 
overlap PCR product of FcεRIγ with silent Sal I restriction enzyme site, lane 2 - 
NEB 100bp DNA ladder. 
3.2.1.2 Cloning of FcεRI-γ in pGEMT easy vector 
pGEMT easy vector (Promega) is a cloning vector with T-overhangs at 3’ end, for 
easy ligation and cloning. Insert should be amplified with Econotaq (Lucigen) to 
allow TA cloning. Gel eluted FcεRI-γ with silent Sal I restriction enzyme site, 
amplified with Econotaq was used as an insert and ligation was set up as per the 
instructions mentioned in the pGEMT easy vector system kit. Next day, XL-1 blue 
cells transformation was done with the ligation mixture (protocol described in 
Materials and Methods, Chapter 2) and cells were plated on LB Agar, Ampicillin, 




IPTG, X-Gal plates. IPTG, X-Gal is for blue-white screening (white colonies are 
supposed to be of recombinant bacteria). After overnight incubation, next morning a 
lot many blue and white colonies were observed. 13 white colonies were screened 
for desired plasmid by colony PCR (protocol described in Materials and Methods, 
Chapter 2) using vector specific primer and gene specific primer. (primer 5 and 
primer 2). Figure 3.6.a shows agarose gel electrophoresis image of colony PCR 
amplification products. Expected band size of ~400bp was observed in all the 
colonies. First five colonies were inoculated in LB broth with ampicillin and after 
overnight incubation, next morning growth was observed in all.  Plasmid purification 
was done by in house method. Plasmids were digested with EcoRI restriction 
enzyme (protocol described in Materials and Methods, Chapter 2). Figure 3.6.b 
shows agarose gel electrophoresis image of EcoRI restriction enzyme digestion of 
FcεRI-γ /pGEMTeasy plasmids. Expected band size of ~300bp was observed for 
FcεRI-γ /pGEMTeasy Cl #1, 2, 3 and 4. FcεRI-γ /pGEMTeasyCl #2 was sequenced 
by primers 1, 2, 3, 4, 5 and 6 (listed in Chapter 2, section 2.5, Materials). Sequence 
alignment was done using Clustal W multiple sequence alignment software and 
sequence was found to match fully with standard FcεRI-γ sequence. After sequence 
confirmation, glycerol stock was prepared for FcεRI-γ /pGEMTeasy Cl #2 (protocol 
described in Materials and Methods, Chapter 2). 
 
 






Figure 3.6: Agarose gel electrophoresis image to check FcεRI-γ gene containing 
colonies and plasmids. FcεRIγ was cloned in pGEMT vector. a. Agarose gel 
electrophoresis image of colony PCR amplified products. Lane1-13- PCR product 
FcεRI-γ /pGEMTeasyColony#1-13, lane 14- NEB 100bp DNA ladder, lane 15 – 
PCR product without any template(Negative control). Expected band size of ~400bp 
was observed for all the colonies and in negative control there was no band; b. 
Agarose gel electrophoresis image of EcoRI restriction enzyme digested plasmids. 
Lane 1–2- FcεRI-γ / pGEMTeasy Cl#1-2, lane 3- NEB 1Kb DNA ladder, lane4-6- 
FcεRI-γ / pGEMTeasy Cl#3-5, lane 7- NEB 100bp DNA ladder . Expected band size 
of ~300bp was observed for FcεRI-γ /pGEMTeasy Cl#1, 2, 3 and 4. 
 
3.2.1.3 Cloning of FcεRI-γ in pXC 18.4 vector 
After cloning FcεRI-γ in cloning vector, it was then cloned in pXC18.4. FcεRI-γ 
/pGEMTeasyCl #2 and pXC 18.4 were digested with EcoRI restriction enzyme. 
Figure 3.7. a shows agarose gel electrophoresis image of EcoRI restriction digestion 
of pXC 18.4 and FcεRI-γ /pGEMTeasy Cl #2. pXC 18.4 plasmid was linearized and 
FcεRI-γ /pGEMTeasy Cl #2 was digested to release the insert FcεRI-γ of ~ 300bp 
and other pGEMT easy vector band of 2997bp. Linearized vector band of pXC 18.4 
and ~300bp band of FcεRI-γ were gel extracted. Gel eluted products were 
quantitated by Nano drop. After digestion and gel extraction, vector and insert were 




ligated in the ratio of 1:3 by T4DNA Ligase (protocol described in Materials and 
Methods, Chapter 2). XL-1 blue cells transformation was done, by heat shock 
method, with the ligation mixture and cells were plated on LB Agar, ampicillin 
plates. After overnight incubation, a good number of colonies were observed. 11 
colonies were screened for desired plasmid by colony PCR (protocol described in 
Materials and Methods, Chapter 2) using vector specific primer and gene specific 
primer (primer 7 and primer 3). Figure3.7.b shows agarose gel electrophoresis 
image of colony PCR amplification products. Expected band size of ~187bp was 
observed in colonies no. # 2, 3, 5 and 11. The positive colonies were inoculated in 
LB broth with ampicillin and after overnight incubation, plasmid purification was 
done and plasmids were quantitated by Nanodrop. Plasmids were confirmed by 
carrying out PCR with vector specific primers (primer 7 and primer 8 - listed in 
Chapter 2, section 2.5, Materials) and expected band size of ~450bp was observed 
for all FcεRI-γ /pXC 18.4plasmids. Faint band was also observed for negative 
control i.e. no template control. Figure 3.7.c shows agarose gel electrophoresis 
image of PCR amplification products. FcεRI-γ /pXC 18.4 Cl #2 was sequenced by 
primers 1, 2, 3, 4, 7 and 8 (listed in Chapter 2, section 2.5, Materials). Sequence 
alignment was done using Clustal W multiple sequence alignment software and 
sequence was found to match fully with standard FcεRI-γ sequence. Glycerol stock 
was prepared for FcεRI-γ /pXC 18.4 Cl #2. 
 





Figure 3.7: Agarose gel electrophoresis image to check FcεRI-γ gene containing 
colonies and plasmids. FcεRIγ was cloned in pXC 18.4 vector. a. Agarose gel 
electrophoresis image of EcoRI restriction enzyme digestion of vector and insert. 
Lane 1 - NEB 100bp DNA ladder , lane 2 - FcεRI-γ /pGEMT (with Sal I site silent) 
Cl # 2, lane 3- EcoRI digested  FcεRI-γ /pGEMT (with Sal I site silent) Cl #2, lane 
4- pXC 18.4 vector, lane5- EcoRI digested pXC 18.4, lane 6- NEB 1Kb DNA ladder. 
Insert release (FcεRI-γ) of ~300bp was observed in lane 3 and expected band size of 
~4,000bp for linearized pXC 18.4 vector was observed in lane 5; b. Agarose gel 
electrophoresis image of colony PCR amplified products. Lane1- 5- PCR product 
FcεRI-γ /pXC 18.4 colony# 1-5, lane 6- NEB 100bp DNA ladder, lane 7-12 – PCR 
product FcεRI-γ /pXC 18.4 colony# 6-11. Expected band size of ~187bp was 
observed for colonies no. # 2, 3, 5 and 11; c. Agarose gel electrophoresis image of 
PCR amplified products to confirm the positive plasmids. Lane1- 4- PCR product of 
FcεRI-γ /pXC 18.4 Cl#2, 3, 5 and 11amplified with vector specific primers, lane 5- 
PCR product without any template (Negative control), lane 6- NEB 100bp DNA 
ladder. Expected band size of ~450bp was observed for colonies no. #2, 3, 5 and 
11and in negative control there was a faint band. 
 
3.2.2 CD16a cloning 
3.2.2.1 CD16a gene amplification and silencing Sal I restriction enzyme site: 
CD16a sequence was derived from Patent- US 2008/0247990. Primers were 
designed to amplify the gene (primer 9 and primer10 -listed in Chapter 2, section 
2.5, Materials). Forward primer included Hind III enzyme sequence (AAGCTT) and 




the Kozak sequence (GCCGCCACC) on the 5’ end and reverse primer included 
EcoRI site (GAATTC) at 3’ end. Figure 3.8 shows modified nucleotide sequence of 














Figure 3.8: Nucleotide Sequence of CD16a. Nucleotide Sequence of CD16a was 
amplified with primers that would modify the gene so as to ease its cloning and 
expression. The modified gene design includes HindIII site (in red), Kozak sequence 
(in blue), CD16a sequence (in black) with Sal I site silent i.e. A nucleotide instead of 
G (in purple), EcoRI site (in green).  
The CD16a gene was amplified from Human leukocyte cDNA library (Clonetech, 
7182-1) using Pfu native DNA polymerase enzyme by amplification PCR (protocol 
described in Materials and Methods, Chapter 2). Total gene amplified product was of 
786bp. Figure 3.9. a shows agarose gel electrophoresis image of amplified PCR 
product of CD16a. The gene amplified product was gel eluted and sequenced. The 
sequence matched with the standard CD16a nucleotide sequence and it was found to 
have Valine at 158 position of the polypeptide. This allotypic form of CD16a where 




it is Valine instead of Phenylalanine at 158 position was more preferable since it has 
high affinity for Fc region of the antibody and thus elicits better ADCC activity 
(Koene et al., 1997).  
CD16a also had Sal I restriction enzyme site (GTCGAC) which needed to be silent 
so that later double gene could be constructed using Sal I and Not I restriction 
enzyme sites. So, primer set was designed to modify Sal I site in CD16a gene using 
Gene design and Vector NTI softwares (primer11 and primer12). G nucleotide in 
GTCGAC was replaced with A nucleotide. Two fragments were amplified, taking 
gel eluted CD16a as template sequence, using Pfu turbo DNA polymerase enzyme 
(protocol described in Materials and Methods, Chapter 2). First fragment of 264bp 
was amplified using primer9 and primer 12 and second fragment of 532bp was 
amplified using primer10 and primer 11. Figure3.9.b shows agarose gel 
electrophoresis image of amplified PCR products of fragments of FcεRI-γ. The 
bands were gel eluted using Qiagen gel extraction kit. An overlap PCR (Touchdown 
PCR) of the two fragments of CD16a was carried out, taking gel eluted fragments as 
templates and using PCR Thermo master mix (protocol described in Materials and 
Methods, Chapter 2). Primer9 and primer10 were used. The final CD16a of 790bp 
has silent Sal I restriction enzyme site. Figure 3.9.c shows agarose gel 
electrophoresis image of the same. The band was gel eluted using Qiagen gel 










 Figure 3.9: Agarose gel electrophoresis image to show CD16a gene amplification. 
 a. CD16a was amplified from human leukocyte cDNA library. Lane1- NEB 100bp 
DNA ladder, lane 2 – 786 bp of CD16a amplified PCR product; b. Two fragments of 
CD16a were amplified using primer sets to silent Sal I restriction enzyme site. Lane 
1 – 264bp of first fragment of CD16a, lane 2 -- NEB 100bp DNA ladder , lane3- 
532bp of second fragment of CD16a; c. Overlap PCR of two fragments of CD16a. 
Lane 1 – 790bp of overlap PCR product of CD16a with silent Sal I restriction 
enzyme site, lane 2 -- NEB 100bp DNA ladder. 
3.2.2.2 Cloning of CD16a in pGEMT easy vector 
Gel eluted CD16a with silent Sal I restriction enzyme site was used as an insert and 
ligation was set up as per the instructions mentioned in the pGEMT easy vector 
system kit. Next day, XL-1 blue cells transformation was done with the ligation 
mixture (protocol described in Materials and Methods, Chapter 2) and cells were 
plated on LB Agar, ampicillin, IPTG, X-Gal plates. After overnight incubation, next 
morning a lot many blue and white colonies were observed. Four white colonies 
were inoculated in LB broth with ampicillin and after overnight incubation, next 
morning growth was observed in all.  Plasmid purification was done by in house 
method and plasmids were quantitated by Nanodrop. Plasmids were digested with 




EcoRI restriction enzyme (protocol described in Materials and Methods, Chapter 2). 
Figure3.10 shows agarose gel electrophoresis image of EcoRI restriction enzyme 
digestion of CD16a /pGEMTeasy plasmids. Expected band sizes of 2997bp, 789bp 
and166bp were observed for CD16a /pGEMTeasy Cl #3. CD16a /pGEMTeasy Cl #3 
was sequenced by primers 5, 6, 11, 12, 13 and 14 (listed in Chapter 2, section 2.5, 
Materials). Sequence alignment was done using Clustal W multiple sequence 
alignment software and sequence was found to match entirely with standard CD16a 
sequence. After sequence confirmation, glycerol stock was prepared for CD16a 
/pGEMTeasy Cl #3 (protocol described in Materials and Methods, Chapter 2). 
                 
Figure 3.10: Agarose gel electrophoresis image to check CD16a gene containing 
plasmids. CD16a was cloned in pGEMT vector. Agarose gel electrophoresis image 
of EcoRI restriction enzyme digested plasmids. Lane 1–4 - CD16a 
/pGEMTeasyCl#1-4 , lane 5- NEB 100bp DNA ladder, lane 6- NEB 1Kb DNA 
ladder. Expected band sizes of 2997bp, 789bp and166bp were observed for CD16a 
/pGEMTeasy Cl#3. 




3.2.2.3 Cloning of CD16a in pXC 17.4 vector 
CD16a was subcloned in pXC 17.4 vector after cloning in pGEMTeasy vector. 
CD16a /pGEMTeasy Cl #3 and pXC 17.4 were digested with Hind III- EcoRI 
restriction enzymes for directional cloning. Figure 3.11.a shows agarose gel 
electrophoresis image of Hind III- EcoRI restriction digestion of pXC 17.4 and 
CD16a /pGEMTeasy Cl #3. pXC 17.4 plasmid digested and CD16a /pGEMT easy 
Cl #3 was digested to release the insert CD16a of 789bp and other pGEMT easy 
vector bands of 2997bp, 16bp and 9bp. Vector band of pXC 17.4 and CD16a were 
gel extracted. Gel eluted products were quantitated by Nano drop. Ligation was 
setup using T4DNA Ligase (protocol described in Materials and Methods, Chapter 
2), where vector is to insert ratio was 1:3.  This was followed by transformation of 
XL-1 blue cells with the ligation mixture and cells were plated on LB Agar, 
ampicillin plates. Next day only 3 colonies were observed which were inoculated in 
LB broth with ampicillin and plasmid purification was done. Plasmids were 
quantitated by Nanodrop and confirmed by Hind III - EcoRI digestion. Expected 
band size of 6983bp and 789bp were observed for CD16a /pXC 17.4 Cl#2. 
Figure3.11.b shows agarose gel electrophoresis image of Hind III –EcoRI digested 
CD16a /pXC 17.4 plasmids. CD16a /pXC 17.4 Cl #2 was sequenced by primers 13, 
14, 15 and 16 (listed in Chapter 2, section 2.5, Materials). Sequence alignment was 
done using Clustal W multiple sequence alignment software and sequence was a 
perfect match to standard CD16a sequence. Finally, glycerol stock was prepared for 
CD16a /pXC 17.4 Cl #2. 




Figure 3.11: Agarose gel electrophoresis image for cloning CD16a gene in pXC 
17.4 plasmid. .CD16a was cloned in pXC 17.4 vector. a. Agarose gel electrophoresis 
image of Hind III - EcoRI restriction enzyme digestion of vector and insert. Lane 1 – 
Undigested pXC 17.4vector, lane 2- Hind III - EcoRI restriction enzyme digested 
pXC 17.4 vector, lane 3- NEB 1Kb DNA ladder, lane 4-undigested CD16a /pGEMT 
(with Sal I site silent) Cl # 3, lane 5- Hind III - EcoRI restriction enzyme digested, 
CD16a /pGEMT (with Sal I site silent) Cl # 3. Expected band size of 6893bp for 
pXC 17.4 vector was observed in lane2 and insert release (CD16a) of 789bp was 
observed in lane 5; b. Agarose gel electrophoresis image of Hind III - EcoRI 
restriction enzyme digested plasmids. Lane 1 – 3- CD16a /pXC 17.4 Cl#1-3 , lane 4- 
NEB 100bp DNA ladder, lane 5- NEB 1Kb DNA ladder. Expected band sizes of 
6893bp and 789bp were observed for CD16a /pXC 17.4 Cl#2. 
 
3.2.3 Double gene construction 
CD16a and FcεRI-γ need to be in the same vector for better and easy expression. So 
the double gene was constructed. CD16a /pXC 17.4 Cl #2 and FcεRI-γ /pXC 18.4 Cl 
#2 were digested with Not I and Sal I restriction enzymes. Figure3.12.a and b 
shows agarose gel electrophoresis image of Not I and Sal I restriction digestion of 
CD16a /pXC 17.4 Cl #2 and FcεRI-γ /pXC 18.4 Cl #2. CD16a /pXC 17.4 Cl #2 
plasmid was digested to release the 6950bp and 723bp bands and FcεRI-γ /pXC 18.4 
Cl #2 released 2325bp and 2016bp fragments on restriction enzyme digestion. 
6950bp band of CD16a /pXC 17.4 Cl #2 and 2325bp band of FcεRI-γ /pXC 18.4 Cl 




#2 were gel extracted. Gel eluted products were quantitated by Nano drop. Vector 
and insert were ligated in the ratio of 1:3 by T4DNA Ligase (protocol described in 
Materials and Methods, Chapter 2). After transformation of XL-1 blue cells with the 
ligation mixture, the cells were plated on LB Agar, ampicillin plates and next day lot 
many colonies were observed. Six colonies were inoculated in LB broth with 
ampicillin for plasmid purification and plasmids were quantitated by Nanodrop. 
Plasmids were confirmed by Not I – Sal I digestion and expected band size of 
6950bp and 2325bp were observed for CD16a + FcεRI-γ /pXC 17.4 Cl# 2, 4, 5 and 
6. Figure3.12.c shows agarose gel electrophoresis image of Not I –Sal I digested 
CD16a + FcεRI-γ /pXC 17.4 plasmids. CD16a + FcεRI-γ /pXC 17.4 Cl# 5 was 
sequenced by primers1, 2, 7, 8, 13, 14, 15, and 16 (listed in Chapter 2, section 2.5, 
Materials). Sequence alignment was done using Clustal W multiple sequence 
alignment software and sequence aligned fully with standard FcεRI-γ and CD16a 
















Figure 3.12: Agarose gel electrophoresis image for constructing CD16a + FcεRI-γ 
/pXC 17.4 Cl# 5. CD16a + FcεRI-γ /pXC 17.4 Cl# 5 double gene was constructed. a. 
Agarose gel electrophoresis image of Not I and Sal I restriction enzyme digestion of 
CD16a /pXC 17.4 Cl #2. Lane 1 –Not I and Sal I restriction enzyme digested CD16a 
/pXC 17.4 Cl #2, lane 2- Undigested CD16a /pXC 17.4 Cl #2, lane 3- NEB 1Kb 
DNA ladder. Expected band sizes of 6950bp and 723bp for the digested plasmid 
were observed in lane-1; b. Lane 1- Not I and Sal I restriction enzyme digested 
FcεRI-γ /pXC 18.4 Cl #2, lane 2- undigested FcεRI-γ /pXC 18.4 Cl #2, lane 3- NEB 
1Kb DNA ladder. Expected band sizes of 2325bp and 2016bp for the digested 
plasmid were observed in lane-1; c. Agarose gel electrophoresis image of Not I and 
Sal I restriction enzyme digested plasmids. Lane 1 – 5- Not I and Sal I restriction 
enzyme digested CD16a + FcεRI-γ /pXC 17.4 Cl# 1-5 , lane 6- NEB 1Kb DNA 
ladder, lane 7- Not I and Sal I restriction enzyme digested CD16a + FcεRI-γ /pXC 
17.4 Cl# 6. Expected band sizes of 6950bp and 2325bp were observed for pXC 17.4 
+ CD16a + FcεRI-γ Cl# 2, 4, 5 and 6. 
 
Plasmid DNA purification 
For transfection high quality DNA is required which is free from bacterial 
endotoxins, genomic DNA, RNA and proteins. To get transfection grade CD16a + 
FcεRI-γ /pXC 17.4 Cl# 5 plasmid DNA, Mega prep (Qiagen, Cat no. 12183) was 
done (procedure as mentioned in the kit). It was eluted in 1ml T.E. buffer and 
quantitated by Nanodrop. Total yield was 4mg (A260/280 ratio-1.88).  




3.3 Expression studies 
3.3.1 Stable transfection  
Transfection is the delivery of the genetic material into the eukaryotic cells. It can be 
transient transfection or stable transfection. In transient transfection genetic material 
is introduced into the nucleus but not in the chromosome whereas in stable 
transfection, genetic material is integrated in the chromosome or it stays in the form 
of episome. For transient transfection, super-coiled DNA is more favorable but in the 
case of stable transfection, efficiency of transfection increases, when DNA is 
linearized (Stuchbury and Münch, 2010). Linearization of the DNA is required so 
that during chromosomal integration, there are better chances that recombination will 
occur in non-essential plasmid regions. Here, DNA was linearized with PvuI 
restriction enzyme. Figure 3.13 shows agarose gel electrophoresis image of 
linearization of pXC 17.4+ CD16a+ FcεRIγ Cl #9 plasmid. 
 




                                      
Figure 3.13: Agarose gel electrophoresis image to show Pvu I linearization of pXC 
17.4 + CD16a + FcεRIγ Cl #9. pXC 17.4 + CD16a + FcεRIγ Cl #9 was linearized 
with PvuI restriction enzyme before stable transfection. Lane 1- NEB 1 Kb DNA 
ladder, lane 2 - Uncut pXC 17.4 + CD16a + FcεRIγ Cl #9 plasmid, lane 3 - Pvu I 
digested pXC 17.4 + CD16a + FcεRIγ Cl #9. 
 
After linearization, pXC 17.4 + CD16a + FcεRIγ Cl #9 was subjected to ethanol 
precipitation (protocol as described in methods section) in order to purify and 
concentrate the DNA.  
Stable transfection was carried out by electroporation. The CHOKISV GS-KO cells 
were revived and subcultured for two passages, in their growth media 
(CDCHO+6mM L-glutamine). The cells were electroporated two days after 
subculturing, when they were in exponential growth phase. The cell viability was 
measured by trypan blue dye and was above 95%. Electroporation was performed 
(protocol as described in methods section) as per the protocol suggested by Lonza. 
Voltage was noted to be 297 volts and time constant was noted to be 19.4 milli 




seconds. Transfectants were transferred to twenty 96-well plates and incubated for 
three weeks in CO2 incubator, set at 10% CO2 in air. Cells were also transfected with 
reporter plasmid i.e. GFP encoding plasmid to serve as positive control. A good GFP 
expression was observed under fluorescence microscope, two days post transfection 
and was observed to be the stable expression. Figure3.14 shows transfection results 
of pXC 14.4 + GFP. 
    
 
Figure 3.14: Fluorescence microscopy images of CHOKISV GS-KO cells 
transfected with pXC 14.4+GFP. A good GFP expression was observed in 
CHOKISV GS-KO cells transfected with pXC 14.4 + GFP.(a) In blue light. (b) In 
white light. Images are 10X magnified. 
 
3.3.2  Clone development and selection of clone with highest receptor 
expression (Cell based ELISA and FACS)  
After 21 days of transfection of pXC 17.4 + CD16a + FcεRI-γ in CHOKISV GS-KO 
cells, 40 colonies were observed.  These 40 colonies were expanded from 96-well 
plate to 24-well plate and after 4-6 days they were expanded to T-25 flasks. Cell 
based ELISA was developed, as a novel method, for screening CD16a expressing 
a b 




cell lines (Grunow et al., 1994) (for protocol refer methods- Chapter 2) and based 
on those ELISA results, 28 higher CD16a expressing cell lines were expanded to T-
75 flask stage. Further at T-75 flask stage, cell based ELISA was performed and 14 
high CD16a expressing cell lines were expanded to T-175 flask stage.  Once again at 
T-175 flask stage, cell lines were screened by cell based ELISA and for the best 9 
clones, FACS analysis was done to check and compare CD16a expression on 
engineered CHOKISV GS-KO cell. CD16a expression was observed on transfected 
CHOKISV GS-KO cells. Clone # 2F11 was found to have the highest CD16a 
expression and was selected as the final engineered clone. Lead cell line 













Figure 3.15: Identification of a lead cell line with highest CD16a expression based 
on ELISA and FACS analysis. Cell based ELISA was done to screen cell lines at T-
25 flask stage, T-75 flask stage and T-175 flask stage. FACS analysis was done 
finally at T-175 flask stage to select among 9 highest CD16a expressing cell lines, 









3.3.3  Cell Banking  
A master cell bank was prepared for CHOKISV GS-KO / pXC 17.4 + CD16a + 
FcεRIγ Cl # 2F11. Cells were expanded to 2, T-175 flasks and with these cells 2 
Roller bottles were seeded and cultured in shaker incubator.  Working cell bank of 
100 vials was prepared at passage 7, as per the protocol described in Materials and 
Methods, Chapter 2 (Chapter 2). Number of cells per vial was 10 million. One of 
the vials was revived and checked for contamination. Cells were fine in terms of 
growth and also contamination was not observed. 
3.4 Standardization of the assay 
FACS analysis was carried out to check and compare the binding of the different 
isotypes of mAbs (1 μg/ml) to CD16a receptor expressing cell line (protocol 
described in Materials and Methods, Chapter 2 (Chapter 2)). Figure 3.16 shows 
FACS analysis of mAbs binding to CD16a. Panitumumab and Natalizumab being 
IgG2 and IgG4 respectively did not show any binding to CD16a receptor whereas 
Rituximab and Trastuzumab being IgG1 bound to the receptor. Thus FACS based 
CD16a receptor binding assay can be developed to assess the CD16a receptor 
binding  ability of the drugs. Further the assay was standardized for Trastuzumab by 












                 
Figure 3.16: Histogram depicting FITC expression of various mAbs. Panitumumab 
and Natalizumab being IgG2 and IgG4 respectively did not show any increase in 
FITC expression when compared to basic expression on cells stained with only 
secondary antibody conjugated to FITC. On the otherhand, Rituximab and 
Trastuzumab being IgG1 showed higher FITC expression. CD16a specifically binds 
to IgG1 mAbs. 
 
3.4.1 Cell number 
For determination of optimal cell density of engineered CHOKISV GS-KO cells to 
be used for CD16a receptor binding bioassay, assay was carried out with 1X106 cells 
and 0.5X106 cells. 30,000 events would be recorded for each analysis. Minimum cell 
number which gives highest MFI values at any given antibody concentration needs 
to be determined. In the assay, Trastuzumab was used as the primary antibody and 
the assay was repeated in triplicates.  The assay was carried out as per the protocol 




mentioned in Materials and Methods- Chapter 2. It took same time to record the 
events. A bar graph was plotted to compare the responses with both the cell numbers 
(Figure 3.17).  
 
                   
Figure 3.17: Optimization of the cell number for the assay. Each point in the graph 
represents mean ±SD of triplicates. Dose response is almost same with both the cell 
numbers. 
 
The results indicated almost the same response with both the cell numbers, so 
0.5X106 cells can be used for carrying out the assay. 
3.4.2 Selection of secondary antibody  
Secondary antibody is required for detection and affects assay performance. This 
optimization was carried out to select more specific and sensitive secondary antibody 
among Anti-human IgG (γ chain specific)-FITC antibody produced in goat - (F0132) 
and Anti-human IgG (Fab specific)-FITC antibody produced in goat (F5512). In the 
assay, Trastuzumab was used as the primary antibody at a concentration of 10 μg/ml 




and assay was carried out in triplicates. Secondary antibody was used at 1:50 
dilution. Figure 3.18 shows the comparison of the two secondary antibodies. 
 
                    
Figure 3.18: Secondary antibody selection data. Each point in the graph represents 
mean ±SD of triplicates.F5512 antibody is more specific and sensitive. 
 
The data illustrated that F5512 antibody was giving less background than F0132, 
hence F5512 is more specific. Higher MFI values were observed for the cells stained 
with F5512 i.e. F5512 was binding to more amount of antigen (Trastuzumab), so it 
had better sensitivity than F0132. The results were consistent for all the triplicates. 
Based on these observations, Anti-human IgG (Fab specific)-FITC antibody 
produced in goat (F5512) was selected for regular analysis, as it had better signal to 
noise ratio. 
3.4.3 Concentration of secondary antibody 
Secondary antibody concentration needs to be optimized because using higher 
concentration would increase background noises and would be less economic. On 
the other hand if concentration would be too low than targeted primary antibody 




would not be detected.  The optimization here was carried out by keeping primary 
antibody (Trastuzumab) concentration constant at 10μg/ml. The assay was set up and 
anti-human IgG (Fab specific)-FITC antibody produced in goat (F5512) was used at 
different dilutions (1:50, 1:100, 1:500 and 1:1,000). Table 3.1 summarizes the 
secondary antibody concentration optimization data. 
Table 3.1 Secondary antibody concentration optimization data. 
 
 
  Dilution 
MFI 
Cells + Primary Ab Cells + Secondary 
Ab (background) 
Cells + Primary 
Ab+ Secondary Ab 
1:50 193  2588  28451  
 1:100 204  1541  28532  
1:500 164  745  20672  
1:1,000 169  456  19888  
 
Highest MFI values are obtained with 1:50 and 1:100 dilutions. However, less 
background was observed at 1:100 dilutions as compared to 1:50 dilution so 1:100 
dilution of secondary antibody can be used for further assays as it showed best signal 
to noise ratio i.e. maximum sensitivity and minimum background.  
3.4.4  Working range for primary antibody 
For determining working range of the Trastuzumab and Rituximab antibodies which 
would show gradations, a serial two-fold dilutions of antibodies were prepared, 
ranging from 100 μg/ml to 0.78 μg/ml. Assay was performed in triplicates, with 
necessary controls. A graph of antibody concentration versus MFI values was plotted 
for both Trastuzumab and Rituximab separately (Figures 3.19.a and b). 





Figure 3.19: Evaluation of working range concentration for Trastuzumab and 
Rituximab. Each point in the graph represents mean ±SD of triplicates. The graphs 
indicated that MFI responses for Trastuzumab and Rituximab shows good gradation 
in the concentration range of 100 μg/ml to 1.5 μg /ml.  
 
From the above graphs it is evident that MFI responses for Trastuzumab and 
Rituximab shows good gradation in the concentration range of 100 μg/ml to 1.5 μg 
/ml. Above 50 μg/ml concentration, no significant increase in MFI values was 
observed, indicating saturation and below 1.5 μg/ml no significant decrease in MFI 
values was observed and hence the doubling dilutions of Trastuzumab and 
Rituximab, in the range 100 μg/ml to 1.5 μg /ml could be used for regular analysis.  
Table 3.2 Summary of CD16a receptor binding bioassay optimization. 
S.No Parameter Result 
1. Cell density 0.5X106 cells 
2. Selection of secondary 
antibody 
Anti-human IgG (Fab specific)-FITC 
antibody produced in goat (F5512) 
3. Concentration of secondary 
antibody 
1:100 times dilution. 
4. Working range of the primary 
antibody which shows 
gradation 
100 μg/ml to 1.5 μg /ml 
a 




3.5 Bioassay validation 
It is important to establish a validated assay which is in compliance with guidelines 
established by the FDA and other regulatory agencies. Validation exhibits that an 
assay is appropriate for its intended purpose and can be used for routine analysis. For 
validation exercise specificity, precision, accuracy, linearity and robustness of the 
assay were evaluated. 
3.5.1 Criterion: Specificity 
Specificity examines ability of an assay to explicitly differentiate between the 
intended target and other irrelevant targets. Specificity was evaluated by assaying 
nonspecific monoclonal antibody i.e. IgG2mAb (Panitumumab) and IgG4mAb 
(Natalizumab) against the IgG1mAbs (Trastuzumab and Rituximab). IgG2 and IgG4 
mAbs being used as the nonspecific antibody were prepared having 100ug/ml as the 
highest concentration followed by 7 subsequent two-fold dilutions and compared 
against the IgG1 mAbs having 100ug/ml as the highest concentration followed by 7 
subsequent two-fold dilutions. All the test concentrations were assayed in triplicates. 
The assay was executed as per the procedure provided in the materials and method- 
chapter 2. To show the comparison between different mAbs, a line graph was plotted 
with antibody concentration vs Mean Fluorescence Intensity (MFI) (Figure 3.20). 
 





Figure 3.20: Comparison  of CD16a receptor binding with IgG1 mAbs, IgG2 and 
IgG4 mAbs. Each point in the graph represents mean ±SD of triplicates. A proper 
dose response curve is observed for IgG1 mAbs (Rituximab and Trastuzumab) 
whereas IgG2 mAb (Panitumumab) and IgG4 mAb(Natalizumab) did not show any 
response indicating that CD16a receptor binding assay is specific to IgG1 mAbs. 
 
Increase in MFI values on increasing IgG1 mAbs (Trastuzumab and Rituximab)  
concentration is observed while no such gradation in MFI values is seen for IgG2 
mAb (Panitumumab) and IgG4mAb (Natalizumab). % CV of MFI values were less 
than 15%. Hence the CD16a receptor binding assay is specific for IgG1 mAbs. 
3.5.2 Criterion: Precision 
Precision relates to the closeness of individual response of an analyte when the test 
method is applied repeatedly to the given analyte. Precision can be measured at three 
different levels: repeatability, intermediate precision and reproducibility. Here 
repeatability is being evaluated under this criterion. 





Repeatability evaluates intra assay precision. Three set were analysed on the same 
day. The sets were prepared independently, each having 100% of Trastuzumab 
standard (100 μg/ml) as the highest concentration followed by 7 subsequent two-fold 
dilutions to be compared against the Trastuzumab standard (100 μg/ml) as the 
highest concentration followed by 7 subsequent two-fold dilutions. All the sets were 
assayed on the same day to assess the intra-assay precision. The assay was executed 
as per the assay protocol mentioned in Materials and Methods, Chapter 2 and each 
sample concentration was assayed in triplicates. Standard deviation and % CV 
values were calculated.  The relative potencies were estimated by PLA-2.0 software. 
Graph was also plotted to compare the dose response of the three sets (Figure 3.21). 
The observations for the various acceptance criteria, based on which the conclusions 
were drawn, were tabulated (Table 3.3).  
                  
Figure 3.21: Comparison of CD16a receptor binding response of three sets to 
evaluate Repeatability. All the three sets were assayed on the same day. Each point 
in the graph represents mean ±SD of triplicates. Comparable dose response curves 
are observed for all the three sets. 
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CV- Coefficient of Variation 
The above tabulated observations show that relative potency of each set is well 
within the acceptance criteria of 80-120%. The % CV value for response of the 
sample with repetitions is also less than 15%. Hence it can be concluded that the 
assay is highly repeatable. 
3.5.3 Criterion: Accuracy 
Accuracy refers to the closeness of response between the calculated value and the 
expected value. For determining accuracy, simulated potency samples of 70%, 80%, 
100%, 120% and 130% are assayed against the 100% standard for 3 days. For 
preparing 70%, 80%, 100%, 120% and 130% simulated potency samples, 
Trastuzumab standard is taken as test sample at 70 μg/ml(70%), 80 μg/ml (80%), 
100 μg/ml (100%), 120 μg/ml (120%) and 130 μg/ml (130%) as the highest 
concentration, followed by 7 subsequent two-fold dilutions from the highest 
concentration. All these samples are compared against the Trastuzumab standard 
(100%) with 100µg/ml as the highest concentration, followed by 7 subsequent two-
fold dilutions. The assay is repeated for three days as per the assay protocol 
mentioned in the validation protocol and the relative potencies were calculated by 




PLA-2.0 software. Graphs were plotted to show comparison of different 
concentrations for each day (Figures 3.22 a, b and c) and relative potencies are 
summarized in Table 3.4. The closeness of response between the calculated value 
and the expected value is represented by the ratio between them and is presented in 
graph (Figure 3.22d) 
  
Figure 3.22: Evaluation of Accuracy. a, b and c. Graphs to compare CD16a receptor 
binding response of different simulated samples at Day1, 2 and 3 respectively. Each 
point in the graph represents mean ±SD of triplicates. Comparable dose response 
curve is observed for all the simulated samples at Day1, 2 and 3; d. Graph presenting 
accuracy. The points representing ratio of observed value vs expected value were 
between 0.8 and 1.2. 
 




Table 3.4: The observations for the various acceptance criteria, based on which the 
conclusions are drawn. 
CV- Coefficient of Variation 
The above tabulated results show observed potency values are well within potency 
range and the percentage coefficient of variations were also found to be less than 
15%, thus the entire assay is highly accurate and capable of recovering potency from 
70% to 130%. 
3.5.4 Criterion: Linearity 
Linearity is the capability of the test to obtain test responses that are directly 
proportional to the concentration of the analyte. Linearity was demonstrated by 
plotting the data of observed or the obtained average relative potency versus the 
expected or the stated relative potency obtained as a part of accuracy section. The 




linear regression analysis was performed. Graph was plotted for the observed 
average potency against the expected potency (Figure 3.23). 
Table 3.4: Evaluation of linearity. Data from the accuracy section was considered 






potency     
(%) 
Observed Potency  
Expected   
Potency Day 1 Day 2 Day 3   Average 
1 70 0.583 0.711 0.706 0.667 0.7 
2 80 0.688 0.783 0.786 0.752 0.8 
3 100 0.909 0.999 0.841 0.916 1 
4 120 1.191 1.209 1.397 1.266 1.2 











Figure 3.23: Evaluation of Linearity for the observed average potency against the 
expected potency. R-square (correlation coefficient) value was found to be an 
acceptable value of 0.9785.  
 
The above tabulated results show that correlation coefficient complies with the 
acceptance criterion of not less than 0.95 and it was indicative of high significance. 
3.5.5 Criterion: Robustness 
The robustness determines whether the assay is reliable for routine analysis. It 
assesses the test’s ability to remain unaltered by small variations in test parameters.  
For evaluating robustness a set of assay was performed using 100% Trastuzumab 
sample having normal 100 μg/ml as the highest concentration followed by 7 
subsequent two-fold dilutions, to be compared against Trastuzumab having 100 
μg/ml as the highest concentration followed by 7 subsequent two-fold dilutions. 
Here, the following conditions were altered: 
 Primary antibody incubation time was shortened by 0.5 h. 
 Secondary antibody incubation time was lengthened by 0.5 h. 




The assay was executed as per the assay protocol mentioned in the protocol and the 
relative potencies were calculated by PLA-2.0 software. Graph was plotted to 
compare different responses (Figure 3.24) and observations were tabulated 
(Table3.6). 
        
Figure 3.24: Dose responses of samples with altered incubation time to evaluate 
Robustness. Each point in the graph represents mean ±SD of triplicates. Dose 
response curves of sample with altered incubation times are comparable to the 
standard dose response. 
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The above tabulated results show that the assay is robust enough to accommodate 30 
min less or more antibody incubation time. 
The key parameters, their relevant acceptance criteria and the results for those 
acceptance criteria are summarized in the table below. 
Table 3.6: Summary of the observations of the validation test method. 
Requirement Acceptance Criteria Results 
Specificity 
1)The standard is supposed to give a proper 
dose response curve where the MFI increases 
with the increase in antibody concentration of 
the drug, the nonspecific antibody is supposed 
to generate a flat dose response curve where 
no gradation is observed. 
No dose response was seen with 
the non-specific antibodies (IgG2 
and IgG4 mAbs) while proper 
response curve were seen with the 
IgG1 mAbs. Graph in Figure 3.20 
confers with the same.  
Precision 
Repeatability: 
1) Relative potency should be between 80 to 
125% of a 100% standard. 
2) The % CV value of relative potency 
between 3 sets of 100% sample on the same 
day should be less than 15%. 
3) The % CV value between triplicates of 
each concentration should be less than 15%. 
 
1) Table 3.3 justifies this criterion. 
 
2) Table 3.3 justifies this criterion. 
 
 
3) The PLA 2.0 raw data justify 
this criterion. 
Accuracy 
1) The average relative potency for all the 
samples (70%, 80%, 100%, 120% and 130% 
of the normal concentration) must be between 
80 to 125% of the expected value. 
2) The % CV value of relative potency 
between 3 sets of each simulated 
concentration (70%, 80%, 100%, 120% and 
130% of the normal concentration) on 
different days should be less than 15%. 
3) The % CV value between triplicates of 
each concentration should be less than 15%. 









3) The PLA 2.0 raw data justify 
this criterion. 
Linearity 
Data is to be obtained from the accuracy 
section and the correlation coefficient of the 
expected vs obtained relative potencies must 
be not less than 0.95. 
Graph in Figure 3.23 justifies this 
criterion. 
The correlation coefficient of the 
expected vs obtained relative 
potencies is 0.9785 justifying the 
acceptance criterion. 
 Robustness 
Potency of a 100 % sample will be evaluated 
by reducing the primary antibody incubation 
time 1 h to 0.5 h and increasing from 0.5 hrs 
to 1 h. The relative potency obtained should 
be between 80 to 125% of the expected value. 
Table 3.5 justifies this criterion 
 




The CD16a receptor binding bioassay for Trastuzumab was validated using the 
following criteria: Specificity, Precision, Accuracy, Linearity and Robustness. All 
parameters were found to be well within the limits. Hence the assay is validated for 
characterization of Trastuzumab. 
In this chapter, CD16a receptor binding assay was developed for Trastuzumab to 
compare the drug products and drug substances with innovator drug in the market. 
The assay can be technology transferred to Q.C. and can be used by them for their 
routine analysis. The assay further can be standardized for other drugs such as 
Rituximab, Cetuximab etc. which have ADCC as their mechanism of action. If we 
compare the assay with traditional cell based ADCC assays which employ PBMCs 
as effector cells, they are technically complicated to perform and suffer from inter 
donor variabilities. These variabilities arise due to inconsistencies in the immune 
status of the donors as well as the genetic background of the donor including CD16a 
allele polymorphism (158Vor 158F) and its copy number (Armour et al., 2010). In 
the recent years, to address these limitations, alternate assay formats have come up 
with precise and robust ADCC assay solutions. CD16a engineered NK92 cell line 
was generated to develop the improved ADCC assays (Schnueriger et al., 2011). 
Although this is a suitable approach to develop functional ADCC assay as it involves 
NK cells as effector cells which will exactly mimic the physiological situation but 
NK-92 cell line has very poor transfection efficiency and transfection is difficult to 
achieve in the standard  laboratory setup  (Boissel et al., 2009). Further, the 
commercial kit based reporter gene ADCC assays are also available where they have 
engineered Jurkat T cells with CD16a receptor which has nuclear factor of activated 
T cells (NFAT) controlled NFκB firefly luciferase reporter gene (Cheng et al., 2014). 




The bioassays are being used as surrogate ADCC assays for precise results but they 
are highly priced. In a very recent report, similar work was done to generate CD16a 
engineered Jurkat T cell lines i.e. J2 and J9 with renilla luciferase gene which even 
takes care of the fluctuations in the cell number (Gurjar et al., 2017). However, in 
both of the above assays, engineered T cell lines show reduced dose response over 
increased passage number as luciferase reporter gene expression gets affected due to 
changed cell physiology. Hence the assay setup has ready to use cryopreserved cells 
but those can be used only once after thawing. This increases the cost of such kit 
based assays. There are other approaches where CHO cell lines expressing CD16a 
receptor have been used since long, to develop the receptor binding assay (Armour et 
al., 2010). These assays evaluate CD16a receptor binding with accuracy and 
precision. In this Chapter the study presents the laboratory comprehensive method to 
engineer CHOKISV GS-KO (from Lonza) with CD16a receptor and to develop the 
assay using the same. The cell line thus generated had much higher expression of 
CD16a and also being suspension gave much better read outs as compared to 
previously engineered CHO cells based assays. To conclude, the CD16a expressing 
CHOKISV GS-KO cell line would be a reliable and stable source of cell surface 
receptor to compare the Fc functional activity of the biosimilar drugs. Further ADCP 












            Chapter 4 
VEGFR2 receptor binding assay 








The aim of this chapter is to describe the development of VEGFR2 receptor 
binding assay for Ramucirumab. VEGFR2 is the main receptor which responds to 
VEGF binding and signals for the cellular responses including endothelial cell 
proliferation and migration. VEGFR2 has emerged as an important therapeutic 
target in cancer therapy and its market is growing wildly with increase in number 
of drugs hitting the market every year (Peng et al., 2017). Ramucirumab is also 
recently approved by FDA in 2014. It is a humanized IgG1 monoclonal antibody 
against the extracellular domain of VEGFR2. It blocks ligand (VEGF) binding to 
VEGFR2 as it has higher affinity for VEGFR2 as compared to VEGF. Thus it 
inhibits tumour growth by inhibiting tumour neovascularization (Wadhwa et al., 
2013b). 
For developing VEGFR2 receptor binding assay for Ramucirumab, a cell line 
expressing VEGFR2 receptor is required. Mainly primary cell lines like HUVEC 
express VEGFR2. So engineering a cell line with VEGFR2 receptor will hold the 
potential to develop the bioassay for Ramucirumab. In the VEGFR2 receptor 
binding assay, primary antibody i.e. Ramucirumab would be incubated with the 
CHOKI SV GS-KO cell line expressing VEGFR2.  The Fab portion of the test 
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antibody binds to extracellular domain of VEGFR2 receptors on the cells. 
VEGFR2 expressing cells would be incubated with increasing concentrations of 
the test antibody. The secondary antibody conjugated to FITC is then allowed to 
bind to Ramucirumab. The fluorescence intensity, due to FITC conjugated to 
secondary antibody is measured by FACS and it is expressed in MFI (mean 
fluorescence intensity) units. The test antibody is expected to bind the receptor in a 
dose dependent manner. So with increasing concentrations of test antibody, 
increase in MFI values would be observed. These dose responses can be used to 
compare the VEGFR2 binding ability of the drugs and hence the potency of the 
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Figure 4.1: Diagrammatic representation of the VEGFR2 receptor binding 
assay.CHOKISV GS-KO cells expressing VEGFR2 receptor binds to 
increasing concentrations of primary or the test antibody. Secondary antibody 
then binds to primary antibody. Fluorescence due to FITC conjugated to 
secondary antibody is analyzed by the flow cytometry. Higher test antibody 
concentrations corresponds to higher fluorescence intensity indicating more 
VEGFR2 binding to the antibody.  
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Developing VEGFR2 receptor binding assay 
 
For developing the assay, a cell line expressing VEGFR2 receptor needed to be 
generated, followed by VEGFR2 receptor binding assay optimization. Figure 4.2 
summarizes the main steps involved in the development of the assay. Lonza’s GS 
Xceed expression system was used for generating the cell line expressing 
VEGFR2 receptor. The gene was commercially synthesized and subcloned in pXC 
17.4 vector by the traditional method of restriction enzyme digestion to insert the 
gene of interest in the vector. CHOKISV GS-KO cells were transfected with 
vector construct having VEGFR2 gene sequence. Transfection was done by 
electroporation. The highest VEGFR2 expressing cell line selected after screening 
and a cell bank was prepared for the same. 
 
After engineering the cell line, the VEGFR2 receptor binding assay was developed 
for Ramucirumab by optimizing various parameters including concentration of 
secondary antibody, selection of most suitable secondary antibody and working 
range for the primary antibody and finally the assay was validated. 




Figure 4.2: Major steps for the development of VEGFR2 receptor binding assay. 
 
4.2 Cloning of the VEGFR2 Receptor 
VEGFR2 receptor gene needed to be cloned and expressed on the CHOKI SV GS-
KO cell line. VEGFR2 was amplified from human cDNA library and cloning 
(blunt end cloning) was tried in pBSKS vector but it did not work. VEGFR2 
sequence was then sent for commercial synthesis from Gene Art. Few 
modifications were included in the gene to ease its further cloning. Commercial 
VEGFR2 was received in pMK (KanR) vector. The gene was verified and was 
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subcloned in pXC 17.4 expression vector from Lonza. Figure 4.3 outlines the 
cloning strategy.  
  Figure 4.3: Outline of construction of pXC17.4+VEGFR2. 
 
4.2.1 VEGFR2 amplification 
VEGFR2 sequence was derived from Gene Bank (NCBI Reference Sequence: 
NM_002253.2) i.e. Homo sapiens kinase insert domain receptor (KDR; a type III 
receptor tyrosine kinase), mRNA.  
http://www.ncbi.nlm.nih.gov/nuccore/NM_002253).  
After the gene sequence was confirmed, primers were designed to amplify the 
gene (primer17 and primer18 - listed in Chapter 2, section 2.5, Materials). 
VEGFR2 was amplified from Human universal cDNA library (Clontech, 7182-1) 
by Pfu native and Pfu Ultra DNA polymerase enzyme using Touchdown PCR 
(protocol described in Materials and Methods, Chapter 2). Total gene amplified 
product was of 4689bp. Figure 4.4 shows agarose gel electrophoresis image of 
amplified PCR product of VEGFR2. VEGFR2 was reamplified. The band were gel 
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eluted using Qiagen gel extraction kit (protocol described in Materials and 
Methods, Chapter 2) and quantitated.  
                                                               
Figure 4.4: Agarose gel electrophoresis image to show VEGFR2 amplification.  
VEGFR2 was amplified from human universal cDNA library. Lane1- NEB 1Kb 
DNA ladder, lane 2 – empty, lane3- 4689bp of VEGFR2 amplified PCR product 
using Pfu Ultra DNA polymerase, lane 4-empty, lane 5-4689bp of VEGFR2 
amplified PCR product using Pfu Native DNA polymerase. VEGFR2 amplification 
was observed in lane 5. 
Gel eluted VEGFR2 gene was sequenced and sequence alignment with the 
standard sequence was the perfect match. VEGFR2 gene cloning (blunt end) was 
tried in pBSKS and pUC19 vector but could not clone it.  
VEGFR2 gene modification for commercial synthesis 
VEGFR2 gene sequence was modified keeping in mind cloning and expression 
strategy for cloning in pcDNA3.1 (+) and pXC 17.4 vector. VEGFR2 gene 
modifications included silencing of the the restriction enzyme site(Hind III, EcoRI, 
EcoRV, SmaI and StuI). Restriction enzyme sites were silenced using Gene design 
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software. Also Hind III restriction enzyme site was added at the 5’ end and EcoRI 
site was added at the 3’ end and Kozak sequence was also included at the 5’ end. 
 
VEGFR2 gene design after modification: 
    
Modified VEGFR2 gene was sent for commercial synthesis. Figure 4.5 shows the 








































































Figure 4.5: Nucleotide Sequence of VEGFR2.  Nucleotide Sequence of VEGFR2 
was modified so as to ease its cloning and expression. The modified gene design 
includes HindIII site (in green), Kozak sequence (in red), VEGFR2 sequence (in 
black) with Hind III, EcoRI, EcoRV, SmaI and StuI site silent, EcoRI site (in 
pink). It was of 4092bp. 
 
VEGFR2 gene was commercially synthesized and received as lyophilized powder 
of pMK (KanR) +VEGFR2, which was reconstituted. XL-1 blue competent cells 
were transformed with pMK (KanR) +VEGFR2 by heat shock method and plated 
on LB Kanamycin plate. After overnight incubation at 37C, next morning a good 
number of colonies were observed. A single colony was inoculated in LB broth 
with Kanamycin and plasmid was purified. pMK (KanR)+VEGFR2 plasmid was 
sequenced and sequence was aligned with standard VEGFR2 sequence using 
Clustal W multiple sequence alignment software. It was found to match entirely 
with standard VEGFR2 sequence. Glycerol stock was prepared forVEGFR2/ pMK 
(KanR). 
4.2.2 Sub cloning of VEGFR2 in pXC 17.4 vector 
VEGFR2 was subcloned in pXC 17.4 vector. VEGFR2 / pMK (KanR) and pXC 
17.4 were digested with Hind III- EcoRI restriction enzymes for directional 
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cloning. Figure 4.6.a and b shows agarose gel electrophoresis image of Hind III- 
EcoRI restriction digestion of pXC 17.4 and VEGFR2 / pMK (KanR). VEGFR2 / 
pMK(KanR) was digested to release the insert VEGFR2 of 4086 bp and other 
pMK(KanR) band of 2299bp and pXC 17.4 plasmid was also digested. The bands 
of vector pXC 17.4 and VEGFR2 were gel extracted. Vector and insert were 
ligated in the ratio of 1:7 by T4DNA Ligase. XL-1 blue cells transformation was 
done, with the ligation mixture and after transformation cells were plated on LB 
Agar, ampicillin plates. After overnight incubation, only five colonies were 
observed which were inoculated in LB broth with ampicillin for plasmid 
purification. Plasmids were confirmed by Hind III - EcoRI digestion and expected 
bands size of 6893bp and 4086bp were observed for VEGFR2 /pXC 17.4 Cl# 1, 4 
and 5. Figure4.6.c shows agarose gel electrophoresis image of Hind III –EcoRI 
digested VEGFR2 /pXC 17.4 plasmids. VEGFR2 /pXC 17.4 Cl #5 was sequenced 
by primers 19 to 35 (listed in Chapter 2, section 2.5, Materials). Clustal W 
multiple sequence alignment software was used for sequence alignment and after 
sequence confirmation, glycerol stock was prepared for VEGFR2 /pXC 17.4 Cl #5. 
 
   




Figure 4.6: Agarose gel electrophoresis image for cloning VEGFR2 in pXC 17.4 
plasmid. VEGFR2 was cloned in pXC 17.4 vector. a. Agarose gel electrophoresis 
image of Hind III - EcoRI restriction enzyme digestion of insert. Lane 1 – 
Undigested VEGFR2 / pMK(KanR) (6385bp), lane 2- Hind III - EcoRI restriction 
enzyme digested VEGFR2 / pMK(KanR), lane 3- NEB 1Kb DNA ladder. 
Expected band size of 2299bp for pMK(KanR) vector and 4086bp for VEGFR2 
was observed in lane2; b. Agarose gel electrophoresis image of Hind III - EcoRI 
restriction enzyme digestion of vector. Lane 1 – Undigested pXC 17.4vector, lane 
2- Hind III - EcoRI restriction enzyme digested pXC 17.4 vector, lane 3- NEB 
1Kb DNA ladder. Expected band size of 6893bp for pXC 17.4 vector was 
observed in lane2; c. Agarose gel electrophoresis image of Hind III - EcoRI 
restriction enzyme digested plasmids. Lane 1 – 5- VEGFR2 /pXC 17.4 Cl#1-5, 
lane 6- NEB 1Kb DNA ladder. Expected band sizes of 6893bp and 4086bp were 
observed for VEGFR2 /pXC 17.4 Cl#1, 4 and 5. 
Plasmid DNA purification 
Maxi prep (Qiagen) was done (procedure as mentioned in the kit) for VEGFR2 
/pXC 17.4 Cl# 5 to prepare DNA for transfection and eluted in 1ml T.E. buffer. 
Total yield was found to be 2.8mg (A260/280 ratio-1.82) when quantitated by 
NanoDrop spectrophotometer.  
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4.3 Expression studies 
4.3.1 Stable transfection  
For stable transfection, linearized DNA was required, so the DNA was linearized 
with PvuI restriction enzyme. Figure 4.7 shows agarose gel electrophoresis image 
of linearization of VEGFR2/ pXC 17.4 Cl #5 plasmid. 
                                          Figure 4.7: Agarose gel electrophoresis image to show Pvu I linearization of 
VEGFR2/ pXC 17.4 Cl #5. VEGFR2/ pXC 17.4 Cl #5 was linearized with PvuI 
restriction enzyme before stable transfection. Lane 1- Pvu I linearized VEGFR2/ 
pXC 17.4 Cl #5, lane 2 - NEB 1 Kb DNA ladder, lane 3 - Uncut VEGFR2/ pXC 
17.4 Cl #5 plasmid. 
 
After linearization, VEGFR2/ pXC 17.4 Cl #5 was subjected to ethanol 
precipitation (protocol as described in methods section) in order to concentrate the 
DNA. Electroporation was carried out to achieve stable transfection. The 
CHOKISV GS-KO cells were subcultured for two passages after revival in their 
growth media i.e. CDCHO + 6 mM L-glutamine. On the day of transfection, cells 
were harvested and the cell viability as assessed by trypan blue dye was above 
    1          2        3   
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95%. Electroporation was performed following Lonza’s protocol and the voltage 
was noted to be 297 volts. Time constant was 17.8 milli seconds. After the pulse, 
the transfectants were transferred to twenty 96-well plates and incubated for three 
weeks in CO2 incubator. Reporter plasmid i.e. GFP encoding plasmid was also 
included as the positive control. A good GFP expression was observed when the 
transfected cells were analyzed by FACS implying the integration of GFP gene in 
the host genome. Figure 4.8 shows transfection results of pXC 14.4 + GFP. Since 
the positive control worked well, it was concluded that electroporation was 
successful. 
 
Figure 4.8: FACS analysis of CHOKISV GS-KO cells transfected with pXC14.4 
+GFP.CHOKISV GS-KO cells transfected with pXC 14.4+GFP had higher MFI 
values corresponding to fluorescence due to GFP expression in the cells as 
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4.3.2 Clone development and selection of clone with highest receptor 
expression (Cell based ELISA and FACS)  
Three weeks after pXC 17.4+VEGFR2 Cl#5 transfection in CHOKISV GS-
KO cells, 96-well plate were observed for any colonies and 478 colonies were 
identified visibly.  All the 478 colonies were expanded from 96-well plate to 
24-well plate and after 6 days they were analysed by VEGFR2 cell based 
ELISA (protocol mentioned in Chapter 2-Materials and Methods). Data is 
summarized in the Figure 4.9.a. Based on the ELISA results, 80 best 
VEGFR2 expressing cell lines were expanded to T-25 flasks. After this stage 
VEGFR2 expression was analysed by FACS based assay (protocol mentioned 
in Chapter2-Materials and Methods). VEGFR2 expression was observed on 
transfected CHOKISV GS-KO cells.  As per the FACS analysis, 21 higher 
VEGFR2 expressing cell lines were expanded to T-75 flask stage. Further at 
T-75 flask stage, FACS analysis was performed and 9 high VEGFR2 
expressing cell lines were expanded to T-175 flask stage.  Once again at T-
175 flask stage, cell lines were screened. Highest VEGFR2 expression was 
observed on cell line # 9D10 and therefore it was selected as the lead cell line. 
VEGFR2 engineered CHOKISV GS-KO cell line screening data is 


















Figure 4.9: Screening of the lead cell line with highest VEGFR2 expression. 
Identification of the lead cell line with highest VEGFR2 receptor expression based 
on ELISA and FACS analysis. a) Cell based ELISA was done to screen cell lines 
at 24-well plate stage. Cell lines marked in yellow were expanded to T-25 flasks. 
b) FACS analysis was done at T-25flask stage, T-75 flask stage and finally at T-
175 flask stage to select the highest VEGFR2 expressing cell line, and cell line 
9D10 was found to have highest VEGFR2 expression. 
 
b) 
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4.3.3 Cell Banking  
A master cell bank was prepared for CHOKISV GS-KO / pXC 17.4 + VEGFR2 
Cl# 9D10. Cells were expanded in two roller bottles and cultured in shaker 
incubator. A master cell bank of 20 vials was prepared at passage 6 and a working 
cell bank of 80 vials was prepared at passage 11, as per the protocol described in 
Materials and Methods, Chapter 2 (Chapter 2). Each vial contained 10x106 cells. 
One of the vials was revived and checked for the contamination. Cells were found 
to be free of any contamination. 
4.4 Standardization of the assay 
VEGFR2 expression was confirmed on the transfected CHOKISV GS-KO cells by 
FACS analysis [protocol described in Materials and Methods, Chapter 2 (Chapter 
2)]. Figure 4.10 shows FACS analysis data. CHOKISV GS-KO cells expressing 
VEGFR2 were stained with FITC conjugated secondary antibody only as a control 
sample.. CHOKISV GS-KO cells expressing VEGFR2, when stained with 
Ramucirumab showed an increase in FITC expression  whereas CHOKISV GS-
KO cells expressing VEGFR2, stained with Bevacizumab (non specific antibody), 
and untransfected CHOKISV GS-KO cells stained with Ramucirumab did not 
show any VEGFR2 expression. It was thus concluded that transfected CHOKISV 
GS-KO cells show VEGFR2 expression. The VEGFR2 receptor binding assay was 
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Figure 4.10: FACS analysis to confirm VEGFR2 expression on transfected 
CHOKISV GS-KO cells.  Histogram depicting FITC expression of CHOKISV 
GS-KO cells expressing VEGFR2. Untransfected CHOKISV GS-KO cells and 
CHOKISV GS-KO cells expressing VEGFR2 but stained with Bevacizumab (non-
specific antibody) did not show any VEGFR2 expression,  while CHOKISV GS-
KO cells expressing VEGFR2 and stained with Ramucirumab showed an increase 
in FITC expression as compared to basic expression on VEGFR2 expressing cells 
stained only with secondary antibody conjugated to FITC.  
4.5 Selection of a secondary antibody  
A labelled secondary antibody, binds to primary antibody and indirectly detects 
the antigen. Secondary antibody selection depends on the host species, isotype of 
primary antibody and the label preference. Secondary antibody selection was 
carried out to select the one that generates better signal to noise ratio among anti-
human IgG (Fc specific)-FITC antibody produced in goat - (F9512), anti-human 
IgG (Fab specific)-FITC antibody produced in goat (F5512) and anti-human IgG 
(whole molecule)-FITC antibody produced in goat (F3512). In the assay, 
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Ramucirumab was used as the primary antibody at a concentration of 10 μg/ml and 
secondary antibodies were used at 1:50 dilution. Figure 4.11 depicts the secondary 
antibody selection data.  
 
Figure 4.11: Comparison of the secondary antibodies. Selection of a secondary 
antibody. Anti-human IgG (whole molecule)-FITC antibody produced in goat 
(F3512) was found to be more sensitive and specific. 
 
The data illustrated that anti-human IgG (whole molecule)-FITC antibody 
produced in goat (F3512) was giving same background (specificity) and higher 
MFI values (better sensitivity) than the other two. The results were consistent for 
all the triplicates. Based on these observations, anti-human IgG (whole molecule)-
FITC antibody produced in goat (F3512) was selected for regular analysis, as it is 
more sensitive and specific.  
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4.5.1 Concentration of a secondary antibody 
Secondary antibody concentration optimization was required because at very low 
concentrations targeted primary antibody would not be detected, and at higher 
concentrations there would be higher background noise. Also, it would be less 
economic. While optimizing secondary antibody concentration, primary antibody 
(Ramucirumab) concentration was kept constant at 10 μg/ml. For the assay set up, 
secondary antibody i.e. anti-human IgG (Fab specific)-FITC antibody produced in 
goat (Sigma, F5512) was used at different dilutions (1:50, 1:100, 1:200, 1:500 and 
1:1,000). Figure 4.12 summarizes the secondary antibody concentration 
standardization data. 
 
Figure 4.12: Histogram graph representing secondary antibody concentration 
optimization data. At 1:50 and 1:100 dilutions, highest MFI values were achieved. 
However, at 1:100 dilutions less background was observed as compared to 1:50 
dilution, and hence it was decided to use 1:100 dilution of secondary antibody for 
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4.5.2 Working range for primary antibody 
For determining working range of the Ramucirumab that would show gradations, a 
serial ten-fold dilutions of antibodies were prepared, ranging from 1000 μg/ml to 
0.0001 μg/ml in one set and 500 μg/ml to 0.0005 μg/ml in other set. Assay was 
performed in triplicates, with necessary controls. A graph of antibody 
concentration versus MFI values was plotted for both the sets separately (Figures 
4.13.a and b). 
 
Figure 4.13: Evaluation of working range for Ramucirumab. Each point in the 
graph represents mean ± SD of triplicates. The graphs indicated that MFI 
responses for Ramucirumab shows good gradation in both the concentration 
ranges. 
 
From the above graphs, it was evident that MFI responses for Ramucirumab shows 
good gradation in both the concentration ranges. There is no saturation observed 
even at 1,000 µg/ml but it is not feasible to use 1,000 µg/ml of antibody 
concentration for the routine analysis and hence the ten-fold dilutions of 
Ramucirumab in the range 100 μg/ml to 0.0001 μg /ml could be used for regular 
analysis.  
b 





Table 4.1: Summary of VEGFR2 receptor binding bioassay optimization. 
 
S.No Parameter Result 
Selection of a secondary 
antibody 
Anti-human IgG (whole 
molecule)-FITC antibody 
produced in goat (Sigma, F3512) 
2. Concentration of secondary 
antibody 
1:100 times dilution. 
3. Working range of the primary 
antibody which shows 
gradation 
100μg /ml to 0.0001 μg /ml 
4.6 Bioassay validation 
For validating this assay, specificity, precision, accuracy, linearity and robustness 
of the assay were evaluated. 
4.6.1 Criterion: Specificity 
Specificity was evaluated by assaying nonspecific monoclonal antibody i.e. 
Bevacizumab and Trastuzumab against Ramucirumab. Untransfected CHOKI SV 
GSKO cells were also included as one of the control and incubated with 
Ramucirumab to show that it binds to VEGFR2 receptor engineered CHOKI SV 
GSKO cells only. Bevacizumab specifically binds to VEGF and Trastuzumab 
binds to Her2. Nonspecific antibody dilutions were prepared with 100 µg/ml as the 
highest concentration followed by 6 subsequent ten-fold dilutions. These were 
compared against the Ramucirumab with 100 µg/ml as the highest concentration 
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followed by 6 subsequent ten-fold dilutions. All the test concentrations were 
assayed in triplicates. The assay was executed as per the procedure provided in the 
materials and method- Chapter 2. Figure 4.14 shows a line graph which was 
plotted to show the comparison between different mAbs. 
 
 
Figure 4.14: VEGFR2 receptor binding is specific to Ramucirumab. A proper 
dose response curve was observed for Ramucirumab whereas Bevacizumab, 
Trastuzumab and untransfected CHOKISV GS-KO cells did not show any 
response indicating that VEGFR2 receptor binding assay is specific to 
Ramucirumab. Each data is presented as a mean ± SD of triplicates. 
 
Increase in MFI values on increasing Ramucirumab concentration was observed 
while no such gradation in MFI values was seen for Bevacizumab and 
Trastuzumab. Untransfected CHOKISV GS-KO cells also did not show any 
binding with Ramucirumab. % CV of MFI values were < 15%. Hence it can be 
concluded that the VEGFR2 receptor binding assay is specific for Ramucirumab. 
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4.6.2 Criterion: Precision 
For this assay repeatability was evaluated under this criterion. 
Repeatability 
For evaluating Repeatability as a part of intra assay precision, three sets were 
analysed on the same day. These sets were prepared independently, each 
having 100% of Ramucirumab standard (100 µg/ml) as the highest 
concentration followed by 7 subsequent two-fold dilutions to be compared 
against the Ramucirumab standard (100 µg/ml) as the highest concentration 
followed by 7 subsequent two-fold dilutions. All these sets were assayed on 
the same day and the assay was performed as per the assay protocol 
mentioned in Materials and Methods Chapter 2. The concentration of each 
sample was assayed in triplicates and standard deviation and % CV values 
were calculated.  The relative potencies were estimated by PLA-2.0 software. 
Figure 4.15 shows the data plotted to compare the dose response of the three 
sets. The observations for the various acceptance criteria, based on which the 
conclusions were drawn are tabulated in Table 4.2.  
 




Figure 4.15: Comparison of VEGFR2 receptor binding response of three sets to 
evaluate Repeatability. All the three sets were assayed on the same day. Each point 
in the graph represents mean ±SD of triplicates. Comparable dose response curves 
were observed for all the three assay sets. 
 
 Table 4.2: The various acceptance criteria to assess Repeatability. 
 
CV- Coefficient of Variation   
The data from Table 4.2 showed that relative potency of each set was well within 
the acceptance criteria of 80-120%. The %CV value for response of the sample 
with repetitions was also < 15%. Hence it could be concluded that the assay is 
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4.6.3 Criterion: Accuracy 
The accuracy was estimated by comparing the 100% standard with the 
simulated potency samples of 70%, 80%, 100%, 120% and 130% for 3 days. 
For preparing 70%, 80%, 100%, 120% and 130% simulated potency samples, 
Ramucirumab standard was taken as test sample at 70 µg/ml (70%), 80 µg/ml 
(80%), 100 µg/ml (100%), 120 µg/ml (120%) and 130 µg/ml (130%) as the 
highest concentration, followed by 7 subsequent two-fold dilutions from the 
highest concentration. All these samples were compared against the 
Ramucirumab standard (100%) with 100µg/ml as the highest concentration, 
followed by 7 subsequent two-fold dilutions. The assay was repeated for three 
days as per the assay protocol mentioned in the validation protocol and the 
relative potencies were calculated by PLA-2.0 software. Figures 4.16 (a, b 
and c) shows the data that were plotted to show comparison of different 
concentrations for each day. Relative potencies are summarized in Table 4.3. 
The proximity of the calculated value and the expected value was represented 
by the ratio between them and is presented in graph Figure 4.16 d. 




Figure 4.16: Evaluation of Accuracy.  a, b and c. Graphs to compare VEGFR2 
receptor binding response of different simulated samples at Day1, 2 and 3 
respectively to evaluate Accuracy. Each point in the graph represents mean ±SD of 
triplicates. Comparable dose response curve was observed for all the simulated 
samples at Day1, 2 and 3; d. Graph presenting accuracy. The points representing 









Table 4.3: Various acceptance criteria for the formulation of conclusion. 
 
CV- Coefficient of Variation  
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The above tabulated results showed that observed potency values were well within 
potency range and the percentage coefficient of variation was also found to be 
<15%, thus the entire assay is highly accurate and capable of recovering potency 
from 70% to 130%. 
4.6.4 Criterion: Linearity 
Linearity was demonstrated by plotting the data of observed or the obtained average 
relative potency versus the expected or the stated relative potency obtained as a part 
of accuracy section. The linear regression analysis was performed. Figure 4.17 
shows the data plotted for the observed average potency against the expected 
potency. 
Table 4.4: Evaluation of linearity. Data obtained from experiments performed for 
determining the accuracy was also considered for determining the linearity.  
 
 
  Stated 
potency     
(%) 
                        Observed Potency  
Expected   
Potency Day 1 Day 2 Day 3 Average 
70 0.624 0.599 0.602 0.608 0.7 
80 0.716 0.814 0.644 0.725 0.8 
100 0.916 0.94 0.95 0.935 1 
120 1.345 1.263 1.134 1.247 1.2 
130 1.511 1.477 1.528 1.505 1.3 
 
 




Figure 4.17: The observed average potency against the expected potency to 
evaluate Linearity.  The R-square (correlation coefficient) value was found to be an 
acceptable value of 0.9765.  
 
The above tabulated results show that correlation coefficient complies with the 
acceptance criterion of not less than 0.95 and it is indicative of high significance. 
4.6.5 Criterion: Robustness 
For evaluating robustness a set of assay was performed using 100% Ramucirumab 
sample having normal 100 µg/ml as the highest concentration followed by 7 
subsequent two-fold dilutions, to be compared against Ramucirumab having 100 
µg/ml as the highest concentration followed by 7 subsequent two-fold dilutions. 
Here, the following conditions were altered: 
 Primary antibody incubation time was shortened by 0.5 h. 
 Secondary antibody incubation time was lengthened by 0.5 h. 
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The assay was executed as per the assay protocol mentioned in the protocol and the 
relative potencies were calculated by PLA-2.0 software. Figure 4.18 shows the 
graph that was plotted to compare different responses and observations are 
tabulated as in Table 4.5. 
 
Figure 4.18: Illustration of the evaluation of robustness of the assay. Comparison of 
sample dose response with change in incubation times for the primary and secondary 
antibodies to evaluate Robustness. Each point in the graph represents mean ±SD of 
triplicates. Dose response curves of sample with altered incubation times are 
comparable to the standard dose response. 
 
Table 4.5: Evaluation of Robustness of the assay.  
 
Condition  
Relative potency  























VEGFR2 receptor binding assay 
150 
 
The above tabulated results show that the assay is robust enough to accommodate 
half an hour less or more antibody incubation period. 
The key parameters, their relevant acceptance criteria and the results for those 
acceptance criteria are summarized in the Table 4.6. 
 Table 4.6: Summarized data of the validation test methods. 
Requirement Acceptance Criteria Results 
Specificity 
1)The standard is supposed to give a 
proper dose response curve where the 
MFI increases with the increase in 
antibody concentration of the drug, 
the nonspecific antibody is supposed 
to generate a flat dose response curve 
where no gradation is observed. 
 
No dose response was 
seen with the 
untransfected CHOKISV 
GS-KO cells and non-
specific primary antibody 
(Bevacizumab) while 
proper response curve 
were seen for 
Ramucirumab with 
VEGFR2 expressing cells. 
Graph in Figure 4.14 
confers with the same.  
Precision 
Repeatability: 
1) Relative potency should be 
between 80 to 125% of a 100% 
standard. 
2) The % CV value of relative 
potency between 3 sets of 100% 
sample on the same day should be < 
15%. 
3) The % CV value between 
 
1) Table 4.2 justifies this 
criterion. 
2) Table 4.2 justifies this 
criterion. 
 
3) The PLA 2.0 raw data 
justify this criterion. 




1) The average relative potency for all 
the samples (70%, 80%, 100%, 120% 
and 130% of the normal 
concentration) must be between 80 to 
125% of the expected value. 
2) The % CV value of relative 
potency between 3 sets of each 
simulated concentration (70%, 80%, 
100%, 120% and 130% of the normal 
concentration) on different days 
should be < 15%. 
3) The % CV value between 
triplicates of each concentration 
should be < 15%. 











3) The PLA 2.0 raw data 
justify this criterion. 
Linearity 
Data is to be obtained from the 
accuracy section and the correlation 
coefficient of the expected vs 
obtained relative potencies must be 
not less than 0.95. 
Graph in Figure 4.17 
justifies this criterion. 
The correlation 
coefficient of the expected 
vs obtained relative 
potencies is 0.9765 
justifying the acceptance 
criterion. 
Robustness 
Potency of a 100 % sample will be 
evaluated by reducing the primary 
antibody incubation time 1 h to 0.5 h 
and increasing from 0.5 h to 1 h. The 
relative potency obtained should be 
between 80 to 125% of the expected 
value. 
Table 4.5 justifies this 
criterion 
 
After validating the assay using the criteria of Specificity, Precision, Accuracy, 
Linearity and Robustness, the assay can be used for characterization of 
Ramucirumab and could be technology transferred to Q.C. for their routine analysis.  
The assay further can be used for characterization of anti VEGF drugs like 
Bevacizumab. In that case, the constant concentration of VEGF would be neutralized 
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with increasing concentrations of Bevacizumab. Neutralization mixture can be added 
to the VEGFR2 expressing cells. Washing the cells will remove VEGF bound to 
Bevacizumab. This can then be followed by adding labelled secondary antibody 
against VEGF, thus targeting to the remaining VEGF that has bound to the VEGFR2. 
Labelled secondary antibody can then be detected to assess the concentration of 
VEGF that has bound to VEGFR2. The more is the concentration of VEGF that has 
bound to VEGFR2, the lesser is the concentration of Bevacizumab that has blocked 
the VEGF, and hence the bioactivity of Bevacizumab can be evaluated. 
As it has already been discussed in previous chapters, that the drugs where receptor 
binding is crucial for their mechanism of action, there receptor binding analysis data 
forms the indispensable part of the comparative data, required to establish 
biosimilarity of the proposed drugs to the FDA approved drug already in the market 
(FDA, 2015). The assay can be used to compare the relative potency of the drug 
sample and its reference standard. The cell based receptor binding assay is 
advancement to ELISA and SPR as it is physiologically more relevant and more 
precise as it does not require immobilization of the soluble receptors. So the 
VEGFR2 receptor binding assay developed and described in this chapter would be a 
useful tool to establish the biosimilarity of anti VEGFR2 and even anti VEGF drugs.  
In the literature, primary cells including porcine aortic endothelial cells (PAE), 
human umbilical vein endothelial cells (HUVECs) and human dermal microvascular 
endothelial cells (HMVECs) have been used for such analysis (Oommen et al., 
2011). But such assays being based on primary cells are complex and highly 
variable. Recent reports have shown development of reporter gene assays using 
VEGFR2 engineered HEK293 cells, based on VEGFR2-NFAT signalling pathway 
(Wang et al., 2016). It has been already discussed in previous chapter that such 
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luciferase reporter gene assays shows decreased dose response over increased 
passages and hence can be used only once after thawing  and so they are quite costly. 
For this study VEGFR2 was expressed on CHOKISV GS-KO cells which ensures 



























5 EA.hy926 cell proliferation inhibition assay 
 
5.1 Introduction 
Anti VEGF drugs have now become an integral part of anticancer therapy (reviewed 
in Chapter 1). Cell based bioassays available for these drugs are mainly HUVEC or 
other primary cell based assays. Primary cells are tedious to isolate, have limited life 
span i.e. up to few passages only and suffer from lot to lot variations as they are 
derived from multiple donors. So there is an unmet need of continuous cell line 
based assays in angiogenesis research. EA.hy926 cell line is one of the best 
characterized continuous endothelial cell line (Bouïs et al., 2001). Other benefits of it 
being a choice of cell line included ease of culturing and maintenance. However 
EA.hy926 cells does not respond to VEGF as effectively as HUVECs or other 
primary cells do since they have relatively lesser VEGFR2 expression (BARANSKA 
et al., 2005). So was hypothesized that if EA.hy926 cells overexpress VEGFR2 
receptor, then there are better prospects of developing convenient, reproducible and 
robust cell based bioassays. This chapter explains the work done to investigate this 
hypothesis.  
VEGFR2 expression was compared on Ea.hy926 cells and HUVEC cells by FACS 
analysis. Both HUVEC and EA.hy926 cells were stained with mouse anti-hVEGFR2 
fluorescein conjugated (IgG1) antibody and its isotype (R&D systems, FAB357F) 
and analysed by FACS. Figure 5.1 illustrates the comparison of VEGFR2 expression 
between the two cells.        




Figure 5.1: FACS analysis for comparing VEGFR2 expression on HUVEC and         
EA.hy926 cells. Histogram depicting comparison of VEGFR2 expression on 
HUVEC and EA.hy926 cells. HUVEC cells have stronger VEGFR2 gene expression 
as compared to EA.hy926cells.  
 
So from the FACS analysis data further it was clarified that VEGFR2 expression on 
EA.hy926 cells is not as intense as compared to HUVECS. So it was decided to 
engineer EA.hy926 cells with VEGFR2 receptor so that they start over expressing 
VEGFR2. VEGF would then stimulate Ea.hy926 cell proliferation by VEGFR2 
signalling and cell proliferation inhibition assay for anti-VEGF drugs can be 
developed. In the bioassay, EA.hy926 cells would proliferate in presence of fixed 
concentration of VEGF. Anti VEGF drug like Bevacizumab would be added in 
increasing concentrations. The drug would block VEGF in dose dependent manner 
and accordingly cell proliferation inhibition would be observed. Cell number would 
be measured by Alamar blue. The dose responses can be used to compare the anti-
VEGF activity of the drugs. Figure 5.2 shows diagrammatic representation of the 
hypothesized EA.hy926 cell proliferation inhibition assay. 
         




Figure 5.2: Diagrammatic representation of the EA.hy926 cell proliferation   
inhibition assay. Anti-VEGF drug blocks VEGF in dose dependent manner. 
Remaining VEGF binds to VEGFR2 receptor on EA.hy926 cells and causes cell 
proliferation which is measured.  
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Developing EA.hy926 cell proliferation inhibition assay 
For developing this assay, an EA.hy926 cell line overexpressing VEGFR2 receptor 
was required to be generated, followed by cell proliferation inhibition bioassay 
optimization. Figure 5.3 outlines the main steps involved in the development of the 
assay. VEGFR2 gene (artificially synthesized, detailed in Chapter 4) was subcloned 
in pcDNA3.1 (+) and pEGFP-N1expression vectors. Different modes of transfection 
were tried to introduce the gene construct in the EA.hy926 cells genome.  After 
generation of the VEGFR2 expressing cell line, a number of different parameters 
were optimized to develop the assay. These included composition of bioassay media, 
concentration of VEGF, cell number and incubation time. Figure 5.3 outlines the 
main involved in developing this bioassay.  




Figure 5.3: Major steps for the development of the EA.hy926 cell proliferation 
inhibition assay. 
5.2 Cloning of the VEGFR2 Receptor 
VEGFR2 receptor gene was cloned and expressed on the EA.hy926 cells. The 
VEGFR2 gene was commercially synthesized and received in pMK (KanR) vector 
(as described in Chapter 4). For expressing VEGFR2 gene on EA.hy926 cell line as 
per the cloning strategy (Figure 5.4), it was subcloned in pcDNA 3.1(+) and 
pEGFP-N1expression vectors.  




Figure 5.4: Outline of construction of pcDNA 3.1(+) +VEGFR2 and pEGFP-N1 
+VEGFR2. 
5.2.1 VEGFR2 subcloning in pcDNA3.1 (+) 
VEGFR2 gene sequence was modified, commercially synthesized and received as 
pMK (KanR) +VEGFR2. Details are mentioned in Chapter 4. For subcloning 
VEGFR2 in pcDNA3.1 (+), pMK (KanR) +VEGFR2 and pcDNA3.1 (+) were 
revived from glycerol stocks and streaked on LB Kanamycin plate and LB 
Ampicillin plate respectively. Single colonies were inoculated and plasmids were 
purified by in house method and quantitated by Nanodrop spectrophotometer. Both 
the plasmids were digested with Hind III- EcoRI restriction enzymes for carrying out 
directional cloning. Figures 5.5. a, b show agarose gel electrophoresis image of 
Hind III- EcoRI restriction enzyme digestion of pcDNA3.1 (+) and VEGFR2 / pMK 
(KanR). VEGFR2 / pMK (KanR) was digested to release the insert of  4086 bp 
corresponding toVEGFR2 gene of and other pMK(KanR) vector band of 2299bp. 
Gel extraction of vector band of pcDNA3.1(+)  and VEGFR2 receptor gene was 
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followed by ligation by T4DNA Ligase (ratio of vector: insert was 1:3). XL-1 blue 
competent cells were transformed and cells were plated on LB Agar, ampicillin, 
IPTG, X Gal. plates. Seven colonies were observed and colony PCR was done to 
check the plasmids using gene specific primer (primer 36) and vector specific primer 
(primer 37) and samples were run on agarose gel. Expected band size of 638bp was 
observed for all the colonies, as shown in Figure 5.5 c. Colonies were inoculated 
and plasmid purification was done followed by quantitation by NanoDrop. For 
confirming the plasmids, Hind III - EcoRI digestion was done. Expected band size of 
5387bp and 4086bp were observed only for VEGFR2 /pCDNA3.1 (+) # 7. Figure 
5.5.d shows agarose gel electrophoresis image of Hind III –EcoRI digested VEGFR2 
/ pcDNA3.1 (+) plasmids. VEGFR2 / pcDNA3.1 (+) # 7 was sequenced by primers 
19 to 38 (listed in Chapter 2, section 2.5, Materials). Sequence alignment (Clustal 
W multiple sequence alignment software) was done and sequence aligned with 
standard VEGFR2 sequence (given in Chapter 4, figure 4.5). Glycerol stock was 
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Figure 5.5: Agarose gel electrophoresis images of cloning of VEGFR2 gene in 
pcDNA3.1 (+) plasmid. a. Agarose gel electrophoresis image of Hind III - EcoRI 
restriction enzyme digestion of insert. Lane 1 – NEB 1Kb DNA ladder , lane 2- 
Undigested VEGFR2 / pMK(KanR) (6385bp), lane 3-Hind III - EcoRI restriction 
enzyme digested VEGFR2 / pMK(KanR). Expected band size of 2299bp for 
pMK(KanR) vector and 4086bp for VEGFR2 was observed in lane3; b. Agarose gel 
electrophoresis image of Hind III - EcoRI restriction enzyme digestion of vector. 
Lane1– NEB 1Kb DNA ladder, lane 2-Undigested pcDNA3.1(+) vector, lane 3- 
Hind III - EcoRI restriction enzyme digested pcDNA3.1(+) vector, Expected band 
size of 5387bp for pcDNA3.1(+) vector was observed in lane3; c. Agarose gel 
electrophoresis image of colony PCR. Lane 1 – 4- PCR product of VEGFR2 / 
pcDNA3.1 (+)Cl#1-4 , lane 5- NEB 100bp DNA ladder. Lane 6 – 8- PCR product of 
VEGFR2 / pcDNA3.1 (+) Cl#5-7. Expected band sizes of 638bp was observed for 
VEGFR2 / pcDNA3.1 (+) Cl#1-7; d. Agarose gel electrophoresis image of Hind III - 
EcoRI restriction enzyme digested plasmids. Lane 1 – 7- VEGFR2 / pcDNA3.1 (+) 
Cl#1-7, lane 8- NEB 1Kb DNA ladder. Expected band sizes of 5387bp and 4086bp 
was observed for VEGFR2 / pcDNA3.1 (+) Cl#7. 
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5.2.2 VEGFR2 subcloning in pEGFP-N1 
VEGFR2 was subcloned in pEGFP-N1, for that pMK (KanR) +VEGFR2 and 
pEGFP-N1 were streaked from glycerol stock on LB Kanamycin plates. Next day, 
single colonies were inoculated and plasmids were purified and quantitated by 
Nanodrop spectrophotometer. This was followed by Hind III- EcoRI restriction 
enzymes digestion for both the plasmids. Figures 5.6.a, b show agarose gel 
electrophoresis image of Hind III- EcoRI restriction enzyme digestion of pEGFP-N1 
and VEGFR2 / pMK (KanR). VEGFR2 / pMK(KanR) was digested to release the 
insert VEGFR2 receptor gene of 4086 bp and other pMK(KanR) vector band of 
2299bp. pEGFP-N1  and VEGFR2 receptor gene were gel extracted and ligated. XL-
1 blue competent cells were transformed and cells were plated on LB Agar, 
kanamycin plates. Next day eight colonies were observed. To confirm the plasmids 
colony PCR was done with gene specific primer (primer 39) and vector specific 
primer (primer 40) and samples were run on agarose gel. Expected band size of 
831bp were observed for colonies# 3, 5, 6, 7 and 8 as shown in Figure 5.6.c. 
Plasmids were inoculated and next day growth was observed in all plasmids except 
for VEGFR2/pEGFP-N1 Cl# 3. Plasmid purification was done for rest of the 
plasmids. For confirmation, plasmids were subjected to Hind III - EcoRI digestion 
and expected bands sizes of 4726bp and 4086bp were observed for all the VEGFR2 
/pEGFP-N1 plasmids. Figure 5.6. d shows agarose gel electrophoresis image of 
Hind III –EcoRI digested VEGFR2 / pEGFP-N1 plasmids. VEGFR2 /pEGFP-N1 # 8 
was sequenced by primers 19 to 38 (listed in Chapter 2, section 2.5, Materials and 
Methods). Sequence alignment was done (Clustal W multiple sequence alignment 
software) and after confirmation, glycerol stock of VEGFR2 /pEGFP-N1 Cl #8 was 
prepared. 
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Figure 5.6: Agarose gel electrophoresis image of cloning of VEGFR2 gene in 
pEGFP-N1 plasmid. VEGFR2 was cloned in pEGFP-N1 vector. a. Agarose gel 
electrophoresis image of Hind III - EcoRI restriction enzyme digestion of insert. 
Lane 1 – Undigested VEGFR2 / pMK (KanR) (6385bp), lane 2- Hind III - EcoRI 
restriction enzyme digested VEGFR2 / pMK (KanR), lane 3- NEB 1Kb DNA ladder. 
Expected band size of 2299bp for pMK (KanR) vector and 4086bp for VEGFR2 was 
observed in lane2; b. Agarose gel electrophoresis image of Hind III - EcoRI 
restriction enzyme digestion of vector. Lane1– NEB 1Kb DNA ladder, lane 2-
Undigested pEGFP-N1 vector, lane 3- Hind III - EcoRI restriction enzyme digested 
pEGFP-N1vector, Expected band size of 4726bp for pEGFP-N1 vector was observed 
in lane3; c. Agarose gel electrophoresis image of colony PCR. Lane 1 – 8- PCR 
product of VEGFR2 / pEGFP-N1Cl#1-8 , lane 9- NEB 100bp DNA ladder. Lane 9 
No template control (negative control). Expected band sizes of 831bp was observed 
for VEGFR2 / pEGFP-N1Cl#3, 5, 6, 7 and 8; d. Agarose gel electrophoresis image 
of Hind III - EcoRI restriction enzyme digested plasmids. Lane 1 – 4- VEGFR2 / 
pEGFP-N1Cl#5-8, lane 8- NEB 1Kb DNA ladder. Expected band sizes of 4726bp 
and 4086bp were observed for all VEGFR2 / pEGFP-N1 plasmids. 
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Plasmid DNA purification 
To get high quality DNA which is free from bacterial endotoxins, Maxi prep 
(Qiagen) was done (procedure as mentioned in the kit) for VEGFR2 / pcDNA3.1 (+) 
Cl# 7 and VEGFR2 / pEGFP-N1 Cl#8. They were eluted in 1ml T.E. buffer and 
quantitated by NanoDrop spectrophotometer. Total yield was 2.88mg (A260/280 ratio-
1.87) for VEGFR2 / pcDNA3.1 (+) Cl# 7 and for VEGFR2/pEGFP-N1 Cl#8, it was 
3.5 mg (A260/280 ratio-1.90).  
5.3 Expression studies 
5.3.1 Stable transfection  
EA.hy926 cell line is reported as a hard to transfect cell line and maximum 
transfection efficiency attained is 2%. The transfection efficiency is low because 
endothelial cells are involved in many physiological transport function, so they have 
inherent tendency to divert a macro molecules which is not involved in any of the  
pathway to the degradation pathway in lysosomes (Edgell et al., 1998). EA.hy926 
cells were received from ATCC and a cell bank was prepared. A number of different 
transfection methods were tried.  
For stable transfection DNA was linearized i.e. VEGFR2 / pcDNA3.1 (+) Cl# 7 was 
linearized with PvuI restriction enzyme and VEGFR2/pEGFP-N1 Cl#8 was 
linearized with NotI restriction enzyme. Figure 5.7 shows agarose gel 
electrophoresis image of linearization of both the plasmids. 




Figure 5.7: Agarose gel electrophoresis image to show linearization of VEGFR2/ 
pcDNA3.1 (+) Cl# 7 and VEGFR2/ pEGFP-N1Cl#8 plasmids. VEGFR2/ 
pcDNA3.1(+)Cl# 7was linearized with Pvu I restriction enzyme and VEGFR2/ 
pEGFP-N1Cl# 8 was linearized with Not I restriction enzyme. Lane 1- Uncut 
VEGFR2/ pcDNA3.1(+)Cl# 7 plasmid , lane 2 - Pvu I linearized VEGFR2/ 
pcDNA3.1(+) Cl# 7, lane 3 -NEB 1 Kb DNA ladder, lane 4- Uncut VEGFR2/ 
pEGFP-N1Cl#8 plasmid , lane 5 - Not I linearized VEGFR2/ pEGFP-N1Cl#8. 
 
After linearization, both the plasmids were ethanol precipitated (protocol as 
described in methods section).  
5.3.2 Kill curve of EA.hy926 cells in presence of gentamycin 
Both the plasmids i.e. pcDNA3.1 (+) and pEGFP-N1 has neomycin resistance gene, 
so gentamycin, which is a broad spectrum aminoglycoside antibiotic, was used as 
selection pressure for transfection studies in EA.hy926cells. Each cell line would be 
having specific sensitivity to the antibiotic, so kill curve for EA.hy926 cells was 
performed with gentamycin to select the lowest concentration of the antibiotic at 
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which massive cell death begins. For the kill curve experiment, 0.5X106 cells were 
seeded per well in 6-well plate in 2ml media (DMEM+ 10% FBS + 4 mM L-
glutamine). Different concentration of gentamycin were added including 1,000 
μg/ml, 700 μg/ml, 600 μg/ml, 500 μg/ml, 300 μg/ml, 200 μg/ml, 100 μg/ml and 50 
μg/ml). Cells were incubated at 37C, 5%CO2 and media change was given every 
third day. After two weeks, it was observed that all the cells died in presence of 
gentamycin up til the concentration of 300 μg/ml. So 300 μg/ml of gentamycin can 
be used as the working concentration for EA.hy926 transfection studies. 
5.3.3 Lipofectamine 2000 mediated transfection 
Lipofectamine 2000 is a nucleic acid transfection reagent from Invitrogen. It works 
on the principle of lipofection and transfects eukaryotic cells. Transfection was 
carried out as per the instructions mentioned in the manual protocol. One day before 
transfection, 7.5X105 cells were seeded in 6-well plate. Transfection was done in 
Opti MEM media using 4 µg of DNA. HEK293T cells and EA.hy926 cells were 
transfected. HEK293T cells are easy to transfect and hence they were employed as 
positive control for transfection. HEK293T cells were transfected with pEGFP-N1 
vector. pEGFP -N1 vector was again a positive control as it has GFP gene, so if 
transfection is successful then GFP expressing cells would appear fluorescent green 
under the fluorescence microscope. EA.hy926 cells were transfected with pEGFP-
N1 vector, VEGFR2/ pcDNA3.1 (+) Cl# 7 and VEGFR2/ pEGFP-N1Cl# 8 plasmids. 
Two days after transfection, gentamycin (G418, Sigma) at 300 µg/ml concentration 
was added as the selection pressure and also pEGFP-N1-transfected HEK293T cells 
and EA.hy926 cells were observed under fluorescence microscope. Good GFP 
expression was observed in HEK293T cells but there was no GFP expression in 
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EA.hy926 cells. Media was changed every two days post transfection. After two 
weeks, all the cells died and could not survive the selection pressure. 
5.3.4 Effectene and Superfect mediated transfection 
Effectene and Superfect are the specifically designed formulations from Qiagen that 
condenses DNA and facilitates its entry inside the eukaryotic cells. EA.hy926 
transfection was tried with these reagents by following the protocol in the manual. 
pEGFP - N1 was used as the positive control. HEK293T cells were transfected with 
pEGFP-N1 (positive control) and EA.hy926 cells were transfected with pEGFP-N1 
vector, VEGFR2 / pEGFP-N1Cl#8 and VEGFR2 / pcDNA3.1 (+) Cl# 7 plasmids. 
The next day, G418 (300µg/ml) was added.  Here also GFP expression under 
fluorescence microscope was observed in HEK293T cells but not in EA.hy926 cells. 
After two days all the cells died. 
5.3.5 PEI mediated transfection 
Polyethylenimine (PEI) is a polycation, used as an efficient transfection reagent. 
EA.hy926 cells were transfected with PEI, following the protocol in the paper 
(Boussif et al., 1995). Briefly, 18hrs before transfection, 50,000 cells were seeded in 
24-well plate. Next day cells were rinsed and suspended in serum free media. PEI 
(diluted in 150mM NaCl) and DNA in the ratio of 3:1 were incubated for 10 min and 
added to the cells. Serum was added after 4hrs and G418 (300µg/ml) was added on 
the next day. GFP expression was not observed in EA.hy926 cells transfected with 
pEGFP-N1 (positive control). Transfected EA.hy926 cells died after 5 days. 
 
 




A number of different electroporation conditions were tried and they are tabulated in 
Table 5.1. Since the initial electroporation transfection attempts were unsuccessful, 
different ways of increasing the transfection efficiency were tried. DMSO is known 
to increase the transfection efficiency (Melkonyan et al., 1996), so different 
concentrations of DMSO were tried and it was observed that DMSO increased the 
transfection efficiency. After a number of attempts, good transfection efficiency was 
achieved in EA.hy926 cells. GFP expression enhanced when EA.hy926 cells were 
transfected with pEGFP-N1vector as shown in the Figure 5.8.  
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Table 5.1: Summary of Electroporations for transfecting EA.hy926 cells. 
  
DNA Cells Electroporation media Voltage          
(V) 















DMEM for electroporation and after 
giving pulse, cells were suspended 
in DMEM+ 10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
200 1200 ∞ 
 
 
19.2 All the cells died 







DMEM for electroporation and after 
giving pulse, cells were suspended 
in DMEM+ 10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
200 1200 ∞ 16.8 All the cells died 
within 10 days 
pEGFP-N1 
(positive 




DMEM for electroporation and after 
giving pulse, cells were suspended 
in DMEM+10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
 
 
200 1200 ∞ 21.7 GFP expression 
was not observed 
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6, 3X106 cells 
 
DMEM for electroporation and after 
giving pulse, cells were suspended 
in DMEM+ 10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
Pulse 1-  
1500 
Pulse  2 
- 300 
Pulse 1-  25 
Pulse  2 - 
1500 
990 21 All the cells died 





6, 3X106 cells 
 
DMEM for electroporation and after 
giving pulse, cells were suspended 
in DMEM+ 10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
Pulse 1-  
1500 
Pulse  2 
- 300 
Pulse 1-  25 
Pulse  2 - 
1500 
990 17.4 All the cells died 






6, 3X106 cells 
 
DMEM for electroporation and 
after giving pulse, cells were 
suspended in DMEM+ 10% FBS 
+ 4 mM L-glutamine. After 24 h 
gentamycin (300 µg/ml) was 
added. 
Pulse 1-  
1500 
Pulse  2 
- 300 
Pulse 1-  25 
Pulse  2 - 
1500 
990 223 GFP expression 
was not observed 







DMEM+1% DMSO for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS + 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
250 
(247) 




EA.hy926, P#5, DMEM+1% DMSO for 
electroporation and after giving 
250 1500 ∞ 25.2 All the cells died 
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40µg 3X106 cells 
 
pulse, cells were suspended in 
DMEM+ 10% FBS + 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
(246) within 10 days 
pEGFP-N1 
(positive 




DMEM+1% DMSO for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS + 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
250 
(248) 












DMEM+1% DMSO for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
240 
(236) 
1,000 ∞ 15.4 A good GFP 
expression was 
observed. 









DMEM+5% DMSO for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS+ 4 mM L-
glutamine. After 24 h gentamycin 
(300 µg/ml) was added. 
250 
(248) 









DMEM+5% DMSO for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS+ 4 mM L-
250 
(246) 
1500 ∞ 25.2 Cells died under 
selection 
pressure. 
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glutamine. After 24 h gentamycin 
(300µg/ml) was added. 
pEGFP-N1 
(positive 




DMEM+ 5% DMSO for 
electroporation and after giving the 
pulse cells were suspended in 
DMEM + 10% FBS + 4 mM L-
glutamine. After 24 h gentamycin 
(300µg/ml) was added. 
250 
(246) 
1500 ∞ 24.7 Better GFP 
expression was 
observed as 
compared to EP2 
(Figure 5.8 c, d)  
pEGFP-N1 
(positive 




DMEM+ 10% DMSO for 
electroporation and after giving the 
pulse cells were suspended in 
DMEM + 10% FBS + 4 mM L-
glutamine. After 24 h gentamycin 
(300µg/ml) was added. 
250 
(247) 
1500 ∞ 24.7 GFP expression 
was observed but 
there was lot of 
cell death as 
well.  





6, 2X106 cells 
 
DMEM+5% DMSO+5% FBS for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS+ 4 mM L-
glutamine. After 6 h 100 nM PMA 
was added and after 24 h 
gentamycin (300µg/ml) was added. 
274 
(270) 
1800 ∞ 32.1 All the cells died 





6, 2X106 cells 
 
DMEM+5% DMSO+5% FBS + for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS+ 4 mM L-
glutamine. After 6 h 100 nM PMA 
274 
(271) 
1800 ∞ 31.6 After 6 weeks 
three colonies 
were observed 
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was added and after 24h gentamycin 
(300µg/ml) was added. 
pEGFP-N1 
(positive 
control) , 50µg 
EA.hy926, P# 
6, 2X106 cells 
 
DMEM+5% DMSO+5% FBS for 
electroporation and after giving 
pulse, cells were suspended in 
DMEM+ 10% FBS+ 4 mM L-
glutamine. After 6 h 100nM PMA 
was added and after 24h gentamycin 
(300 µg/ml) was added. 
274 
(271) 
1800 ∞ 39.4 Good GFP 
expression was 
observed 
(Figure 5.8 e, f) 
 
EP, electroporation no; ms, millisecond 
 




Figure 5.8: Fluorescence microscopy images of transfected cells. GFP expression 
was observed in EA.hy926 cells and HEK293T cells (positive control). HEK293T 
cells transfected with pEGFP-N1 during EP3, 10X magnified images (a) in blue light 
(b) in white light; EA.hy926 cells transfected with pEGFP-N1during EP3, 20X 
magnified images (c) in blue light (d) in white light; EA.hy926 cells transfected with 
pEGFP-N1 during EP5, 4X magnified images (e) in blue light (f) in white light. In 
EP3, high GFP expression was observed in HEK 293T cells (positive control) 
whereas faint GFP expression was observed in EA.hy926 cells. After optimizing 
electroporation protocol in EP5, higher transfection efficiency was observed in 
EA.hy926 cells. 
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After six weeks, two colonies were observed for the EA.hy926 cells transfected with 
pcDNA3.1 (+) + VEGFR2. These colonies were expanded from 6-well plate to T-25 
treated flasks to T-75 treated flasks, followed by T-175 treated flask.  
5.3.7 Confirmation of VEGFR2 gene integration and its expression on 
EA.hy926 cells  
At T-175 flask stage, cells were analysed for VEGFR2 expression by FACS. Figure 
5.9 confirms the VEGFR2 expression on transfected EA.hy926 cell lines by FACS 
analysis. EA.hy926 cells were stained with anti-VEGFR2 antibody (Sigma, 
SAB4501645) and then with FITC labelled secondary antibody (Sigma, F9887). 
EA.hy926 + pcDNA 3.1(+) +VEGFR2Cl#2 had the highest VEGFR2 expression. 
VEGFR2 gene integration was further confirmed by checking the presence of 
VEGFR2 gene and vector gene fragments in EA.hy926 + pcDNA 3.1(+) 
+VEGFR2Cl#2 cells. For that, total RNAs of transfected and non-transfected 
EA.hy926 cells were extracted using Qiagen RNA easy mini kit as per the manual 
instructions. Figure5.9 shows the agarose gel image of total RNA isolated from 
EA.hy926 cells and pcDNA 3.1(+) +VEGFR2 Cl#2 transfected EA.hy926 cells. 
Expected band of 1.5Kb and 0.75Kb were observed in both the samples. The cDNAs 
were prepared using High Capacity cDNA Reverse Transcription kit, Applied 
Biosystems. cDNAs were eluted and quantitated by NanoDrop. Amplification PCR 
was performed using two sets of primers including only gene specific primers in one 
set (Primer 19 and 20 - listed in Chapter 2, section 2.5, Materials) and one gene 
and one vector specific primer in other set (Primer 32 and 38). GAPDH 
(housekeeping gene) amplification was employed as positive control. Figure 5.10 a 
shows the agarose gel image of PCR amplifications and Figure 5.10 b shows the 
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image to explain the location of fragment that was amplified using gene and vector 
specific primer set. The gene amplification band with gene and vector specific 
primers was observed only in the transfected EA.hy926 cells, confirming the 
presence of vector construct. 
 
Figure 5.9: FACS analysis of VEGFR2 expression confirmation on transfected 
EA.hy926 cells. Histogram depicting FITC expression of different VEGFR2-
transfected EA.hy926 cell lines. Mean fluorescence intensity (MFI) values were 
higher for transfected EA.hy926 cells as compared to non transfected cells. VEGFR2 
expression was highest in VEGFR2 / EA.hy926 Cl# 2.  
 
 




Figure 5.10: VEGFR2 gene integration confirmation on EA.hy926 cells. a. Agarose 
gel image of PCR amplifications of fragments of VEGFR2 gene constructs in 
EA.hy926 cells. Lane 1-531 bp PCR product- VEGFR2  (Template – EA.hy926), 
lane 2-1009 bp PCR product- VEGFR2 / pcDNA3.1(+) (Template – EA.hy926), lane 
3- ~900 bp PCR product- GAPDH gene-Positive control- (Template – EA.hy926), 
lane 4 -1 Kb Ladder, lane 5-531 bp PCR product- VEGFR2  (Template –VEGFR2-
transfected EA.hy926), lane 6- 1009 bp PCR product- VEGFR2 / pcDNA3.1(+) 
(Template –VEGFR2-transfected EA.hy926) , lane 7 ~900 bp PCR product- GAPDH 
gene-Positive control- (Template –VEGFR2-transfected EA.hy926) , lane 8- 100 bp 
Ladder , lane 9-531 bp PCR product- VEGFR2  (No Template), lane 10- 1009 bp 
PCR product- VEGFR2 / pcDNA3.1(+) (No Template) , lane 11 ~900 bp PCR 
product- GAPDH gene-Positive control- (No Template); b. Diagrammatic 
representation to explain the location of 1009 bp fragment that was amplified using 
gene and vector specific primer set. The agarose gel image shows that 531 bp PCR 
product of VEGFR2 was observed in both VEGFR2 / pcDNA3.1 transfected 
EA.hy926 cells and untransfected EA.hy926 cells but not in the negative control (no 
template). VEGFR2 fragment amplification is faint in untransfected cells as 
compared to transfected cells, since EA.hy926 cells has some VEGFR2 expression. 
Also 1009 bp fragment amplification containing both gene and vector region was 
observed only in VEGFR2 / pcDNA3.1 transfected EA.hy926 cells and not in 
untransfected EA.hy926 cells or negative control (no template). These observations 
confirm that VEGFR2 / pcDNA3.1 transfected EA.hy926 cells have the transfected 
plasmid. 
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5.3.8 Cell banking 
EA.hy926 + pcDNA3.1 (+) + VEGFR2 Cl# 2 cell line has better VEGFR2expression 
than EA.hy926+ pcDNA3.1 (+) + VEGFR2 Cl#1.  EA.hy926 + pcDNA3.1 (+) + 
VEGFR2 Cl#2 cell line was taken forward and five vials were frozen at passage 4 
and cells were further expanded to prepare a bank. A mini cell bank of 40 vials was 
prepared at passage #12 having 1million cells per vial. 
5.4 Standardization of the assay 
5.4.1 Standardization of bioassay media and VEGF concentration. 
Usually in cell proliferation bioassay, cells are first cultured in compromised media 
and then the analyte which affects cell proliferation is added and its effect on cell 
proliferation is monitored. For culturing EA.hy926 cells, DMEM + 2mM L-
_Glutamine + 10% FBS was used. For standardizing bioassay media, cells were 
cultured in less (0.5% and 5%) or no serum with different concentrations of VEGF 
(10 ng/ml, 25 ng/ml, 50 ng/ml and 100 ng/ml). The assay was carried out in 
triplicates. Untransfected and VEGFR2-transfected EA.hy926 cells were compared. 
Figure 5.11 shows the bioassay media and VEGF concentration optimization data. 
 




Figure 5.11: Histogram graphs representing bioassay media and VEGF 
concentration optimization data. 0%, 0.5% and 5% serum concentrations were tried 
at different VEGF contentrations ranging from 10 ng/ml to 100 ng/ml. Comparison 
was done for untransfected (a) and VEGFR2-transfected EA.hy926 cells (b). Each 
point in the graph represents mean ± SD of triplicates. Untransfected EA.hy926 cells 
were responding to VEGF but not as much as VEGFR2-transfected EA.hy926 cells. 
Untransfected EA.hy926 cells, rate of growth is proportional to percentage of serum 
used in the bioassay media. In VEGFR2- transfected EA.hy926 cells, VEGF effect 
on cell proliferation is more profound in cells with no serum. Also, saturation in cell 
number was observed after a concentration of 25 ng/ml VEGF concentration. Hence 
bioassay media with 0% serum and 25 ng/ml VEGF were optimised for further 
bioassays (purple tick). 
 
The above data illustrated that cell proliferation rate was optimum in bioassay media 
with 0% serum aT-25 ng/ml VEGF. The results were consistent for all the triplicates. 
Based on these observations, 0% serum aT-25 ng/ml VEGF was selected as the final 
bioassay media composition. 




5.4.2 Standardization of cell number and incubation time 
Cell number which shows maximum cell proliferation in presence of VEGF after 
incubating for particular number of days would have to be determined for bioassay 
optimization. So different cell numbers per well i.e. 10,000, 20,000, 30,000 and 
40,000 cells were seeded in bioassay media in the absence and presence of VEGF 
and incubated for 2, 3 and 4 days. The assay was carried out in triplicates. 
Untransfected and VEGFR2-transfected EA.hy926 cells were compared. Figure 5.12 
shows the cell number and incubation time optimization data. 
 




Figure 5.12: Cell number and incubation time optimization. Different cell number 
i.e. 10,000 cells/well, 20,000 cells/well , 30,000 cells/well  and 40,000 cells/well  
were incubated for different number of days i.e. Day2, Day3, Day4. Comparison was 
done for untransfected and VEGFR2-transfected EA.hy926 cells.  Each point in the 
graph represents mean ±SD of triplicates. In untransfected EA.hy926 cells, VEGF 
treated cells had higher proliferation rate than VEGF untreated cells, though the 
difference was very less as compared to VEGFR2-transfected EA.hy926 cells. 
Maximum difference in cell proliferation rate between VEGF treated and nontreated 
cells was observed at Day 3 in 30,000 cells /well combination (ticked in green). 
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Out of the different combinations shown in the above figure, maximum difference 
in cell proliferation rate, in the presence and absence of VEGF was observed at 
day3 with 30,000 cells/well. Also untransfected cells have less difference in cell 
proliferation rate in the presence and absence of VEGF as compared to VEGFR2-
transfected EA.hy926 cells. The results were consistent for all the triplicates.  
5.4.3 For standardization of Bevacizumab concentration 
Untransfected and VEGFR2-transfected EA.hy926 cells were seeded at 30,000 
cells/well in bioassay media without serum aT-25ng/ml VEGF and incubated for 3 
days. A serial two-fold dilutions of Bevacizumab were added, ranging from 
10,000ng/ml to 0.076ng/ml. Bioassay was carried out as per the protocol mentioned 
in Chapter 2–Materials and method. The assay was carried out in triplicates. 
Untransfected and VEGFR2-transfected EA.hy926 cells were compared. Figure 
5.13 shows the dose response curves. 
 
Figure 5.13: EA.hy926 cells proliferation inhibition in presence of Bevacizumab. 
The graphs indicated that better dose response was observed for VEGFR2-
transfected EA.hy926 cells as compared to untransfected EA.hy926 cells. RFU 
responses for Bevacizumab shows good gradation in the concentration range of 2.5 
μg/ml to 0.195 μg /ml.  
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VEGFR2-transfected EA.hy926 cells has better dose response than untransfected 
EA.hy926 cells. From the above graphs it is evident that RFU responses for 
Bevacizumab shows good gradation in the concentration range of 0.195 μg /ml to 10 
μg/ml. Below 0.915 μg/ml concentration, no significant increase in RFU values were 
observed, indicating saturation and above 2.5 μg/ml no significant decrease in RFU 
values were observed.  
These assays were set up using VEGFR2-transfected EA.hy926 cell vial frozen at 
lower passage number i.e. passage # 4. However the results could not be reproduced 
using the cells of higher passage i.e. passage # 12 vials. Further experiments were 
not performed as cells of lower passage were not available. So it was inferred that 
VEGFR2 gene expression was not stable and was lost after few passages. 
Though stable transfection could not be achieved but with the transiently transfected 
EA.hy926 cells, better cell proliferation inhibition response, in presence of 
Bevacizumab was observed and it can be concluded that EA.hy926 cells stably 
expressing VEGFR2 receptor has the potencial to develop robust and precise cell 
based assays for anti-VEGF /VEGFR2 drugs. Such robust cell based functional 
assays reflecting the mechanism of drugs are not yet available. The bioassays for anti 
VEGF/VEGFR2 drugs discussed in Chapter 1 can only be used in combinations to 
assess the potency of drugs. Repoter gene assay involving NFAT signalling pathway 
(Wang et al., 2016), KDR auto phosphorylation assays(Sisko et al., 2006) are not 
truly the functional assays. HUVECs and other primary cells are being used to setup 
functional assays like cell proliferation, tube formation, cell migration 
etc.(Papadopoulos et al., 2012) but such assays would not be precise as they are 
based on primary cells which changes from lot to lot and are difficult to isolate. The 
bioassay described in this chapter can meet the urgent requirement of simple and 
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accurate cell based assay for anti VEGF/VEGFR2 drugs and highlights the important 






















6 ADCP assay 
 
6.1 Introduction 
Anticancer mAbs can kill their target cells by mediating Fc effector functions 
including CDC, ADCC, ADCP and direct cytotoxicity (Jiang et al., 2011b, 
Rajasekaran et al., 2015). In Chapter 3, CD16a receptor binding assay was 
developed for evaluating the CD16a   receptor binding ability of the antibody, which 
is the most crucial step of ADCC mechanism of action. A step ahead would be to 
assess, if further downstream signalling takes place when the drug binds CD16a 
receptor. However, CHOKISV GS-KO cells lack the ability to elicit ADCC on 
receptor binding as NK cells do. But there are studies, which states that Fc receptor 
transfected CHO cells can perform phagocytosis (Nagarajan et al., 1995a). So it was 
hypothesized that CD16a engineered CHOKISV GS-KO cells act as effector cells 
and phagocytose the target cells in the presence of its specific mAb, and antibody 
dependent cellular phagocytosis (ADCP) assay can be developed for the mAb. This 
chapter describes the work done to verify CD16a engineered CHOKISV GS-KO 
cells phagocytic ability to phagocytose WIL2S cells in the presence of Rituximab. 
CHOKISV GS-KO cells phagocytosis assay 
WIL2S (ATCC, CRL-8885) is a human B lymphoma cell line which is CD20 
positive and is often employed as target cells for setting up bioassays for anti-CD20 
drug Rituximab (Miranda-Hern et al., 2015). For the CHOKISV GS-KO cells 




described in Chapter 2) and incubated with increasing concentrations of Rituximab, 
so that the antibody could bind CD20 receptors on target WIL2S cells.  CHOKISV 
GS-KO cells expressing CD16a receptors were distinguished from WIL2S cells by 
labelling them with calcein AM dye and then they were added to the WIL2S cells 
and Rituximab complex. Rituximab binds to CD20 receptor on WIL2s cells at its 
Fab portion and then it binds CD16a receptor on CHOKISV GS-KO cells, at its Fc 
portion. This activates phagocytic pathway of CHOKISV GS-KO cells and they 
phagocytose WIL2S cells. The phagocytosis was detected by FACS. FITC positive 
cells were detected in FL1 channel and PE positive cells in FL2 channel. 50,000 
events were acquired. Single cell events were monitored by dot plots. In the dot plot 
graph, PE positive population was plotted on the Y axis and FITC positive 
population on X axis. PE positive WIL2S appeared in Q1 quadrant and FITC 
positive CD16a engineered CHOKISV GS-KO cells appeared in Q4 quadrant. 
WIL2S cells phagocytosed by CD16a engineered CHOKISV GS-KO cells shifted to 
Q2 quadrant as they were double positives. In the absence of Rituximab nothing was 
observed in Q2 quadrant but as the concentration of Rituximab increased number of 
events increased in Q2 quadrant. Diagrammatic representation of the ADCP bioassay 
is presented in Figure 6.1.  
 
For developing the ADCP assay for Rituximab, CD16a engineered CHOKISV GS-
KO cells (described in Chapter 3-CD16 receptor binding assay) were used as 
effector cells. Different assay parameters were optimized including concentration of 




Figure 6.1: Diagrammatic representation of the ADCP bioassay for Rituximab. 
WIL2S cells and CD16a engineered CHOKISV GS-KO cells were labelled. CD16a 
engineered CHOKISV GS-KO cells phagocytose WIL2S cells in presence of 
Rituximab. Analysis was done by Flow cytometry.  PE positive, WIL2S cells 
appeared in Q1 quadrant; FITC positive, CD16a engineered CHOKISV GS-KO cells 
in Q4 quadrant and phagotosed cells shifted to Q2 quadrant. With increase in 





6.2 Standardization of ADCP bioassay using CD16a engineered 
CHO KI SVGS-KO cells  
FACS analysis was carried out to check if CD16a engineered CHOKISV GS-KO 
cells could perform phagocytosis of WIL2S cells in presence of Rituximab. ADCP 
phagocytosis assay was performed (Bracher et al., 2007) (Karagiannis et al., 2009) 
(protocol described in Chapter 2).  To confirm specificity, CD16a engineered 
CHOKISV GS-KO cells were replaced with untransfected CHOKISV GS-KO cells 
in one set and Rituximab was replaced with Bevacizumab in other set. CHOKISV 
GS-KO cells were labelled with calcein AM (0.05µM), but calcein AM 
concentration was found to be too high, so compensation could not be set to get 
expected scatter for CHOKISV GS-KO cells. Still shift in scatter was observed 
corresponding to PE and FITC positive phagocytosed cell population.  This 
population was gated and represented in the green box. Figure 6.2 shows FACS 
analysis to measure phagocytosis. In the dot plot graphs, shift in scatter in the green 
box was visible only for CD16a engineered CHOKISV GS-KO cells in presence of 
Rituximab and even in bar graph, number of events in the gated green box increased 
only for this combination. This data clarified that not the untransfected CHOKISV 
GS-KO cells but only CD16a engineered CHOKISV GS-KO cells can perform 












Figure 6.2: Phagocytosis of WIL2S cells by CD16a engineered CHOKISV GS-KO 
cells in presence of Rituximab. a. Dot plot graphs of phagocytosis of WIL2S cells by 
CD16a engineered CHOKISV GS-KO cells in presence of different concentrations 
of Rituximab: b. Dot plot graphs of phagocytosis of WIL2S cells by untransfected 
CHOKISV GS-KO cells in presence of different concentrations of Rituximab; c. Dot 
plot graphs of phagocytosis of WIL2S cells by CD16a engineered CHOKISV GS-
KO cells in presence of different concentrations of Bevacizumab. Shift in the 
population (in the green box) is observed with increase in the concentrations of 
Rituximab, where WIL2S cells phagocytosis was performed by CD16a engineered 
CHOKISV GS-KO cells i.e. (a) and not in other two cases i.e.(b and c). d. Bar graph  
representing number of events in the green box which coresponds to cells eliciting 
phagocytosis. Here also, number of events increased with increase in concentration 
of Rituximab for WIL2S cells phagocytosed by CD16a engineered CHOKISV GS-
KO cells and not in other two cases. ADCP is specific to CD16a engineered 








6.2.1 Optimization of calcein AM labelling of CHOKISV GS-KO cells  
Calcein AM is a dye for determining cell viability. Live cells converts non 
fluorescent calcein AM to fluorescent green calcein. Optimization of calcein AM 
concentration was required since expected scatter was not observed when CHOKISV 
GS-KO cells were labelled with calcein AM at 0.05µM concentration. On the other 
hand DiI labelling of WIL2S was found to be perfect. Calcein AM staining intensity 
needed to be reduced to a level where compensation could be ajdusted such that a 
scatter corresponding to FITC positive population could be obtained. So calcein AM 
concentration was reduced ten-folds to 0.005 µM and further to 0.0005 µM, 0.00005 
µM concentrations were also tried. Figure 6.3 shows the dot plot graphs where 
CHOKISV GS-KO cells were labelled with different concentrations of calcein AM. 
At 0.005µM calcein AM concentration, expected scatter of FITC positive CHOKISV 
GS-KO was observed. So CHOKISV GS-KO cells would be labelled with calcein 
AM at 0.005µM concentration for further ADCP assays.   
 
Figure 6.3: FACS dot plot analysis of CHOKISV GS-KO cells labelled with 






6.2.2 Optimization of effector:target cell ratio   
Different effector: target cell ratios (CD16a engineered CHOKISV GS-KO cells: 
WIL2S cells ratio) were tried ranging from 5:1, 2:1, 1:1, 1:2 and 1:5. FACS analysis 
was done and dot plots were plotted as described previously. In the Q4+Q2 quadrant, 
PE in FITC MFI values were considered for evaluation of phagocytosis as it 
corresponds to PE positive WIL2S cells phagocytosed by FITC positive CD16a 
engineered CHOKISV GS-KO cells. So if PE- MFI increases in FITC with increase 
in mAb concentration, then it would imply that phagocytosis is increasing. Figure 
6.4 shows comparison of ADCP responses for different effector: target cell ratio. 
Similar rate of increase in PE- MFI values with increase in mAb concentration was 
observed in all the effector: target cell ratio combinations.  
 
Figure 6.4: Comparison of PE in FITC in Q2+Q4 for different effector: target cell 
ratios. In all the combinations, increase in PE, MFI was observed i.e. double positive 
population  was increasing with increase in Rituximab concentration and the rate of 





6.2.3 Repeating ADCP assay after optimization 
After optimization of calcein AM concentration for labelling effector cells and 
effector: target cell ratio, ADCP bioassay was again repeated in presence of different 
concentrations of Rituximab. Figure 6.5 shows the fluorescent microscopic images 
of the phagocytosed cells and Figure 6.6 shows the FACS analysis data illustrating 
ADCP assay. Compensations were adjusted such that labelled FITC positive CD16a 
engineered CHOKISV GS-KO cells scatter appeared in Q4 quadrant and labelled PE 
positive WIL2S cells scatter appeared in Q2 quadrant. There was some unstained 
CD16a engineered CHOKISV GS-KO cells population also, which separated out in 
Q3 quadrant. Cells in Q4 quadrant were expected to be double positives which 
would correspond to phagocytosed cells. It was observed that CD16a engineered 
CHOKISV GS-KO cells scatter rosed up even in the absence of Rituximab, but still 
with increase in Rituximab concentration, number of events increased in Q4 
quadrant and PE (in Q2+Q4) in FITC also increased indicating increasing 
phagocytosis in dose dependent manner. 
 
Figure 6.5: Fluorescent and superimposed images of CD16a engineered CHOKISV 
GS-KO cells and WIL2S cells. Phagocytosed WIL2S cells by CD16a, engineered 
CHOKISV GS-KO cells can be seen in the centred superimpose image ( white and 






Figure 6.6: FACS analysis of phagocytosis of WIL2S cells by CD16a engineered 
CHOKISV GS-KO cells in presence of Rituximab. a. Dot plot graphs of controls 
and phagocytosis in presence of different concentrations of Rituximab.Scatter in Q1 
quadrant comprises of WIL2S cells, scatter in Q2 quadrant comprises of double 
positive population of WIL2S cells phagocytosed by CHOKISV GS-KO cells, 
scatter in Q3 quadrant comprises of unstained CHOKISV GS-KO cells and scatter in 
Q4 quadrant comprises of stained CHOKISV GS-KO cells. Shift in the population 
(in the Q2 quadrant) is observed with increase in the concentrations of Rituximab i.e. 
double positive, population undergoing phagocytosis is increasing; b. Bar graph  
representing PE in FITC in Q2+Q4,which coresponds to PE positive WIL2S cells 
phagocytosed by FITC positive CHOKISV GS-KO cells. Here also,PE in FITC i.e. 
the double positives  were increasing with increase in concentration of Rituximab.  
 
From these data, the hypothesis was verified that CD16a engineered CHOKISV GS-
KO cells could perform phagocytosis of target cells in the presence of specific mAb 




optimized for Rituximab, but still there was room for improvement and the bioassay 
could further be streamlined by optimizing incubation time, working range etc. The 
CD16a expressing  CHOKISV GS-KO cells can further be used as effector cells for 
developing ADCP bioassay for other drugs like Trastuzumab, where target cells 
would be different depending on the specific mAb.   
In this phase of the study, the development of ADCP assay using CD16a expressing 
CHOKISV GS-KO cells as the effector cells was achieved. Conventional ADCP 
assays employ PBMCs as the source of monocytes and macrophages which would 
act as effector cells (Oflazoglu et al., 2009). As it has been discussed, there are 
issues with PBMCs including tedious methods involved, batch variations etc. In the 
efforts to create better assay solution , the reporter gene assays are developed where 
Fc receptor engineered Jurkat cells has luciferase gene controlled by NFAT response 
element (Zhi-jie Jey Cheng, 2016). Such assays assess the activation of Fc receptors 
with accuracy and precision. However, they are not the genuine functional assays as 
engulfment of target cells by effector cells is not evaluated.  
Another advancement to these reporter assays are the assays where target cell death 
is the final assay read out (Simone S. Krupka1, 2016). In these bioassays, target cells 
are engineered to stably express Killing-Mediated Immune Lysis Reporter (KILR) 
protein. These assays depict the ADCP function but target cells vary with different 
drugs creating the need to engineer multiple target cell lines. In conclusion, the 
ADCP bioassay developed using CD16a engineered CHOKISV GS-KO cells would 
be genuine functional ADCP assay which can measure target cell phagocytosis with 






















7 Summary and Conclusions 
 
7.1 Introduction  
Bioassays are indispensable for drug discovery, development and manufacturing. In 
vitro cell based assays in this field are simple to perform, faster, high throughput and 
cost effective as compared to the in vivo assays. In vitro cell based assays involve 
cell lines with specific receptors that respond to the drugs. For many drugs such cell 
lines with required receptors are not available. In vitro cell based assays for these 
drugs could therefore be developed by engineering the cell lines with specific 
receptors. 
The goal of the current study was to engineer the cell lines and develop functional 
assays and receptor binding assays for two important classes of anticancer drugs 
including anti-VEGF/VEGFR2 drugs and the mAbs which have Fc mediated 
effector functions as their mechanism of action. Figure 7.1 summarizes the work 
carried out for this study. 




Figure 7.1: Summary of the project work carried out for the current PhD study. 
 
7.2 Engineering CD16a receptor in CHOKISV GS-KO cells and 
developing CD16a receptor binding assay 
Monoclonal antibodies for cancer therapy that activate immune mediated effector 
functions have ADCC as one of their main mechanism of action (Coulson et al., 
2014). Conventional ADCC bioassays utilizes PBMCs as the effector cells, which 
are difficult to isolate and suffer from donor to donor variability. Robust ADCC 
bioassays are either unavailable or have cost implications (Parekh et al., 2012a). As 
described in Chapter 3, CD16a receptor binding assay was developed to assess the 
CD16a receptor binding ability of the mAbs which is the key step in ADCC 
response. CD16a receptor expression requires other co-receptor expression as well, 
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like FcɛRIγ. So CD16a and FcɛRIγ were amplified from human cDNA library, 
cloned in cloning vectors and subcloned in Lonza’s pXC 17.4 and pXC 18.4 vectors 
respectively. A double gene with both the genes was constructed and transfected in 
CHOKISV GS-KO cells by electroporation. 40 colonies were observed after 
incubation. In this report, cell based ELISA was developed as a novel method to 
screen the CD16a positive colonies. For screening the lead cell line cell based 
ELISA and FACS analysis was done. A cell bank of 100 vials was prepared for 
CD16a expressing lead cell line. CD16a receptor binding assay was optimized and 
validated for Trastuzumab. The receptor binding assay was found to be specific to all 
IgG1 mAbs and can also can be used to compare their CD16a receptor binding 
ability. It can be used as a surrogate ADCC assay. 
7.3 Engineering VEGFR2 receptor in EA.hy926 cells and 
developing cell proliferation inhibition assay for anti-VEGF drugs 
The pivotal role of VEGF in tumour angiogenesis is well established (Ferrara, 
2004a). Ongoing research for the development of novel VEGF inhibitors has led to 
many drugs entering the market, with many more in the pipeline (Meadows and 
Hurwitz, 2012). The increasing global market growth of anti-VEGF drugs has 
created great demand for bioassays for these drugs at all the stages of drug 
discovery, development and release. The bioassays available for anti VEGF drugs 
are either based on in vivo animal studies or employ the use of primary cell lines. 
These assays are discussed in Chapter 1, Literature review. As of now, not a single 
in vivo existing bioassay, on its own is sufficient to assess the therapeutic drug but in 
combination, these bioassays can be used to assess the safety and potency of the 
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drugs. Also, none of them qualify as QC lot release assay. Cell based bioassays use 
primary cell lines such as HUVEC’s which are isolated from human umbilical vein. 
Use of primary cell lines for bioassay is not desirable as it involves tedious method 
of isolating cells and there are constrains of obtaining the primary source material. 
They are difficult to propagate and are stable up to few passages only. Also each 
time, the cell population obtained would be distinct resulting in variations. It would 
be better to have cell based bioassays with stable cell lines. But for anti-VEGF 
drugs, such cell based bioassays are not developed. This may be because 
immortalized endothelial cell lines do not show all the required characteristics of 
endothelial cells including the expression of all the required receptors. Currently to 
face this challenge few approaches are being developed like 293\KDR cell line, 
being developed by transfecting VEGFR2 receptor in HEK 293 cell line which is 
being used for KDR auto phosphorylation assays (Sisko et al., 2006). PAE-VEGF-
R2 cell line, developed by overexpressing VEGF-R2 on Porcine aortic endothelial 
cells (PAE), is also being used for binding and receptor phosphorylation bioassays 
(Kendrew et al., 2011). Advancement to these could be the transfection of stable 
human endothelial cell lines with required receptors for the development of 
functional cell based assays like cell proliferation assay, cell migration assay and 
tube formation assay.  
EA.hy926 is a hybrid endothelial cell line having very less VEGFR2 expression and 
so it do not respond to VEGF as convincingly as primary endothelial cells like 
HUVEC cells do. Therefore, for the current study, it was hypothesized that if 
EA.hy926 cells overexpress VEGFR2 receptors, than cell based assays can be 
developed for anti-VEGF drugs. Work done to achieve this aim is described in 
Chapter 5. VEGFR2 gene was artificially synthesized and sub-cloned in expression 
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vectors. Although VEGFR2 was cloned in pcDNA3.1 (+) and pEGFP-N1 vector and 
transfection of both the vector construct was tried in EA.hy926 cells by various 
means, but only VEGFR2 + pcDNA3.1 (+) construct got transfected in EA.hy926 
cells and three clones were observed. These VEGFR2 + pcDNA3.1 (+) expressing 
EA.hy926 cell lines were confirmed for VEGFR2 expression by flow cytometry and 
RT-PCR. Highest VEGFR2 expressing cell line was selected and a cell bank was 
prepared for the same. Cell proliferation inhibition bioassay was optimized for 
Bevacizumab using the cell line but however it was noticed that the VEGFR2 
expression in the EA.hy926 transfected cells was lost at higher passage. From the 
observations of current study, it was concluded that if EA.hy926 cell line, which is 
hard to transfect cell line can be stably transfected with VEGFR2 gene by Amaxa 
neucleofection (Geng et al., 2011), lenti viral transfection or any other method, then 
there is a possibility to develop the cell based functional assays for anti-VEGF and 
anti-VEGFR2 drugs.  
7.4 Engineering VEGFR2 receptor in CHOKISV GS-KO cells 
and developing VEGFR2 receptor binding assay 
Cell based receptor binding assay was also developed for anti-VEGFR2 drugs as 
described in Chapter 4. VEGFR2 gene was artificially synthesized and cloned in 
pXC 17.4 vector. CHOKISV GS-KO cells were transfected with pXC17.4+VEGFR2 
vector construct by electroporation and 478 clones were observed. For screening the 
VEGFR2 expressing cell lines, in this study, a cell based ELISA was developed as a 
high throughput quantitative method. The cell lines were screened by cell based 
ELISA and flow cytometry and highest VEGFR2 expressing cell line was selected. 
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A cell bank of 100 vials was prepared. FACS based VEGFR2 receptor binding assay 
was successfully optimized and validated for Ramucirumab. It is an antiVEGFR2 
drug which binds and blocks VEGFR2 receptor thus preventing tumour angiogenesis 
(Javle et al., 2014). Although VEGFR2 receptor binding assays using other cell line 
have been previously reported (Kendrew et al., 2011), for this study, CHOKISV GS-
KO cell line was engineered with VEGFR2 receptor. It is a choice of cell line to 
achieve stable protein expressions which would allow long term reproducible and 
precise results. Additionally, the Ramucirumab’s receptor binding ability was 
evaluated using this assay. Further this assay would be applicable for comparing and 
determining receptor binding ability of other anti VEGFR2/VEGF drugs where it 
would provide comparative data required to demonstrate biosimilarity of the drug to 
the approved drug in the market since receptor binding is an inherent part of these 
drug’s mode of action.  
7.5 Exploring VEGFR2 engineered CHOKISV GS-KO cells 
proliferation in presence of VEGF 
Endothelial cells having VEGFR2 receptors proliferate in response to VEGF (Cebe-
Suarez et al., 2006). For developing cell based bioassay for anti-VEGF drugs, 
EA.hy926 cells were transfected with VEGFR2 receptor but since these cells are 
hard to transfect, stable transfection was not achieved (Chapter 5). On the other 
hand, for developing receptor binding bioassay for anti-VEGFR2 drugs, CHOKISV 
GS-KO cells were engineered with VEGFR2 receptor, as described in Chapter 4. 
Although there are no studies where CHO cells responding to VEGF pathway is 
stated, still VEGFR2 engineered CHOKISV GS-KO cells response to VEGF was 
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examined in the current study. Bioassays were performed where CHOKISV GS-KO 
cells were grown in serum deprived DMEM media with VEGF. Cell proliferation 
was assessed on Day 2 and Day 3 by varying different parameters including 
concentrations of serum (0%, 0.2% and 2%), VEGF (0 ng/ml, 50 ng/ml, 100 ng/ml 
and 200 ng/ml) and cell numbers per well (10,000 cells/well, 20,000 cells/well, 
30,000 cells/well). Cell viability was measured by adding Alamar blue reagent and 
then measuring the relative fluorescence. Figure 7.2 shows the graphs presenting the 
response of VEGFR2-transfected cells under varied parameters after two days and 
three days incubation.  
 
 




Figure 7.2: VEGFR2-transfected CHOKISV GS-KO cell viability under different 
combination of parameters. Different cell number i.e. 10,000 cells/well, 20,000 
cells/well , 30,000 cells/well  were incubated for 2 and 3days. Cell viability in each 
case was compared with cell viability where VEGF was not added. (a), (b) and (c) 
represents day 2 data with 10,000, 20,000 and 30,000 cells/well respectively whereas 
(d), (e)and (f) represents the day3 data at 10,000, 20,000 and 30,000 cells/well 
respectively. Each point in the graph represents mean ± SD of triplicates. 
Considerable variation in RFU values between presence and absence of VEGF was 
not observed.  
 
Various combinations were tried where CHOKISV GS-KO cells could proliferate in 
presence of VEGF and not in its absence but much variation in cell number in 
presence and in absence of VEGF was not observed. Also, it was observed that RFU 
values declined on Day 3 as compared to Day 2. This could be because cells could 
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not survive in bioassay media till Day3. So Day 2 data was considered as till second 
day cells seemed to be healthy and from here it was concluded that CHOKISV GS-
KO cells do not respond to VEGF. As a result this cell line cannot be used to 
develop functional cell based assays like cell proliferation inhibition, cell migration 
etc. for anti-VEGF /VEGR2 drugs. 
7.6 Investigating CD16a engineered CHOKISV GS-KO cells 
phagocytic activity for developing ADCP bioassay  
Monoclonal antibodies that kill target cancer cells by their Fc mediated effector 
functions have ADCP as one of their effector functions along with ADCC, CDC, and 
direct cytotoxicity (Moore et al., 2010). Currently cell based ADCP bioassays are 
based on use of PBMCs as a source of effector cells. Other costly kit based reporter 
bioassays are being used as surrogate ADCP assays (Ulrike Herbrand, 2016). These 
assays suffer from the same limitations as discussed in previous section (section 7.2) 
thus creating the need for cell line based ADCP bioassays. Previous research has 
shown that CHO cells expressing Fcγ receptors can elicit phagocytosis (Joiner et al., 
1990, Le Cabec et al., 2002, Hackam et al., 1998). For developing CD16a receptor 
binding assay as has already been discussed and described in Chapter 3, CHOKISV 
GS-KO cells were engineered with CD16a or FcγRIIIa receptors. So it was 
hypothesized that these cells hold the potential to elicit phagocytosis and thus can be 
employed as effector cells for developing ADCP bioassay. For investigating this 
hypothesis CD16a engineered CHOKISV GS-KO cells phagocytic activity was 
verified by allowing these cells to phagocytose CD20 positive WIL2S cells tagged 
with Rituximab and analysing by FACS. Rituximab is an anti CD20 mAb which 
Summary and Conclusions 
208 
 
kills CD20 positive, tumour B cells by eliciting Fc mediated effector functions 
including ADCP (Montalvao et al., 2013). In the bioassay setup, CD16a expressing 
CHOKISV GS-KO cells were tagged with green flurochrome using Calcein dye 
whereas target WIL2S cells were stained with DiI. Target cells were incubated with 
mAb, followed by incubation with effector cells. Flow cytometry was done where 
phagocytosed target cells were clearly distinguished (Bracher et al., 2007), thus 
confirming phagocytosis. The ADCP assay for the current study was optimized for 
Rituximab. This study thus provides a promising approach to develop functional 
ADCP assay for mAbs eliciting Fc effector functions, which can evaluate and 
compare the potency of biosimilars.  
 
In conclusion, in the current study a novel cell based functional ADCP bioassay was 
developed to assess the potency of mAbs with Fc mediated effector functions. On 
the other hand, an approach to develop EA.hy926 cell based functional assays for 
anti-VEGF/VEGFR2 drugs was also verified. Along with these functional assays, 
receptor binding assays were also optimized and validated for these drugs. 
Altogether these assays would definitely prove to be assets for expediting the drug 
manufacturing and production in a cost effective manner. 
7.7 Future perspectives 
For achieving stable transfection of VEGFR2 containing vector construct in 
EA.hy926 cells, other mode of transfections are being tried including Neon 
transfection from Invitrogen (Kim et al., 2008). The VEGFR2 engineered EA.hy926 
cells can then be employed in developing cell proliferation inhibition assay for 
Bevacizumab and other anti-VEGF and anti-VEGFR2 drugs. 
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CD16a engineered CHOKISV GS-KO cells phagocytosis assay can further be 
streamlined by optimizing other parameters like incubation time etc. Once the assay 
would be validated, it can be used as an ADCP assay for Rituximab. Further the 
assay could be optimized for other mAbs like Trastuzumab, Cetuximab etc. which 





Table 8.1: Materials 
Product Catalog 
Number 
 Lot Number Company 
Enzymes and Buffers 
Pfu Ultra HF DNA Polymerase enzyme 600382-51 0770603 Stratagene 
10 X Pfu Ultra Buffer 600380-52    0660540 Stratagene 
Pfu Native DNA Polymerase enzyme 60036-81    0660489 Stratagene 
10 X Pfu Native Plus Buffer 600135-84 0530270 Stratagene 
Pfu Turbo DNA Polymerase enzyme 600252-52 6140547 Stratagene 
Econotaq Plus Green 2X master Mix F93481-1    3446 Lucigen 
10 X Pfu Reaction Buffer 600153-82 6094700 Stratagene 
BDT dye 
 
4336697 1201096 Applied 
Biosystems 
5X Sequencing Buffer(Big Dye 
Terminator) 
4336697 1003184 Applied 
Biosystems 
T4 DNA ligase  M0202S 1081306 NEB 
T4 DNA ligase Buffer B0202S 1007 NEB 
EcoR I enzyme R0101S 0331205 NEB 
EcoR I buffer  B0101S 0011104 NEB 
EcoRV R01955 43 NEB 
Hind III enzyme  R0104S 63 NEB 
NcoI R0193L 26 NEB 
NotI R0189S 521212 NEB 
PvuI R0150L 36 NEB 
SalI R0138L 53 NEB 
Sma I enzyme R0141S 74 NEB 
XhoI R01468 581109 NEB 
10mM dNTPs 18427-013  Invitrogen 
BSA B9001S104  NEB 
NEB buffer 2(10X) B7002S 0071104     NEB 
NEB buffer 3(10X) B7003S 706 NEB 










Invitrogen Zero Blunt TOPO PCR Cloning 




TOPO XL PCR Cloning kit 45-0008 392554 Invitrogen 
EndoFree Plasmid Mega kit 12381 127152737 Qiagen 







   
MEDIA and other cell cultuire reagents 
CDCHO media 10743-029 1400303 Gibco 
RPMI 1640 media 12-115F 603803 Lonza 
DMEM media BE12-614F 6MB241 Lonza 
DMEM F12 media 12-719F 530107 Lonza 
FBS SH30070.03 AWC10533 Hyclone 
L Glutamine 















PBS 10010-049  Gibco 
Calcein AM dye 
DiI dye 






EBM-2 CC-3156 581107 Lonza 
EGM-2Single quots CC-4176 546492 Lonza 
OTHER REAGENTS 
Human universal(Quick Clone)cDNA 
library 
637260 6060089 Clontech 









IPTG I6758  Sigma 
X-GAL 10077  Amersham 
TOP 10 Competent cells   Inhouse 
prepared 
XL-1BLUE Competent cells   Inhouse 
prepared 
Anti-human IgG (γ chain specific)-FITC 
antibody produced in goat  
F0132  Sigma 




antibody produced in goat  
Anti-VEGFR2 antibody produced in rabbit 
Anti-Rabbit IgG (whole molecule)-FITC 
produced in goat 
Anti-hVEGFR2/KDR Fluorescein 














Vector NTI   Invitrogen 
Clustal W    
CAP3    
Primer 3    
Gene design    
MutationDiscovery.com 
 
   
Instruments 
Class II Biohazard Safety Cabinet, ESCO 
Centrifuge 570R, 5810R, 5415R, Eppendorf 
CO2 incubator, Heraeus 
BD FACS CantoII, BD 
Polar Star Optima, BMG Labtech 
Electroporator, Gene Pulsar X cell, BIO-RAD 
ELISA plate reader, Power Wave XS, BioTek 
Genetic Analyzer 3100,  ABI Prism 
Spectrophotometer, ND-1000, NanoDrop 
Inverted microscope,1X70, Olympus 
Fluorescence inverted microscope, EclipseTE300, Niko 


















Vector map of pcDNA3.1 (+) 
 
www.invitrogen.com 











Table 8.2: Summary of the required important features of the expression vectors. 
 
Name Restriction 
















3.1 plus  
Nhe I, Hind III, 
Kpn I, BamH I, 
EcoR I, EcoR 
V, Not I, XhoI, 
Xba I, Apa I, 
Pme I  
Pvu I , Bgl I, 













Hind III, Kpn I, 
BamH I, EcoR 
I, XhoI, Xma I, 
Apa I, Sma I, 
Sal I, Sac I, Pst 
I  


















































































WALTENBERGER, J., CLAESSONWELSH, L., SIEGBAHN, A., SHIBUYA, M. & HELDIN, C. H. 1994. DIFFERENT SIGNAL-TRANSDUCTION PROPERTIES OF KDR AND FLT1, 2 RECEPTORS FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR. Journal of Biological Chemistry, 269, 26988-26995. WANG, L., XU, G. L., GAO, K., WILKINSON, J., ZHANG, F., YU, L., LIU, C. Y., YU, C. F., WANG, W. B., LI, M., CHEN, W., FAN, F., CONG, M. & WANG, J. Z. 2016. Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies. Journal of Pharmaceutical and Biomedical Analysis, 125, 212-8. WEINER, L. M., SURANA, R. & WANG, S. 2010. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10, 317-327. WENG, D. E. & USMAN, N. 2001. Angiozyme: a novel angiogenesis inhibitor. Current oncology reports, 3, 141-6. WERNERSSON, S., KARLSSON, M. C. I., DAHLSTRÖM, J., HEYMAN, B., MATTSSON, R. & VERBEEK, J. S. 1999. IgG-mediated enhancement of antibody responses is low in Fc receptor γ chain-deficient mice and increased in FcγRII-deficient mice. Journal of Immunology, 163, 618-622. WHITTLE, C., GILLESPIE, K., HARRISON, R., MATHIESON, P. W. & HARPER, S. J. 1999. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF(148) mRNA, a novel truncated splice variant. Clinical Science, 97, 303-312. WILHELM, S. M., DUMAS, J., ADNANE, L., LYNCH, M., CARTER, C. A., SCHUETZ, G., THIERAUCH, K.-H. & ZOPF, D. 2011. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129, 245-255. WOLPIN, B. M., NG, K., ZHU, A. X., ABRAMS, T., ENZINGER, P. C., MCCLEARY, N. J., SCHRAG, D., KWAK, E. L., ALLEN, J. N., BHARGAVA, P., CHAN, J. A., GOESSLING, W., BLASZKOWSKY, L. S., SUPKO, J. G., ELLIOT, M., SATO, K., REGAN, E., MEYERHARDT, J. A. & FUCHS, C. S. 2013. Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. Oncologist, 18, 377-378. WU, J., EDBERG, J. C., REDECHA, P. B., BANSAL, V., GUYRE, P. M., COLEMAN, K., SALMON, J. E. & KIMBERLY, R. P. 1997. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. Journal of Clinical Investigation, 100, 1059-70. YANCOPOULOS, G. D., DAVIS, S., GALE, N. W., RUDGE, J. S., WIEGAND, S. J. & HOLASH, J. 2000. Vascular-specific growth factors and blood vessel formation. Nature, 407, 242-248. YOCKELL-LELIEVRE, J., RIENDEAU, V., GAGNON, S. N., GARENC, C. & AUDETTE, M. 2009. Efficient transfection of endothelial cells by a double-pulse electroporation method. DNA Cell Biology, 28, 561-6. ZHANG, L., SHI, M., HUANG, C., LIU, X., XIONG, J. P., CHEN, G., LIU, W., LIU, W., ZHANG, Y., LI, K., YU, H. & JIANG, H. 2012. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. Journal of Clinical Oncology, 30. ZHI-JIE JEY CHENG, D. G., RICH MORAVAC, FRANK FAN, AND MEI CONG 2016. Fc Effector Reporter Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP. ZICHE, M. 2001. Corneal assay for angiogenesis. Angiogenesis Protocols, 46, 131-142. 
 
